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ABSTRACT 
 
Tamarindus indica (T. indica), or tamarind, is an edible fruit widely used in 
many applications including culinary, industrial, and medicinal purposes. It has been 
shown to exhibit hypolipidaemic effects in hamsters and humans. Previous studies have 
also shown that the methanol extract of T. indica fruit pulp regulated genes related to 
lipid metabolism. However, the lipid-lowering mechanism of the fruit has not been fully 
understood. The objective of this present study is to determine the lipid-lowering 
mechanism of T. indica fruit pulp using proteomic and transcriptomic approaches. 
Proteomic analyses were first performed to formulate a hypothesis on the 
hypolipidaemic action of the fruit. When secreted proteins extracted from control and T. 
indica fruit-treated HepG2 cells were subjected to 2-dimensional gel electrophoresis, 
the expression of seven proteins was found to be significantly different (p < 0.03125). 
As for the HepG2 cell lysate proteins, 20 spots were found to be significantly altered (p 
< 0.05). Fourteen spots were identified and categorised based on their biological 
functions, namely the oxidative phosphorylation, metabolism, protein biosynthesis, cell 
proliferation and differentiation and mRNA splicing. When the altered secreted proteins 
and cell lysate proteins were co-analysed using Ingenuity Pathway Analysis (IPA) 
software, lipid metabolism was found to be the top network being regulated, with a 
score of 31. Further data mining of the proteomic data as well as previously obtained 
microarray data indicated that the fruit pulp extract modulates its lipid-lowering effect 
through the activation of PPARα. To further demonstrate the hypolipidaemic effect of 
the fruit, lipid studies were conducted. DNA microarray analyses were also conducted 
to elucidate its mechanism of action, and fenofibrate, a hypolipidaemic drug which is a 
ligand to PPARα, was used as a comparison to T. indica fruit which was hypothesised 
to lower lipids in a similar mode of action. HepG2 cells were first treated with 0.3 mM 
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palmitic acid to induce hepatic steatosis. The lipid loaded-cells were then treated with 
different concentrations of T. indica fruit pulp extract and the total triglyceride and 
cholesterol levels were measured. Total cellular RNA was then extracted for DNA 
microarray analysis and the significantly regulated genes were subjected to IPA 
software analysis. Results showed that treatment with 0.1 mg/ml T. indica fruit pulp 
extract reduced total triglyceride and total cholesterol by 40 % and 18 % respectively, a 
level comparable to fenofibrate. DNA microarray analyses showed that treatment of 
lipid loaded-HepG2 cells with the same concentration of T. indica fruit extract regulated 
140 genes (p < 0.05) when compared to control. Further data mining using IPA analysis 
showed that 21 genes were involved in lipid metabolism network and PPARα and 
PPARγ activation could be responsible for the lipid-lowering effects, possibly attributed 
to proanthocyanidins, the major polyphenol found in T. indica fruit extract. As a 
conclusion, the methanol extract of T. indica fruit pulp lowers lipid levels significantly, 
particularly triglyceride and it does so through the activation of PPARα, a mechanism 
similar to fenofibrate. 
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ABSTRAK 
 
Buah Tamarindus indica (T. indica), atau asam jawa boleh dimakan serta 
digunakan secara meluas dalam pelbagai aplikasi termasuk masakan, perindustrian, dan 
untuk tujuan perubatan. Ia telah terbukti mempamerkan kesan hipolipidemik dalam 
hamster dan manusia. Kajian kami sebelum ini juga telah menunjukkan bahawa ekstrak 
metanol buah T. indica mengawal atur gen yang berkaitan dengan metabolisme lipid. 
Walau bagaimanapun, mekanisme tindakan hipolipodemik buah T. indica masih belum 
difahami sepenuhnya. Objektif kajian ini adalah untuk menjelaskan mekanisme 
perendahan lipid oleh buah T. indica dengan menggunakan pendekatan proteomik dan 
transkriptomik. Analisa proteomik dijalankan terlebih dahulu untuk merangka hipotesis 
mengenai tindakan hipolipidemik buah asam jawa. Apabila dianalisa melalui kaedah 
elektroforesis 2-dimensi, terdapat perubahan signifikan dikesan bagi ekspresi tujuh 
tompokan protein (p < 0.03125) dalam ekstrak protein dari rembesan sel-sel HepG2 
yang dirawat dengan buah T. indica berbanding dengan sel-sel kawalan yang tidak 
menerima rawatan. Bagi protein lysate sel HepG2 pula, perubahan ekspresi 20 
tompokan protein pada gel didapati signifikan (p < 0.05). Empat belas tompokan 
protein telah dikenal pasti dan dikategori berdasarkan fungsi biologi, iaitu 
pemfosforilan oksidatif, metabolisme, biosintesis protein, percambahan sel dan 
pembezaan dan pemotongan mRNA. Apabila rembesan protein dan protein lysate sel 
dianalisasi dengan menggunakan perisian Ingenuity Pathway Analysis (IPA), rangkaian 
utama yang dikawal atur adalah metabolisme lipid, dengan skor 31. Maklumat lanjut 
analisis perlombongan data proteomik serta data mikroarray kami yang terdahulu 
menunjukkan bahawa ekstrak buah asam jawa merendahkan lipid melalui pengaktifan 
PPARα. Untuk membuktikan kesan hipolipidemik buah tersebut, kajian lipid telah 
dijalankan untuk mengukur kesan perendahan lipid. Analisis mikroarray DNA juga 
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telah digunakan untuk menjelaskan mekanisme tindakan, dan fenofibrate, ubat 
hipolipidemik yang merupakan ligan untuk PPARα telah digunakan sebagai 
perbandingan dengan buah T. indica yang dijangka merendahkan lipid melalui 
mekanisme tindakan yang sama. Sel-sel HepG2 terlebih dahulu dirawat dengan 0.3 mM 
asid palmitik untuk mengaruh steatosis pada sel hepar. Sel yang kaya-lipid, kemudian 
dirawat dengan ekstrak buah T. indica pada kepekatan berbeza dan jumlah trigliserida 
dan paras kolesterol telah diukur. tcRNA sel kemudiannya diekstrak untuk analisis 
mikroarray DNA dan gen yang dikawal atur dengan ketara telah dianalisa menggunakan 
perisian IPA. Hasil kajian menunjukkan bahawa rawatan dengan 0.1 mg/ml ekstrak 
buah T. indica mengurangkan paras trigliserida dan kolesterol masing-masing sebanyak 
40 % dan 18 %, setanding dengan 0.1 mM fenofibrate. Analisis mikroarray DNA 
menunjukkan bahawa rawatan sel HepG2 yang kaya-lipid dengan ekstrak buah T. 
indica pada kepekatan 0.1 mg/ml mengubah ekspresi 140 gen (p < 0.05) berbanding 
dengan kawalan. Perlombongan data menggunakan perisian IPA menunjukkan bahawa 
21 gen terlibat dalam rangkaian metabolisme lipid, dan pengaktifan PPARα dan PPARγ 
bertanggungjawab untuk kesan perendahan lipid, mungkin disebabkan oleh 
proantosianidin, polifenol utama yang terdapat dalam ekstrak buah T. indica. 
Kesimpulannya, ekstrak metanol buah T. indica merendahkan lipid dengan ketara, 
terutamanya trigliserida dan ia merendahkan lipid melalui pengaktifan PPARα, 
mekanisme yang sama dengan fenofibrate. 
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CHAPTER 1  
INTRODUCTION 
 
Lipids are essential building blocks in many biosynthetic pathways. For example 
cholesterol is an important component of the cell membrane and is a precursor for 
steroid hormones and bile acids. Triglyceride, an ester derived from glycerol and three 
fatty acids, functions mainly as energy storage. However, excessive lipid in the blood, a 
condition known as hyperlipidaemia, could lead to diseases such as coronary artery 
diseases. Individuals with high total cholesterol have approximately twice the risk of 
heart disease than those with optimal levels. In fact, ischemic heart disease was the 
leading cause of death in Malaysia in year 2008 (Malaysia Department of Statistics, 
2010) and also the top cause of death in the world in 2012 (WHO, 2012). Other than 
changing to a healthier lifestyle and diet, the current medication for hyperlipidaemia is 
mainly through prescription of lipid-lowering drugs like statins and fibrates. However 
these drugs may cause adverse effects at higher doses and can be costly depending on 
the types and brands of drugs used. In view of this matter, alternative medicinal 
research has come into the limelight in the hope of searching for a cheaper and more 
effective alternative to, or to be used in combination with the existing medications.  
  
 Since the ancient time, many natural products were used as medicines and some 
were well documented for its medicinal properties. Traditional medicines like the 
Ayurveda from India or the Traditional Chinese Medicine (TCM) are a few traditional 
medicinal practices that are still being practised until today. While the scientific 
evidence for the use of many of these medicinal plants still remain to be proven, some 
have indeed been shown to possess potent medicinal properties. In fact, several 
prescription drugs are extracted or derived from these plants. For example vinblastine 
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and vincristine extracted from the flowering plant, Catharanthus roseus, are potent anti-
cancer drugs used in the treatment of leukaemia and Hodgkin’s lymphoma (Moudi, Go, 
Yien, & Nazre, 2013). Lovastatin, a cholesterol-lowering drug, was initially derived 
from fungi. It can also be found naturally in red yeast rice (J. Ma et al., 2000) and oyster 
mushrooms (Bobek, Ozdin, & Galbavy, 1998). This reflects the endless possibilities 
that can be discovered through the research on natural products.  
 
Tamarindus indica or tamarind is a tropical fruit tree native to the African 
savannahs but it can now be found in many tropical countries. The sweet and sour taste 
of its fruit pulp is used to add flavour to local cuisines. Besides culinary, tamarind is 
also used in traditional medicine as laxative, diuretic, anti-bacterial agents as well as in 
treatment of fever and malarial infections (Bhadoriya, Ganeshpurkar, Narwaria, Rai, & 
Jain, 2011; Havinga, et al., 2010). Previous biochemical analyses have demonstrated 
that extracts of T. indica fruit pulp possess high antioxidant activities (Lim, Mat Junit, 
Abdulla, & Abdul Aziz, 2013; Martinello et al., 2006; Sudjaroen et al., 2005). In 
addition, T. indica extracts have also been shown to reduce the levels of blood 
cholesterol and triacylglycerol in hypercholesterolaemic hamsters (Lim, et al., 2013; 
Martinello, et al., 2006), in obese rats (Azman et al., 2012; Jindal, Dhingra, Sharma, 
Parle, & Harna, 2011), and in humans (Iftekhar, Rayhan, Quadir, Akhteruzzaman, & 
Hasnat, 2006). However, the mechanisms of action at the molecular levels have yet to 
be deciphered.   
 
Analysis of the methanol extract of the tamarind fruit pulp by HPLC revealed 
the presence of (+)-catechin, (–)-epicatechin, procyanidins, naringenin, apigenin, 
luteolin, taxifolin and eriodictyol (Sudjaroen, et al., 2005). The jasmine green tea 
epicatechin has been shown to reduce the levels of triacylglycerol and cholesterol in the 
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sera of hamsters fed with a high-fat diet (Chan et al., 1999). The observed 
hypolipidaemic effects of epicatechin were postulated to involve inhibition of the 
absorption of dietary fat and/or cholesterol or through the reabsorption of bile acids 
since it did not inhibit liver HMG-CoA reductase (Chan, et al., 1999). It was also shown 
that tea catechins like epigallocatechin gallate (EGCG) and epigallocatechin (EGC) 
were able to activate PPARα (K. Lee, 2004), a nuclear receptor that promotes fatty acid 
oxidation and is also a target for the hypolipidaemic fibrates. Naringenin from 
grapefruit was shown to regulate lipid metabolism through partial activation of PPARα 
(Goldwasser et al., 2010). Another study showed that the procyanidin B1 flavangenol 
extracted from pine bark was able to enhance fatty acid oxidation (Shimada et al., 
2012). This suggests that T. indica fruit extract may have exerted its hypolipidaemic 
effect through regulating nuclear receptors such as peroxisome proliferator-activated 
receptor (PPAR) and liver X receptor (LXR). Earlier studies have also shown that 
proanthocyanidins, which constitutes more than 73 % of the total phenolic content of T. 
indica extract (Sudjaroen, et al., 2005), were able to modulate the activation of 
LXR/RXR (Jiao, Zhang, Yu, Huang, & Chen, 2010).   
 
More recently, we have shown that the methanol extract of T. indica fruit pulps 
significantly up-regulated the expression of a total of 590 genes and down-regulated the 
expression of 656 genes in HepG2 cells (Razali, Aziz, & Junit, 2010). Amongst the 
genes that were altered in expression were those that encode proteins associated with 
lipoprotein metabolism, including ApoA-I, ApoA-IV, ApoA-V and ABCG5 but not the 
HMG-CoA reductase. Both ApoA-I and ABCG5 are involved in the reverse cholesterol 
transport, where the latter, together with ABCG8, are involved in the hepatobiliary 
cholesterol secretion.  
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1.1 Objectives  
The main objective of this study is to further investigate the mechanism of 
action of the lipid-lowering effect of T. indica fruit pulp extract. Previous microarray 
study by Razali et al. (2010) revealed that T. indica fruit significantly regulated genes 
involved in lipid metabolism and antioxidant activities; however the molecular 
mechanism has yet to be deciphered. Thus this study was designed as a continuation 
from the previous study.  
 
Therefore, the objectives of this study are to 
1) hypothesise a lipid-lowering mechanism of T. indica fruit by performing 
proteomic analyses on cell lysate and secreted proteins of HepG2 cells treated 
with T. indica fruit extract. 
2) evaluate the lipid-lowering effect of T. indica fruit extract on steatotic HepG2 
cells by comparing to a commercial lipid-lowering drug. 
3) verify the lipid-lowering hypothesis by examining the global gene expression of 
T. indica-treated steatotic HepG2 cells. 
 
The integration of the proteomic and transcriptomic approaches may help to 
elucidate and provide a better insight into the relevant molecular pathways associated 
with the multi-functional effects of T. indica fruit pulp.  
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CHAPTER 2  
LITERATURE REVIEW 
 
2.1 Significance of lipid-lowering studies 
 Hyperlipidaemia is characterised by elevated levels of any or all lipids in the 
blood. Hyperlipidaemia is generally classified into 2 subtypes, primary or secondary.  
The primary or familial hyperlipidaemia is usually caused by genetic abnormalities 
while the secondary or acquired hyperlipidaemia is normally a condition caused by 
underlying disorders like diabetes that leads to altered plasma lipid or lipoprotein 
metabolism (Chait & Brunzell, 1990). Hyperlipidaemia is also characterised based on 
the type of lipid that is elevated in the blood, i.e. hypercholesterolaemia, 
hypertriglyceridaemia or combined hyperlipidaemia.  
 
Hyperlipidaemia, particularly hypercholesterolaemia is associated with diseases 
like cardiovascular diseases, which is the leading cause of death in the world (WHO, 
2012). In America, 71 million adults (33.5 %) have high LDL cholesterol and only 1 out 
of every 3 adults with high LDL cholesterol has the condition under control while
 
less 
than half of adults with high LDL cholesterol got treatment (CDC, 2011). Individuals 
with high total cholesterol have approximately twice the risk of heart disease than those 
with optimal levels. The average total cholesterol level for adult Americans is about 200 
mg/dL, which is borderline high risk (Roger et al., 2012) while in Malaysia, the number 
of individuals suffering from high cholesterol rose from 20.7 % in 2006 to 35.1 % in 
2011 (NHMS, 2011). This could be attributed to the sedentary lifestyles and 
consumption of food high in fat content.  
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The liver is the major site for fatty acid oxidation in mammals. Decreased 
turnover of hepatic lipid droplets can lead to the development of fatty liver disease in 
man (Greenberg et al., 2011). Recently, the rapid rise in the prevalence of obesity and 
diabetes in the general population has contributed to a parallel increase in “non-
alcoholic fatty liver disease” (NAFLD) in many parts of the world. It is currently 
estimated that up to 46 % of the adult U.S. population may have hepatosteatosis (C. D. 
Williams et al., 2011). Presently, there are no effective drug therapies for NAFLD, now 
considered a risk factor for Type II diabetes (Anstee, Targher, & Day, 2013). 
 
2.2 Lipid-lowering mechanisms  
2.2.1 Commercial lipid-lowering drugs 
 Other than changing to a healthier lifestyle such as exercising regularly and 
reducing fat intake in food, drugs are also prescribed to aid in the lipid-lowering 
process. Generally, the lipid-lowering drugs exert their effects by reducing cholesterol 
biosynthesis, increasing fatty acid oxidation, increasing lipid clearance or inhibiting 
lipid uptake from food. The most common lipid-lowering drugs are classified mainly 
into 2 groups, statins and fibrates.  
 
Statins are a class of lipid-lowering drug that inhibits the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, a key rate-limiting enzyme 
involved in the cholesterol biosynthetic pathway. As structural analogues of HMG-
CoA, statins inhibit HMG-CoA reductase competitively with an affinity of about 1,000-
10,000 times greater than its natural substrate. The first generation of statins, mevastatin 
and lovastatin, were first discovered in fungi. The second-generation and third-
generation statins such as simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin 
and pitavastatin were either modification from the first-generation statins or chemically 
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synthesised in the laboratory (Steinmetz, 2002). Besides inhibiting the cholesterol 
biosynthetic pathway, statins were also reported to lower plasma cholesterol indirectly 
through the up-regulation of LDL receptor (Vaziri & Liang, 2004).  
 
While statins are mainly used to lower plasma cholesterol level, fibrates are the 
primary drugs used to treat hypertriglyceridaemia. Fibrates are peroxisome proliferator-
activated receptor (PPAR) agonists. PPARs are a group of nuclear receptors that govern 
many metabolic processes such as lipid metabolism, glucose regulation and energy 
production. There are three isoforms of PPARs, PPARα, PPARγ and PPARβ/δ. Fibrates 
exert their lipid-lowering effects by enhancing beta oxidation of fatty acids. The first 
fibrate, clofibrate was discovered in Japan (Ozawa & Ozawa, 2002), and subsequently 
other fibrate derivatives such as bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil 
were developed. Different fibrates act on different PPAR isoforms, for example 
fenofibrate and clofibrate have a 10-fold selectivity towards PPARα than PPARγ 
(Willson & Wahli, 1997). On the other hand, bezafibrate is a pan-agonist which 
activates all three PPARs with similar potency. However, only fenofibrate and 
gemfibrozil are used in treating humans as their effects were milder as compared to 
other fibrates, which were reported to cause hepatomegaly and tumour formation in the 
liver of rodents after prolonged usage (Gray, Beamand, Lake, Foster, & Gangolli, 1982; 
Lazarow, Shio, & Leroy-Houyet, 1982; Leighton, Coloma, & Koenig, 1975; M. S. Rao, 
Subbarao, & Reddy, 1986; Reddy & Krishnakantha, 1975).  
 
Besides these two main lipid-lowering drugs, other lipid-lowering drugs are 
used either stand-alone or with statin/fibrate to treat hyperlipidaemia. Ezetimibe is used 
to lower cholesterol by inhibiting intestinal cholesterol absorption (Vasudevan & Jones, 
2005). Bile acid sequestrants like cholestyramine, colestipol, and colesevelam are also 
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prescribed to lower plasma cholesterol level. These bile acid sequestrants increase the 
rate of bile acid excretion and therefore promote cholesterol conversion to bile acid 
(Steinmetz, 2002). Apart from these, microsomal triglyceride transfer protein (MTTP) 
inhibitor like lomitapide was also used to treat familial hypercholesterolaemia (Perry, 
2013; Raal, 2013). Niacin and its derivatives which are commonly used as supplements 
are also prescribed to lower lipid by modifying lipoproteins (Vasudevan & Jones, 
2005).  
 
2.2.2 Alternative medicine to treat hyperlipidaemia 
 As mentioned earlier, the mainstay to treat hyperlipidaemia is mainly through 
weight reduction, dietary changes, exercise and lipid-lowering drugs. However, these 
oral medications may inevitably lead to adverse effects. High doses of statins have been 
reported to cause myositis and myalgia, possibly caused by dose-dependent reduction of 
coenzyme Q10 (Golomb & Evans, 2008). Fibrates are associated with a slightly 
increased risk (<1.0 %) for myopathy, cholelithiasis, and venous thrombosis (Davidson, 
Armani, McKenney, & Jacobson, 2007). In view of this matter, medicinal plants have 
garnered much attention due to their generally milder, if any, adverse effects that may 
result from the consumption. Epidemiological studies had also shown that high intake 
of fruits and vegetables coupled with low consumption of trans-fat, cholesterol, 
saturated fat and salt reduced the risk of CVD (Bazzano et al., 2002; Bendinelli et al., 
2011; Joshipura et al., 2001). This finding is also supported by the number of deaths 
worldwide associated with low fruit and vegetable consumption (WHO, 2009).  
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2.2.2.1 Flavonoids 
Flavonoids are a family of phenolic compounds with strong bioactivities that are 
present in fruits, vegetables, and herbs. More than 5000 distinct flavonoids have been 
identified in plants, and several hundreds are known to occur in commonly consumed 
fruits, vegetables, grains, herbal products, and beverages. Structurally, flavonoids have 
a common basic chemical structure that consists of 2 aromatic rings linked by a 3-
carbon chain that forms an oxygenated heterocyclic ring. Differences in the generic 
structure of the heterocyclic ring, as well as the oxidation state and functional groups of 
the ring, classify flavonoids as flavonols, flavan-3-ols (flavans), flavanones, flavones 
and isoflavones  (Erdman et al., 2007).  
 
Flavonols are the most widespread flavonoids in foods, and the most prominent 
flavonols in food are quercetin and kaempferol (Erdman, et al., 2007). Red wine and tea 
can also contain a significant amount of flavonols. Flavan-3-ols are present in many 
fruits such as grape products, teas, cocoa, and chocolate. They are found either as 
monomers (epicatechin and catechin) or oligomers (e.g., proanthocyanidins). Catechin 
and epicatechin are the main flavan-3-ols in fruits and cocoa. Flavanones are present in 
high concentrations in citrus fruits. The main aglycones in citrus are naringenin, 
hesperetin, and eriodictyol. In contrast, flavones are less common than flavonols in 
fruits and vegetables. The major flavones in food are luteolin and apigenin. Parsley and 
celery are the primary food sources. Soy and soybean-derived products are the main 
sources of isoflavones, which are structurally analogous to oestrogens. The 3 common 
soybean isoflavones are genistein, daidzein, and glycitein. 
 
Flavonoids are excellent antioxidants (Rice-Evans, 2001), and because of their 
antioxidant activities as well as their abundance in fruit and vegetables, they may partly 
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contribute to the health benefits of plant foods (Arts & Hollman, 2005). Many 
flavonoids are reported to exhibit hypolipidaemic properties. Green tea, which is rich in 
catechin and epigallocatechin gallate, has been shown to lower triglyceride and 
cholesterol in humans and rats (Bursill & Roach, 2006; Nagao et al., 2005; Richard et 
al., 2009; Unno et al., 2005). Naringenin-rich-ethyl acetate fraction of fenugreek seeds 
was also reported to possess lipid-lowering activities when fed to high-cholesterol-fed 
rats (Belguith-Hadriche et al., 2010). The famed resveratrol from red wine has also 
garnered much attention for its cardioprotective and anticarcinogenic potential 
(Boddicker, Whitley, Davis, Birt, & Spurlock, 2011; Guerrero, Garcia-Parrilla, Puertas, 
& Cantos-Villar, 2009; Pal et al., 2003; Szmitko & Verma, 2005). Proanthocyanidin-
rich grape seed extract has also been reported to lower lipid (Yamakoshi, Kataoka, 
Koga, & Ariga, 1999). 
 
2.2.2.2 Other plant compounds with hypolipidaemic effect 
 There are a few well known natural products that possess hypolipidaemic effects 
and red yeast rice is one of them. It has been traditionally used as food and medicine for 
centuries in China to lower cholesterol, improve blood circulation and help digestive 
problems (Monograph. Monascus purpureus (red yeast rice), 2004; J. Wang et al., 
1997). It is made by fermenting a type of yeast, Monascus purpureus over red rice. 
Several studies had shown that red yeast rice was able to lower high cholesterol (Becker 
& Gordon, 2011; Cicero et al., 2013; Feuerstein & Bjerke, 2012; Venero, Venero, 
Wortham, & Thompson, 2010). In a meta-analysis involving 9625 patients in 93 
randomised trials, 3 different commercial preparation of red yeast rice produced a mean 
reduction in total cholesterol of 0.91 mmol/L, LDL-cholesterol of 0.73 mmol/L, 
triglyceride of 0.41 mmol/L and a mean rise in HDL-cholesterol of 0.15 mmol/L (J. Liu 
et al., 2006). The active compound that attributes to the lipid-lowering activities is 
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monacolin K, a compound identical to lovastatin (J. Ma, et al., 2000). As lovastatin is a 
prescription drug, the Food and Drug Administration (FDA) considered monacolin K as 
a drug and prohibited selling of red yeast rice that contains monacolin K. However 
since monacolin K is not listed in the label, the presence of monacolin K in red yeast 
rice supplements remains ambiguous (Childress, Gay, Zargar, & Ito, 2013).  
 
 Berberine is another effective lipid-lowering agent. It is an isoquinoline alkaloid 
that can be extracted from Goldenseal (Hydrastis canadensis), Oregon grape (Berberis 
aquifolium), Barberry (Berberis vulgaris), and Chinese Goldthread (Coptis chinensis). 
Two other berberine-containing plants that are familiar to practitioners of Chinese 
medicine are Phellodendron chinense and Phellodendron amurense. In 2004, a study on 
berberine treatment on 32 hypercholesterolaemic patients reduced serum cholesterol by 
29 %, triglycerides by 35 %, and LDL-cholesterol by 25 % (Kong et al., 2004). Another 
study in 2009 reported that berberine was able to prevent the development of fatty liver 
in rats (W. S. Kim et al., 2009). This was followed by a randomised controlled trial of 
60 humans with fatty liver disease. Patients given 0.5 g berberine twice per day showed 
improvement in their liver ultrasounds and this was accompanied with lowered serum 
triglyceride and cholesterol (Xie, Meng, Zhou, Shu, & Kong, 2011). The lipid-lowering 
activities of berberine is attributed to its ability to activate adenosine monophosphate-
activated protein kinase (AMPK) (Cheng et al., 2006; Y. S. Lee et al., 2006; Q. Wang et 
al., 2011). Since AMPK regulates an array of biological activities that normalise lipid, 
glucose and energy imbalances, its activation is especially useful in treating metabolic 
syndromes that includes hyperglycaemia, diabetes, lipid abnormalities and energy 
imbalances (Srivastava et al., 2012).  
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2.3 Tamarindus indica (T. indica) 
2.3.1 Description of T. indica 
Tamarindus indica or T. indica (Figure 2.1) is a pantropical fruit tree that 
originates from Africa. It is a large evergreen tree (up to 24 m in height and 7m in girth) 
that bears fruit with ligneous pod containing sticky flesh with black, hard seeds. Its 
leaves have alternate, compound, with 10-18 pairs of opposite leaflets and the shape of 
leaflets are narrowly oblong. It bears small pale yellow or pinkish flowers. The fruit pod 
can be straight or curved, and is velvety and rusty-brown in colour. The shell of the pod 
is brittle and the seeds are embedded in a sticky edible pulp. Each pod contains 3-10 
seeds, approximately 1.6 cm long, irregularly shaped, and testa hard, shiny, and smooth 
(Bhadoriya, et al., 2011). 
 
 
Figure 2.1: (From the left) Tamarindus indica fruit pulp seeds, skin, flesh and leaves. 
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2.3.2 Taxonomical classification  
T. indica is categorised as a monospecific genus in the family of Leguminosae 
(Bhadoriya, et al., 2011). The following is the taxonomical classification of T. indica. 
Kingdom: Plantae 
Phylum: Spermatophyte 
Class: Angiosperm 
Sub class: Dicotyledone 
Family: Leguminosae 
Subfamily: Caesalpiniaceae 
Genus: Tamarindus 
Species: indica 
 
2.3.3 Chemical composition of T. indica fruit pulp 
T. indica fruit pulp is characterised by its sweet and sour taste. Its acidity is 
mostly attributed to tartaric acid (2,3-dihydroxybutanedioic acid, C4H6O6, a 
dihydroxydicarboxylic acid), which remains in the pulp upon ripening. However when 
added together with the increasing sugar levels during ripening, the fruit tasted 
simultaneously sweet and acidic (Lewis & Neelakantan, 1964). Other organic acids that 
were found in the tamarind fruit pulp are malic acid, ascorbic acid, oxalic acid, succinic 
acid, citric acid and quinic acid (Ishola, Agbaji, & Agbaji, 1990; Lewis & Neelakantan, 
1964; Lewis, Neelakantan, & Bhatia, 1961).  
 
The ripe fruit also contains saponins, flavonoids, tannins, invert sugar, pipecolic 
acid, citric acid, nicotinic acid, 1-malic acid, vitexin, isovitexin, orientin, isoorientin, 
vitamin B3, volatile oils (geranial, geraniol, limonene), cinnamates, serine, beta-alanine, 
pectin, praline, phenylalanine, leucine, potassium and lipids (Dalimartha, 2006). 
14 
 
Sudjaroen et al. (2005) reported that the methanol extract of tamarind fruit pulp was 
dominated by proanthocyanidins (73.4 %) in various forms (+)-catechin (2.0 %), 
procyanidin B2 (8.2 %), (-)-epicatechin (9.4 %), procyanidin trimer (11.3 %), 
procyanidin tetramer (22.2 %), procyanidin pentamer (11.6 %), procyanidin hexamer 
(12.8 %) along with taxifolin (7.4 %), apigenin (2.0 %), eriodictyol (6.9 %), luteolin 
(5.0 %) and naringenin (1.4 %). 
 
2.3.4 T. indica applications 
2.3.4.1 Food and product 
T. indica fruit pulp is commonly used in culinary to add flavour for its sweet and 
sour taste. Besides adding the juice of the fruit pulp into cooked dishes, it is also eaten 
raw or made into food products. In Malaysia, it is most commonly used as a condiment 
in many local cuisines. Besides this, the fruit is also made into juice, jam, candy and 
syrup. A sweeter cultivar of the fruit produced mainly in Thailand, is usually eaten 
fresh.  
 
In other parts of Asia, the immature green pods are often eaten by children and 
adults dipped in salt as a snack. More commonly, the acidic pulp is used as a favourite 
ingredient in culinary preparations such as curries, chutneys, sauces, ice cream and 
sherbet in countries where the tree grows naturally (Little & Wadsworth, 1964). In Sri 
Lanka, tamarind is widely used in cuisine as an alternative to lime and also in pickles 
and chutneys. It is also used in India, to make ‘tamarind fish’, a sea-food pickle, which 
is considered a great delicacy. The juice is also an ingredient of Worcestershire and 
other barbecue sauces, commonly used in European and North American countries. In 
the Philippines, Sri Lanka and Thailand, fibres are removed from the fruit pulp, which 
is mixed with sugar, wrapped in paper and sold as toffees. The pulp is also used to make 
sweet meats mixed with sugar called ‘tamarind balls’ (Purseglove, 1987); in Senegal, 
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they are called ‘bengal’. Similarly in India, the pulp is eaten raw and sweetened with 
sugar. 
 
2.3.4.2 Medicinal uses 
 The use of plants as herbal medicines had been practiced since the ancient times. 
In fact, it is still being used as the main medicine in many countries especially in 
countries where medical treatments are not easily accessible. In other parts of the world, 
traditional medicine commonly serves as a complementary or alternative treatment to 
the available medical treatment. Traditional medicine is favoured because it is 
commonly believed to have minimal side effects as compared to current medical 
treatments. The use of plants in traditional medicine can be explained by 
physiologically active phytochemical compounds of a species and also by its ascribed 
meaning in a culture (Etkin, 1986). Medicinal plants with a long history of safe and 
effective use are likely to have a pharmaceutical effect (Tabuti, 2008).  
 
T. indica fruit has been used as a traditional medicine to treat several ailments in 
countries where the tree is indigenous. In Africa, tamarind has been used either on its 
own or with other plants to treat diseases of the circulatory system, digestive system, 
genitourinary system, sensory system, infections or infestations, injuries, mental 
problems and pregnancy-related disorders (Table 2.1). In traditional Thai medicine, the 
fruit of the tamarind is used as a digestive aid, carminative, laxative, expectorant, and 
blood tonic (Farnsworth & Bunyapraphatsara, 1992). 
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Table 2.1: Medicinal uses of tamarind fruit in Africa summarised from a review by 
Havinga et al. (2010) 
Disorder 
category 
Medicinal 
use 
Preparation Country Ethnicity 
Unspecified Fortifiant Add decoction of the leaves 
and fruits to millet porridge 
and drink 
Benin and 
Senegal 
Dendi, 
Fulani, 
Gourmant
ché, 
Haussa 
 Jaundice A handful of fruits is 
macerated with powdered 
Cassia siberiana bark and the 
extract drunk 
Nigeria Hausa 
Circulatory Heart 
disease 
Chew unripe fruit with onion 
and swallow to treat 
palpitations 
Benin Dendi, 
Fulani, 
Gourmant
-ché, 
Haussa 
Digestive 
system 
Abdominal 
pain 
Beverage Madagascar Veso-
Sakalava 
Malagasy 
  Fruit or root and bark soaked in 
water for stomach disorders 
Kenya and 
Nigeria 
Suiei 
Dorobo 
Hausa 
 Laxative Decoction of the fruit, 
administered orally 
Togo - 
  Eaten raw or prepared as 
‘lavement’ for constipation 
Madagascar - 
  Processed into laxative 
beverage 
Mali - 
  Infusion or decoction of the 
fruit 
Sudan Several 
tribes 
involved 
  Drink macerate of fruits in 
water, for constipation 
Nigeria Fulani 
  Sweetmeat called ‘bengal’ 
prepared from the fruit pulp by 
Wolof of Senegal. Used as 
laxative mixed with honey or 
lime juice 
West Africa - 
  Mix fruit pulp with water and 
add sugar for taste, then drink 
as laxative, purgative or for 
constipation 
Benin Dendi, 
Fulani, 
Gourmant
-ché, 
Haussa 
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Table 2.1, continued 
 
   
Disorder 
category 
Medicinal 
use 
Preparation Country Ethnicity 
  The fruits are welled with 
leaves of Combretum 
micranthum until the water has 
taken an acid taste, then drink. 
Also used to treat nausea. 
Mali Dogon 
  Crushed and soaked for half a 
day in water with a little salt 
before administration 
Cote 
d’Ivoire and 
Burkina 
Faso 
- 
  Mashed fruit pulp is mixed 
with water or sanglé, a 
beverage based on milk, and 
given to drink with or without 
salt 
Senegal - 
Genitouri-
nary system 
Aphrodisiac - Cote 
d’Ivoire 
- 
Infections/ 
Infestations 
Cold Mix with water and add sugar 
for taste, then drink 
Benin Dendi, 
Fulani, 
Gourmant
-ché, 
Haussa 
 Fever Fruit pulp used in the treatment 
of fever for refreshment and to 
quench thirst. Often followed 
by rubbing the roughly 
dehusked pods with some 
vinegar on to the body of the 
feverish patient 
Senegal - 
  Beverage Madagascar Veso-
Sakalava 
Malagasy 
  Drink boiled, evaporated pulp 
that is partly dissolved in water 
All over 
Soudan 
- 
 Malaria Infusion or decoction of the 
fruit 
Sudan Several 
tribes 
involved 
  Mix fruit with water and add 
sugar for taste, then drink 
Benin 
 
Dendi, 
Fulani, 
Gourmant
ché, 
Haussa 
 Helminth 
infections 
(parasitic 
worms) 
Vermifuge not specified 
 
Nigeria - 
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Table 2.1, continued 
 
   
Disorder 
category 
Medicinal 
use 
Preparation Country Ethnicity 
 Microbial 
infections 
Soaked fruit, oral 
administration to treat 
infectious diseases including 
sex transmitted diseases 
Guinea Malinké 
or Sousou 
 Sleeping 
sickness 
Boil leaves and give to animals 
to drink; grind fruits with raw 
beans and give animals to feed 
Nigeria Hausa, 
Fulani 
 Leprosy In leprosy treatment to enhance 
the emetico-cathartic properties 
of Trichilia emetica; A mixture 
of Cantharides-powder and 
tamarind pulp is taken by the 
patient before the syphilis 
treatment starts 
Senegal Wolof 
 
Injuries Wounds Leaf and fruit decoction used 
as mouthwash for lesions and 
sores 
Burkina 
Faso 
 
 
Mossi 
 
Mental Sleep Mix with water and add 
pepper, then drink 
Benin Dendi, 
Fulani, 
Gourmant
-ché, 
Haussa 
Nutritional Scurvy Not specified Kenya - 
Pregnancy, 
birth, 
puerperium 
Lactation To increase lactation, eat Kunu 
(a kind of porridge) prepared 
with fruit of tamarind and 
Ximenia americana or drink a 
macerate of tamarind fruits in 
water 
Nigeria Fulani 
 
 
 Pregnancy Drink macerate of fruits in 
water to relieve pain upon 
labour 
Nigeria 
 
Fulani 
 
Sensory 
system 
Vertigo Mix with water and add sugar 
for taste, then drink 
Benin Dendi, 
Fulani, 
Gourmant
-ché, 
Haussa 
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2.3.5 Current studies of T. indica  
T. indica fruit pulp has been shown to have good antioxidant activities. 
Sudjaroen et al. (2005) reported that the methanolic extract of T. indica fruit pulp has 
better antioxidant capacity than the seeds even though the total phenolic content of the 
seed is much higher than the T. indica fruit pulp. Lim et al. (2013) showed that the fruit 
had significant amount of phenolic (244.9 ± 10.1 mg GAE/extract) and flavonoid (93.9 
± 2.6 mg RE/g extract) content and possessed considerable antioxidant activities. 
Similarly, Martinello et al. (2006) observed that the fruit pulp extract of T. indica 
showed radical scavenging ability in vitro, and improved the efficiency of the 
antioxidant defense system in vivo when the tamarind extract was administered at a 
concentration of 5 %. Other studies were also in agreement with the considerable anti-
oxidant activities of tamarind fruit extract (Khairunnuur et al., 2009; Lamien-Meda et 
al., 2008; Ramos et al., 2003).  
 
Besides this, the fruit has been shown to have anti-bacterial properties. Nwodo 
et al. (2011) reported that the aqueous and ethanolic extracts of T. indica fruit pulp 
exhibited wide spectrum of antibiotic properties. The methanol and hexane extracts of 
the fruit had antibacterial effect too (Adeola, Adeola, & Dosumu, 2010). Others studies 
(Dabur et al., 2007; Melendez & Capriles, 2006) also supported the antibacterial 
activities of tamarind fruit extract. In a recent study, the fruit has also been 
demonstrated to reduce the secretion of aflatoxin from Aspergillus flavus and A. 
parasiticus, although the aqueous extract did not inhibit their growth (El-Nagerabi, 
Elshafie, & Elamin, 2013). Koudouvo et al. (2011) reported that the aqueous extract of 
tamarind fruit exhibit antiplasmodial activity. 
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T. indica fruit has also been shown to exhibit hypolipidaemic effects. The crude 
extracts from the fruits had been shown to have a lipid-lowering effect in 
hypercholesterolaemic hamsters (Martinello, et al., 2006), and  in cafeteria diet- and 
sulpiride-induced obese rats (Jindal, et al., 2011). Azman et al. (2012) had reported that 
the aqueous extract of T. indica fruit pulp improved obesity-related parameters in blood, 
liver, and adipose tissue in a rat model and suppressed obesity induced by a high-fat 
diet, possibly by regulating lipid metabolism and lowering plasma leptin and fatty acid 
synthase (FAS) levels. A similar effect was reported by Lim et al. (2013) in which the 
methanol extracts of T. indica fruit had high content of phenolic and flavonoid 
compounds and possessed antioxidant activities and lowered triglyceride, cholesterol 
and LDL but not HDL in hyperlipidaemic hamsters. The hypolipidaemic results were in 
agreement with the human study where the dried and pulverised T. indica fruits, 
significantly reduced both total cholesterol and LDL-cholesterol levels in humans 
(Iftekhar, et al., 2006). In vitro study on HepG2 cells by Razali et al. (2010) showed that 
the methanol extract of T. indica fruit pulp significantly regulated thousands of genes 
and many of which were involved in cholesterol synthesis and lipoprotein metabolism. 
 
 Tamarind fruit was shown to ameliorate fluoride toxicity in rats (Dey, Swarup, 
Saxena, & Dan, 2011) and in rabbits (Ranjan, Swarup, Patra, & Chandra, 2009). It has 
also been shown to delay progression of fluorosis by enhancing urinary excretion of 
fluoride (Khandare, Rao, & Lakshmaiah, 2002). Besides this, it also exhibits anti-
spasmolytic effect in rabbits (Ali & Shah, 2010) and anti-nociceptive activities in 
rodents (Khalid et al., 2010). Rimbau et al. (1999) had also reported anti-inflammatory 
effect of the fruit. Landi Librandi et al. (2007) determined the effect of T. indica fruit 
extract on the complement system (CS) in vitro and in vivo; the hydroalcoholic extract 
increased complement components and complement lytic activity in vitro, but had no 
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effect on the CS in vivo. Additional analysis and efforts to isolate the compounds of the 
extract that act on the CS could lead to its therapeutic use as an inflammation 
modulator. 
 
2.4 Foodomics 
 Foodomics is a relatively recent scientific discipline that studies food and 
nutrition with the use of advance “omics” technologies (Herrero, Simo, Garcia-Canas, 
Ibanez, & Cifuentes, 2012). Traditionally, the main aim of food analysis is to ensure 
food safety. Analytical chemistry was, and is still the main tool being used to achieve 
this goal. However there is also a general trend in food science to link food and health. 
Therefore, food is considered not only a source of energy but also an alternative to 
prevent diseases. This has led to the introduction of food analysis using advanced 
“omics” approaches known as foodomics. Foodomics enables us to study the effect of 
food ingredient(s) at the genomic/transcriptomic/proteomic and/or metabolomic level, 
making possible new investigations at the molecular level on food bioactivity and its 
effect on human health. Generally, foodomics is presented as a global discipline in 
which food (including nutrition), advanced analytical techniques (mainly omics tools), 
and bioinformatics are combined (Figure 2.2). This opens up a whole new window to 
study food once thought to require multidisciplinary expertise to achieve, as traditional 
food analysis mostly involve analytical chemistry. This had also permitted us to address 
issues like understanding the beneficial or adverse effects of a certain bioactive food 
compound on cellular or molecular level using nutrigenomic approaches (Wittwer et al., 
2011); determining the effect of bioactive food constituents on crucial molecular 
pathways (Corella et al., 2011);  understanding the gene-based differences among 
individuals in response to a specific dietary pattern following nutrigenetic approaches 
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(C. M. Williams et al., 2008); establishing the global role and functions of gut 
microbiome (Kau, Ahern, Griffin, Goodman, & Gordon, 2011) and etc.  
 
Figure 2.2: Effects of dietary nutrients on nucleic acids, proteins and metabolites, a 
typical representation of tools used in foodomics analyses, and the major applications of 
foodomics. (Adapted from Ganesh & Hettiarachchy, 2012 and Garcia-Canas, et al., 
2012) 
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2.4.1 Proteomics  
 Nutriproteomics is one of the “omics” technologies used in foodomics studies. 
Proteomics is the study of nature of proteins and the correlation with their underlying 
biological processes, therefore allowing the identification of the proteins, their 
expressional changes, levels of production, post translational modifications (PTM), 
amino acid substitution and polymorphisms to be determined (Dutt & Lee, 2000; 
Pandey & Mann, 2000). Physiological, pathological and nutritional alterations can play 
a pivotal role in altering the proteome of an individual (Fuchs et al., 2005; H. Kim, 
Page, & Barnes, 2004; J. Wang, Li, Dangott, & Wu, 2006). A key step in proteomics 
analysis is to separate the protein mixtures in order to quantify or characterise it, 
depending on the objective of the study. This can be accomplished either as gel-based 
or gel-free approaches. In the gel-based approach, two-dimensional gel electrophoresis 
and mass spectrophotometry (MS) are used. Basically, the proteins are separated using 
two dimensions, i.e. to separate them based on their isoelectric points and molecular 
mass, in which the latter involves running an SDS-PAGE. Gel-free approach involves 
the direct digestion of proteins in solution and the resulting peptides are resolved using 
liquid chromatography coupled with mass spectrophotometer. More than one type of 
column is often used in the separation of peptides to give better separation, for example 
a strong cation exchange column and reverse-phase HPLC coupled with MS is a 
common setup for gel-free approach. This is also known as the multi-dimensional 
protein identification technology (MudPIT). Both approaches have their pros and cons. 
Gel-based approach allows high throughput analysis and the ability to detect isoforms 
and PTMs, both of which are not achievable through gel-free approach. Gel-free 
approach is more sensitive and needs only a small amount of sample. It also separates 
protein with extreme characteristics (extremes in isoelectric points, molecular weights, 
quantities and hydrophobicity) better (Ganesh & Hettiarachchy, 2012).  
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2.4.1.1 Two-dimensional gel electrophoresis (2D-GE) 
 2D-GE was first introduced by O’Farrell in 1975 (O'Farrell, 1975). It is a robust 
and common technique used to separate protein mixture from cells, tissues, or other 
biological samples. This technique separates proteins in two steps, the first-dimension 
separation, isoelectric focusing (IEF), which separates proteins according to their 
isoelectric points (pI); and the second-dimension separation, sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), which separates proteins according to 
their molecular mass. The advent of 2D-GE has revolutionised proteomic analyses, 
however its application had only started to gain significance with a number of 
developments. In the original technique introduced by O’Farrell, the first-dimension 
separation was carried in carrier-ampholyte-containing polyacrylamide gels cast in 
narrow tubes. This method was improved with the introduction of immobilised pH 
gradient (IPG) strips which significantly increased the resolution and reproducibility of 
first-dimension separation. The improvement in protein identification from the protein 
spot has also contributed to the robustness in 2D-GE application. This includes more 
sensitive mass spectrometry techniques for rapid identification of small amount of 
peptides or proteins; more powerful, less expensive computers and software rendering 
thorough computerised evaluations of highly complex 2D patterns to become 
economically feasible; and protein sequences are being added on a daily basis to 
databases available on the public domain, thus increasing the possibility to identify a 
protein. 
 
2.4.1.2 Protein sample preparation 
 A good protein sample is crucial for any downstream proteomic applications. 
Therefore, protein sample preparation is the key to successful proteomic analysis. 
Generally, a good protein sample should have minimal degradation and this can be 
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achieved by extracting protein at low temperature, the addition of protease inhibitor in 
lysis buffer and avoiding freeze-thawing protein samples multiple times. The protein 
sample should also be free of contaminating substances that will interfere with the 
protein separation such as salts, detergents, nucleic acids and lipids. Besides this, in 
order to achieve a well-focused first-dimensional separation, the protein sample should 
also be completely solubilised, disaggregated, denatured and reduced. This ensures that 
each protein is present in only one conformation and that aggregation and 
intermolecular interaction is avoided. Therefore, all sample preparation solution for 
first-dimension separation will include denaturant, detergent, reducing agents and 
solubilising agent. Urea is a common denaturant used to solubilise and unfold most 
proteins to their fully random conformation, with all ionisable groups exposed to 
solution. Studies have shown that the use of thiourea in addition to urea can improve 
solubilisation, especially membrane proteins (Molloy et al., 1998; Musante, Candiano, 
& Ghiggeri, 1998; Rabilloud, 1998; Rabilloud, Adessi, Giraudel, & Lunardi, 1997). A 
non-ionic or zwitterionic detergent like 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS) is commonly used to ensure complete sample solubilisation 
and to prevent aggregation through hydrophobic interactions. CHAPS is more effective 
for solubilising a wide range of samples than NP-40 or Triton X-100 (Perdew, Schaup, 
& Selivonchick, 1983), both of which were used originally as non-ionic detergent 
before CHAPS (Bjellqvist et al., 1982; O'Farrell, 1975). SDS, a powerful anionic 
detergent, was not recommended as it is charged and forms complexes with proteins. 
Dithiothreitol (DTT) is used as reducing agents to break any disulfide bonds present and 
to maintain all proteins in their fully reduced state. Lastly, carrier ampholytes or IPG 
Buffer is added to enhance solubility by minimising protein aggregation due to charge-
charge interactions.  
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2.4.1.3 First dimension separation (IEF) and second-dimension separation (SDS-
PAGE) 
In first-dimension separation, also known as isoelectric focusing (IEF), proteins 
are separated according to their isoelectric points (pI) using immobilised pH gradient 
(IPG) strips. Proteins are amphoteric in nature, i.e. they are positively charged, 
negatively charged or neutral depending on the pH of their surrounding environment. 
Isoeletric point (pI) is the specific pH at which the net charge of the protein is zero. By 
applying high voltage, typically 8000V, the proteins will move to pH points where their 
net charges are zero, thus separating the protein mixture.  
 
After IEF, the IPG strip is then equilibrated by saturating the IPG strip with SDS 
buffer system required for the second-dimension separation. The equilibration solution 
typically contains buffer, urea, glycerol, reductant, SDS, and dye. An additional 
equilibration step replaces the reductant with iodoacetamide to stabilise the reduced 
proteins. The function of urea and glycerol is to reduce the effects of electroendosmosis 
which will interfere with protein transfer from the strip to the second-dimension gel by 
increasing the viscosity of the buffer (Gorg, Postel, & Gunther, 1988). SDS functions to 
denature proteins and forms negatively charged protein-SDS complexes. This is 
important as the proteins in the IPG strips are neutral in charge and SDS confers the 
proteins negative charge for separation in SDS-PAGE. 
 
 After equilibration, the strip is ready for second-dimension separation, or SDS-
PAGE, which separates proteins according to their molecular mass. The technique is 
performed in polyacrylamide gels containing SDS. The SDS in the sample and gel 
denatures the proteins and confers them in negative charge which will then be separated 
through polyacrylamide gel electrophoresis. Besides SDS, a reducing agent such as 
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DTT is also added to break any disulfide bonds present in the proteins. When proteins 
are treated with both SDS and a reducing agent, the degree of electrophoretic separation 
within a polyacrylamide gel depends largely on the molecular mass of the protein. In 
fact, there is an approximately linear relationship between the logarithm of the 
molecular mass and the relative distance of migration of the SDS-polypeptide complex. 
It should be noted that this linear relationship is only valid for a certain molecular mass 
range, which is determined by the polyacrylamide percentage. The most commonly 
used buffer system for second-dimension SDS-PAGE is the Tris-glycine system 
described by Laemmli (1970). This buffer system separates proteins at high pH, which 
confers the advantage of minimal protein aggregation and clean separation even at 
relatively heavy protein loads. The Laemmli buffer system has the disadvantage of a 
limited gel shelf life. Other buffer systems can also be used, particularly the Tris-tricine 
system of Schagger and von Jagow (1987) for improving resolution of polypeptides 
with molecular mass values below 10 kDa.  
 
2.4.1.4 Visualisation of 2-dimensional (2D) gels 
 There are a few methods that can be employed to visualise a 2D gel. Generally, 
the desirable features of the gel staining method include high sensitivity, wide linear 
range for quantification, compatibility with mass spectrometry, low toxicity and 
environmentally friendly.  
 
The two most common methods used are silver staining and Coomassie staining. 
Silver staining is a sensitive non-radioactive method that is able to detect protein 
amount of below 1 ng. However, it is a complex, multi-step process utilising numerous 
reagents for which quality is critical. By omitting glutaraldehyde from the sensitiser and 
formaldehyde from the silver nitrate solution, the method becomes compatible with 
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mass spectrometry analysis (Shevchenko, Wilm, Vorm, & Mann, 1996), although at the 
expense of sensitivity. Coomassie staining, although 50- to 100-fold less sensitive than 
silver staining, is a relatively simple method compared to silver staining. Coomassie 
blue is preferable when relative amounts of protein are to be determined by 
densitometry. An improved method of Coomassie blue, colloidal staining methods has a 
higher sensitivity which can detect down to 100 ng/protein spot (Neuhoff, Arold, 
Taube, & Ehrhardt, 1988; Neuhoff, Stamm, & Eibl, 1985).  
 
Other staining methods like negative zinc-imidazole staining has a detection 
limit of approximately 15 ng protein/spot (Fernandez-Patron et al., 1998) and is 
compatible with mass spectrometry, but is a poor quantitation technique. Fluorescent 
labelling (Unlu, Morgan, & Minden, 1997) and fluorescent staining (Mackintosh et al., 
2003) provide significant advantages over Coomassie blue or silver staining. 
Fluorescent detection offers increased sensitivity, simple, robust staining protocols, and 
quantitative reproducibility over a broad dynamic range. The method is also compatible 
with mass spectrometry. Autoradiography and fluorography are the most sensitive 
detection methods (down to 200 fg of protein). To employ these techniques, the sample 
must contain protein radiolabeled in vivo using either 
35
S, 
14
C, 
3
H or, in the case of 
phosphoproteins, 
32
P or 
33
P. For autoradiographic detection, the gel is simply dried and 
exposed to X-ray film or- for quicker results and superior dynamic range of 
quantitation- to a storage phosphor screen. Fluorography is a technique that provides 
extra sensitivity by impregnating the gel in a scintillant such as 2,4-diphenyloxazole 
(PPO) prior to drying. 
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2.4.1.5 Further analysis of protein spots 
 After staining, the gels are scanned using a gel scanner. Dedicated software for 
2D-GE application is used to compare and contrast 2D gels. The protein spot of interest 
can be excised and digested using enzyme, typically trypsin, into peptides. The peptides 
are then mixed with matrix-assisted laser desorption ionisation time of flight mass 
spectrometry (MALDI-TOF MS) matrix material, and spotted onto MALDI-TOF MS 
plates. Time-of-flight mass spectrometry is a technique for analysing molecular weights 
based on the motion of ionised samples in an electrical field. In MALDI-TOF MS, a 
matrix-bound sample is bombarded with a pulsed laser beam to generate ions for 
subsequent detection. The MS spectrum generated from these peptides can then be 
identified using public databases such as SWISS-PROT and NCBI. 
 
2.4.2 Transcriptomics 
 Nutritranscriptomics is another “omics” technology used in the foodomics 
studies. Transcriptomics examines the mRNA expression levels in a cell population. 
The most common method used in transcriptomic studies is DNA microarray 
technology. Recently, a technique named RNA-seq which employs next-generation 
sequencing technology emerged as a method of choice to measure the transcriptomes in 
an organism (Z. Wang, Gerstein, & Snyder, 2009), although DNA microarray is still 
being used. In the nutrition field, the global analysis of transcripts could elucidate the 
effect of a nutrient or diet on metabolic pathways; identify potential biomarkers in 
chronic diseases; and determine the impact of a diet and/or a single nutrient on a human 
pathology (Garcia-Canas, et al., 2012; Wittwer, et al., 2011).  
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2.4.2.1 DNA microarray 
 DNA microarray is a useful tool to simultaneously and rapidly examine the 
expression of thousands of genes. Before the advent of DNA microarray, Northern blot 
was used to visualise gene expression of targeted genes. Ever since the establishment of 
microarray two decades ago (DeRisi et al., 1996; Lockhart et al., 1996; Schena, Shalon, 
Davis, & Brown, 1995), it has become one of the most widely used technique to study 
transcriptomes of an organism. A microarray is a glass slide or silicon chip onto which 
DNA molecules (probes) are bound at fixed locations called spots. This allows the 
labelled cDNA transcribed from mRNA of sample of interest to hybridise to the probes, 
which can then be quantified by measuring the fluorescence intensity emitted by the 
labelled cDNA. Generally there are two types of microarray: spotted microarrays like 
cDNA microarray and oligonucleotide microarray, and the Affymetrix GeneChip 
system, which involves direct synthesis of oligonucleotides onto a chip.  
 
2.4.2.2 Types of DNA microarray 
Spotted cDNA microarray was the first widely used microarray technique. In a 
typical spotted microarray, cDNA fragments, representing different genes, are amplified 
using PCR and printed at high density onto microscope glass slides with special surface 
chemistry that allows binding of the spotted DNA. Two different cDNA populations 
derived from independent RNA samples are labelled with red (Cy5) and green (Cy3) 
fluorescent dyes, respectively, and hybridised to the slide. The array is subsequently 
washed and scanned by lasers that excite the different dyes. A fluorescent signal is 
computed for each spot on the array and the ratio of Cy3:Cy5-induced fluorescence for 
each spot corresponds to the relative amount of transcript in the samples. While this 
method is especially useful for examining transcriptomes in organisms that have little or 
no genome sequences, its uniformity across each microarray slides remains challenging 
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due to probes of varying length. This method also measures only one gene per probe as 
compared to Affymetrix GeneChip which has multiple probes for a gene, this impacts 
on the sensitivity of spotted microarray in detecting the genes.  
 
The next microarray technology to emerge involved in situ-synthesised 
oligonucleotide arrays using photolithographic technology (Affymetrix). Affymetrix 
GeneChip technology employs a series of 25-mer oligonucleotides, which are designed 
using a computer algorithm to represent known or predicted open reading frames 
(Lipshutz, Fodor, Gingeras, & Lockhart, 1999). However, it is only limited to 
organisms with a significant amount of genome information. There are between 10 and 
20 different oligonucleotides representing each gene to control for variation in 
hybridisation efficiency due to factors such as GC content. A control for cross-
hybridisation with similar short sequences in transcripts other than the one being probed 
for is a mismatch oligonucleotide next to each oligonucleotide with a single base pair 
change at its centre. Under stringent hybridisation conditions, this control should not 
hybridise to the exact match cDNA. The level of expression of each gene is calculated 
using a procedure provided by the Affymetrix software, which computes the weighted 
average of the difference between the perfect match and mismatch. The high density 
arrays are constructed on silicon wafers using a technique called photolithography and 
combinatorial chemistry. The process used to prepare the arrays is expensive and 
processing requires a proprietary hybridisation station, scanner and software, thus is 
more expensive than the spotted microarrays. The target cDNA is labelled using 
amplified RNA and only a single sample is hybridised to each chip.  
 
 Another technique that uses in situ synthesis oligonucleotide arrays is the ink-jet 
technology by Agilent. Instead of using 25-mer probes like in Affymetrix GeneChips, 
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this technique uses longer oligonucleotide probes (60-mer). Unlike the Affymetrix 
counterpart, this technique is analogous to the spotted cDNA microarray in the sense 
that it only detects one gene per probe as oppose to multiple probes detecting a gene in 
Affymetrix GeneChip technique and it also uses a 2-dye system. Agilent microarrays 
have improved selectivity over conventional spotted cDNA microarray due to increased 
probe length and sequence optimisation. However, this advantage may be compromised 
by relatively high background fluorescence.  
 
2.4.2.3 Normalisation and data analysis 
 DNA microarray data were obtained as scanned image files. Before subjecting 
those files for expression analysis, they have to be normalised to standardise microarray 
data and to differentiate between real (biological) variations in gene expression levels 
and variations due to the measurement process. Generally, normalisation of data from 
two-colour microarray systems like spotted cDNA microarray is achieved by linear 
regressions. This process requires raw data manipulation, owing to differences in the 
chemistry of the dyes, before differences in transcript levels can be identified. It is 
necessary to normalise the fluorescence ratios in order to compensate for systematic 
variations (Bilban, Buehler, Head, Desoye, & Quaranta, 2002). Normalisation of 
Affymetrix GeneChip array expression data is often done by utilising the Robust Multi-
array Average (RMA) algorithm. RMA is a method for normalising and summarising 
probe-level intensity measurements from Affymetrix GeneChips. Starting with the 
probe-level data from a set of GeneChips, the perfect-match (PM) values are 
background-corrected, normalised and finally summarised resulting in a set of 
expression measures. The background correction used in RMA is a non-linear 
correction, done on a per-chip basis. It is based on the distribution of PM values 
amongst probes on an Affymetrix array. The normalisation used in RMA is quantile 
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normalisation, which is non-linear method. This usually gives very sharp 
normalisations. Once the probe-level PM values have been background-corrected and 
normalised, they are summarised into a single expression measure per probe-set, per 
chip. The summarisation used is motivated by the assumption that observed log-
transformed PM values follow a linear additive model containing a probe affinity effect, 
a gene specific effect and an error term. For RMA, the probe affinity effects are 
assumed to sum to zero, and the gene expression level is estimated using median 
polishing. Median polishing is a robust model fitting technique that protects against 
outlier probes. 
 
 After normalising the microarray expression data, the data are ready to be 
analysed. The most basic method to analyse the huge amount of microarray expression 
data is to filter them by fold-change when comparing samples with two or more 
different parameters. Often changes of ≥ 1.5-fold may be sufficient to identify a list of 
candidate genes. To further strengthen the fact that the changes in genes identified are 
likely to be due to the defined parameter rather than random fluctuations, one- or two-
way analysis of variance (ANOVA) is performed. ANOVA is performed separately for 
each gene, and only those genes that pass the significance level are retained for further 
analysis. Another method is based on grouping genes that have similar patterns of gene 
expression throughout the whole experiment. There are two ways of grouping, class 
discovery analysis or class prediction analysis. Class discovery analysis is also known 
as unsupervised classification or knowledge discovery. The idea of clustering genes 
together in groups based on iterative pattern recognition or statistical learning methods 
to find an optimal number of clusters in data allows the discovery of new groups that 
otherwise were not reported (Peterson, 2013). Examples of class discover analysis 
include hierarchical cluster analysis, k-means cluster analyses, self-organising maps and 
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model-based cluster analysis (Rimbach, Fuchs, & Packer, 2005). Another clustering 
method is the class prediction analysis or supervised classification. It uses sample 
associated parameters or classes to identify gene lists that can associate unknown 
samples with these parameter or classes (Soinov, 2003). Principle component analysis 
(PCA) is a common method used to reduce the number of dimensions prior to data 
analysis (Peterson, 2013). It identifies the correlations between gene expression profiles 
and attempts to explain a majority of the variance in the entire data set. It is a 
decomposition technique that produces a set of expression patterns that are known as 
principle components. Diagonal or 3D combinations of these patterns can be assembled 
to represent the behaviour of all of the genes in a given data set (Remy & Michnick, 
2003). 
 
2.4.2.4 Validation of microarray analysis 
 As mentioned earlier, DNA microarray is an extremely powerful tool for the 
analysis of gene expression. However it should be noted that there are technical 
limitations that may distort the data analysis. The type (cDNA or oligonucleotide), the 
size (in bp), and the location in the target gene of microarray probes may affect 
efficiency of the hybridisation reaction and thus the ability of the technique to 
accurately detect differences in gene expression levels. Therefore, an additional test or 
assay is normally performed to confirm and increase confidence of the microarray 
expression results. 
 
 Quantitative real-time polymerase chain reaction or qRT-PCR is the most 
common method used to validate microarray results. qRT-PCR allows the continuous 
measurement of products produced during the course of PCR reaction. This can be done 
by using either TAQman based fluorescent probe method or by using Sybr Green to 
detect double stranded DNA products. Both chemistries rely on the detection of product 
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molecule present throughout the numerous cycles occurring during a complete PCR 
reaction. The exponential growth in PCR products is related to the cycle threshold point 
and from this crossing point (CT value), the number of targets present in the input 
sample can be determined. 
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CHAPTER 3  
MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Chemicals 
Merck, Germany:  
i. Sodium carbonate 
ii. Silver nitrate 
iii. Ammonium peroxodisulphate 
iv. EDTA disodium 
v. Potassium hexacyanoferrate (III) 
vi. Sodium hydrogen carbonate 
vii. N,N,N’,N’-Tetramethylethylenediamine (TEMED) 
viii. Iodoacetamide 
ix. Dithiothreitol (DTT) 
x. Urea 
xi. Ammonium hydrogen carbonate 
xii. Acetonitrile 
xiii. Glycine 
xiv. Thiourea 
xv. Isopropanol  
xvi. Sodium acetate trihydrate 
xvii. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)  
xviii. Sodium thiosulphate pentahydrate 
xix. Sodium hydroxide 
xx. Formaldehyde solution 37%  
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xxi. Acrylamide 
xxii. Trifluoroacetic acid (TFA) 
 
Sigma-Aldrich Chemical Company, USA: 
i. Fenofibrate 
ii. Palmitic acid 
iii. Oil Red O 
iv. Gluteraldehyde 
v. Albumin from bovine serum, fatty acid free 
vi. Tris-base 
vii. Trypsin-EDTA 
viii. Trypan blue 
ix. Orange G 
x. Glycerol 
xi. Sterile dimethylsulphoxide (DMSO) 
xii. N,N’-methylenebisacrylamide 
 
GE Healthcare, USA: 
i. Sodium dodecyl sulphate (SDS) 
ii. Glycine 
iii. Drystrip cover fluid 
iv. Immobiline pH gradient (IPG) strips, pH 3-10 NL, 13 cm 
v. IPG buffer, pH 3-10 NL 
 
Hyclone, Australia: 
i. Dulbecco’s modified Eagle medium (DMEM) 
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ii. Foetal bovine serum (FBS) 
iii. 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  (HEPES) 
 
Thermo Scientific, USA: 
i. Halt protease inhibitor cocktail 100X 
ii. Trypsin 
 
Fisher Scientific, UK: 
i. Methanol analytical grade 
ii. Ethanol  
 
Invitrogen, UK: 
i. Ethidium bromide  
 
Vivantis, USA: 
i. Agarose 
 
Flowlab, Australia: 
i. Penicillin and streptomycin 
 
Bio-rad, USA: 
i. Bradford reagent 
ii. Beta-mercaptoethanol 
SRL, India: 
i. Deoxycholic acid sodium salt 
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Oxoid, UK: 
i. Phosphate buffered saline (Dulbecco A) 
 
Calbiochem, USA: 
i. 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 
 
Acros Organics, USA: 
i. Bromophenol blue 
 
Applichem, Germany: 
i. Triton X-100 
 
Applied Biosystems, USA: 
i. Fast SYBR® Green Master Mix 
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3.1.2 Apparatus 
i. Rotary evaporator (Buchi, Switzerland) 
ii. Weighing machine (Denver Instrument, USA) 
iii. Vortex mixer (Labnet, USA) 
iv. Orbital shaker (Biometra, Germany) 
v. Sorvall Legend Micro 17 centrifuge (Thermo Scientific, USA) 
vi. JOUAN CR3i Multifunction centrifuge (Thermo Scientific, USA) 
vii. Sorvall Biofuge Primo R centrifuge ( Thermo Scientific, USA) 
viii. Magnetic stirrer (Thermo Scientific, USA) 
ix. PCR Thermocycler (Biometra, Germany) 
x. Dry Block Heating Thermostat (Biosan, Latvia) 
xi. ELISA Plate Reader (Bio-Rad, USA) 
xii. Hybridization Oven 640 (Affymetrix, USA) 
xiii. Fluidics Station 450 (Affymetrix, USA) 
xiv. GeneQuantpro Spectrophotometre (GE Healthcare, USA) 
xv. Gel Doc 1000/2000 (Bio-Rad, USA) 
xvi. StepOne Real-Time PCR System (Applied Biosystems, USA) 
xvii. Ettan IPGphor III Isoelectric Focusing System (GE Healthcare, Sweden) 
xviii. SE 600 Ruby electrophoresis system (GE Healthcare, Sweden) 
xix. ImageScanner III (GE Healthcare, Sweden) 
xx. Applied Biosystems 4800 Plus MALDI TOF/TOF (Applied Biosystems, 
USA) 
xxi. Vivaspin® 20 ultrafiltration device with 5 kDa molecular weight cut off PES 
membrane (Sartorius Stedim, Germany) 
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3.1.3 Kits 
i. RNeasy Mini Kit (Qiagen, Germany) 
ii. High Capacity RNA-to-cDNA kit (Applied Biosystems, USA) 
iii. RNase-free DNase set (Qiagen, Germany) 
iv. BCA assay (Pierce, Thermo Scientific, USA) 
v. 2D-cleanup kit (GE Healthcare, USA) 
vi. Western Dot 625 Goat Anti-Rabbit Western Blot kit (Invitrogen, USA) 
vii. Triglyceride quantification kit (Abcam, UK) 
viii. Cholesterol/cholesteryl ester quantification kit (Abcam, UK) 
ix. Applause WT-AMP ST System (NuGEN Technologies, USA) 
x. Encore Biotin Module (NuGEN Technologies, USA)  
xi. MinElute Reaction Cleanup Kit (Qiagen, Germany) 
 
3.1.4 Software 
i. Image Master 2D Platinum V 7.0 software (GE Healthcare, Sweden) 
ii. GPS Explorer software (Applied Biosystems, USA) 
iii. MASCOT program (Matrix Science, UK) 
iv. ImageJ software (http://rsb.info.nih.gov/ij/) 
v. Ingenuity Pathways Analysis (IPA) software (Ingenuity® Systems, 
www.ingenuity.com) 
vi. Partek Genomics Suite TM (Partek, USA) 
vii. Microarray Suite 5 software (Affymetrix, USA) 
viii. GeneChip Operating Software (GCOS) (Affymetrix, USA) 
ix. Sequence Detection System (SDS) software (Applied Biosystems, USA) 
x. Quantity One Software (Bio-Rad, USA) 
xi. StepOne Software (Applied Biosystems, USA) 
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xii. Primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
 
3.1.5 Cell culture 
i. Human hepatoblastoma cell line, HepG2 (American Type Culture 
Collection, ATCC) 
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3.2 Methods 
3.2.1 Nomenclature 
Human gene symbols are italicised with all letters in uppercase while mouse or 
rat gene symbols are italicised with the first letter in uppercase followed by all 
lowercase letters. Protein symbols are at uppercase and not italicised. With regards to 
proteomics, in the context of 2D-GE, the terms “protein abundance” and “differentially 
modulated” are used to reflect the variations in protein levels, including transcription 
(up-regulation and down-regulation), post-translational modifications, translocation, 
degradation, accumulation and trafficking (Cohen et al., 2008, Godovac-Zimmermann 
et al., 2005, Nesvizhskii & Aebersold, 2005) that occur when proteomes are perturbed 
in various conditions especially. In contrast, the term “differentially expressed” is more 
tractable and suitable for describing detected protein from MS-based proteomics. 
 
3.2.2 Sampling and sample preparation 
Whole, ripe T. indica fruits were collected from Kedah in the northern region of 
Malaysia. The voucher specimen of the sample with an identification number, KLU 
45976, was deposited in the Rimba Ilmu Herbarium, the University of Malaya. A 
measure of 10 g of T. indica fruit pulp powder was suspended in 200 ml of methanol at 
room temperature. The mixture was then stirred with a magnetic stirrer for 1 h and 
incubated in the dark for 24 h.  The supernatant was filtered with a filter paper. The 
crude extracts of T. indica fruit pulp were obtained after evaporating methanol to 
dryness in a rotary evaporator. 
 
3.2.3 Cell culture and treatment 
HepG2 cells were cultured in Dulbecco’s modified Eagle medium (DMEM), 
with 5 mM glucose, supplemented with 10 % foetal bovine serum (HyClone, Australia), 
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0.37 % (w/v) sodium bicarbonate and 0.48% (w/v) HEPES, pH 7.4, in a CO2 humid 
incubation chamber at 37 °C. To study the effects of methanol extract of T. indica fruit 
pulp on HepG2 cells, the cells were seeded at a density of 9.0 ×10
6
 in 75 cm
2
 flask for 
18–24 h, then the cells were extensively washed with PBS to remove any remaining 
serum. The cells were then incubated in serum-free DMEM with a final concentration 
of 0.02 % DMSO (vehicle) as control and 60 µg/ml methanol extract of T. indica fruit 
pulp as treatment. After 24 h, the secreted proteins and the cell lysate were harvested. 
 
3.2.4 Recovery of secreted proteins from cell culture media 
The medium containing the secreted proteins was collected and centrifuged at 
1000 x g for 5 min to remove cellular debris. The medium was further filtered through 
0.22 µm syringe filter. The supernatant was then concentrated by ultrafiltration through 
a spin column with 5 kDa molecular weight cut off membrane (Sartorius Stedim, 
Germany) at 7000 x g for 2 h. The protein concentration in the concentrated medium 
was then determined using Bradford assay kit (Bio-Rad). 
 
3.2.5 Cell lysate extraction 
The cells were detached using trypsin-EDTA. They were then spun at 261 x g to 
pellet the cells. The pellet was washed with ice-cold PBS twice and thiourea rehydration 
solution (7 M urea, 2 M thiourea, 2 % w/v CHAPS, 0.5% v/v IPG buffer, orange G, 
protease inhibitor) was added to lyse the cells. Vigorous pipetting and sonication were 
performed to ensure the cells were thoroughly ruptured. The mixture was then 
incubated on ice and vortexed every 10 min for a time span of 30 min.  After 
incubation, the mixture was centrifuged at 17,000 x g for 20 min at 4 °C to remove the 
cell debris. The supernatant containing the proteins were then aliquoted and kept at -80 
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°C for downstream application. Protein concentration was determined using Bradford 
assay. 
 
3.2.6 Cell viability 
To ensure that the cell was still above 90% viable after the treatment, the 
percentage of viable cells during secretion period and after treatment was estimated by 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. 
Briefly, cells were plated at a density of 1.5   104 cells per well in a 6-well plate and 
cultured exactly as mentioned. Medium was then removed and 100 μl of 5 mg/ml MTT 
(Merck, Germany) was added to each well. Cells were incubated for 4 h and the MTT 
solution was discarded and the precipitate in each well was resuspended in 2 ml of 
isopropanol. The optical density (OD) of the samples was read at 570 nm.  
 
3.2.7 Two-dimensional gel electrophoresis (2D-GE) 
2D-GE is a method employed to separate proteins based on two dimensions; the 
first dimension separates proteins based on their isoelectric focusing points (pI) using 
immobilised pH gradient (IPG) gel strip, while in the second dimension the proteins 
were separated based on their molecular mass through SDS-polyacrylamide gel 
electrophoresis. The gel can then be stained using Coomassie blue or silver staining to 
visualise the protein spots. The gel is then scanned and image can be analysed for 
downstream application. 
 
3.2.7.1 Sample preparation and rehydration of IPG gel strips 
The optimum amount of protein to load per gel and sample preparation was 
optimised for better separation of proteins. Forty micrograms of secreted protein or cell 
lysate was first cleaned-up using 2D clean-up kit (GE Healthcare, Piscataway, USA). 
46 
 
The resulting protein pellet after cleaning up was reconstituted in 20 µl of thiourea 
rehydration solution (7 M urea, 2 M thiourea, 2% w/v CHAPS, 0.5% v/v pH 3-10 NL 
IPG buffer, Orange G), 80 µl of sample buffer (7 M urea, 2 M thiourea, 4% w/v 
CHAPS, 2% v/v pH 3-10 NL IPG buffer, 40 mM DTT) and topped up to 250 µl with 
thiourea rehydration solution. For cell lysate sample, the sample buffer was slightly 
modified with DTT reduced by half and the addition of DeStreak reagent (GE 
Healthcare, USA). Treated and untreated samples, containing the same protein amount, 
were rehydrated passively for 18 h at room temperature on immobilised pH gradient 
strips (13 cm, non-linear, pH 3-10, GE Healthcare, Uppsala, Sweden). 
 
3.2.7.2 First dimension separation of protein through IEF 
First dimension separation was carried out with Ettan IPGphor III Isoelectric 
Focusing System and a standard strip holder (GE Healthcare, Uppsala, Sweden). 
Isoelectric focusing (IEF) was performed under the following conditions: (i) 500 V, 1 h 
10 min, step and hold; (ii) 1000 V, 1 h, gradient; (iii) 8000 V, 2 h 30 min, gradient and 
(iv) 8000 V, 55 min, step and hold. The temperature was maintained at 20°C and the 
current was kept at 50 µA per strip. The strips were either used immediately for second 
dimension separation or kept in -80 °C for further use. 
 
3.2.7.3 Second dimension separation of protein through SDS-PAGE 
Upon completion of IEF, strips were equilibrated in equilibration buffer (6 M 
urea, 75 mM Tris-HCl, pH 8.8, 29.3 %  v/v glycerol, 2 % w/v SDS, 0.002 % w/v 
bromophenol blue, 1 % w/v DTT) for 15 min. The solution was then discarded and 
replaced with equilibration buffer containing 4.5 % w/v iodoacetamide instead of DTT 
for another 15 min. The second dimension separation was carried out at 15 °C on 12.5 
% SDS slab gels using a SE 600 Ruby electrophoresis system (GE Healthcare, Uppsala, 
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Sweden), with the IPG strips sealed on the top of the gels with 0.5 % (w/v) agarose in 
SDS-electrophoresis buffer (25 mM Tris base, 192 mM glycine, 0.1 % w/v SDS and a 
trace amount of bromophenol blue). SDS-PAGE was run at constant power of 50 V and 
40 µA/gel for 20 min, and then switched to 500 V and 40 µA/gel until the bromophenol 
blue marker was 1 mm away from the bottom of the gel.  
 
3.2.8 Silver staining of gel 
After SDS-PAGE, the gel was fixed in fixing solution (40 % (v/v) ethanol, 10 % 
acetic acid) for 40 min. The solution was discarded and the gel was immersed in 
incubation solution (30 % (v/v) ethanol, 0.5 M sodium acetate, 8 mM sodium 
thiosulphate, 0.13 % (v/v) glutaraldehyde) for 40 min. Gluteraldehyde was added 
freshly prior to gel immersion. The gel was then washed three times in distilled water 
for 5 min. Silver staining solution (5.9 mM silver nitrite, 0.02 % (v/v) formaldehyde) 
was then used to stain the gel. Formaldehyde was only added prior to use. To develop 
the stained gel, developing solution (0.24 M sodium carbonate, 0.2 % (v/v) 
formaldehyde) was added. Formaldehyde was added immediately before use. After 
developing the gel, the reaction was halted by adding the stop solution containing 40 
mM EDTA-Na2.2H20. All the silver staining steps were performed on orbital shaker at 
60 rpm. After staining, the gels were scanned with ImageScanner III (GE Healthcare, 
Uppsala, Sweden). 
 
 For gels to be used for mass spectrophotometry analyses, gluteraldehyde and 
formaldehyde were omitted from the silver staining protocol, but at the expense of 
reduced sensitivity. To compensate with that, the protein amount loaded was doubled 
for gels that were used in mass spectrophotometry analyses. 
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3.2.9 Gel image and data analysis 
The 2D gel images were analysed using the Image Master 2D Platinum V 7.0 
software (GE Healthcare, Uppsala, Sweden). In brief, the 2D gel images were subjected 
to spot detection and quantification in the differential in-gel analyses module. To 
minimise the variations in between gels within the same groups, the protein spots were 
normalised using percentage of volume. Statistically significance (p < 0.05, Student’s t-
test) and presence in all 4 gels were two criteria for the acceptance of the differentially-
expressed protein spots. The selected spots were filtered based on an average expression 
level change of at least 1.5-fold.  
 
3.2.10 In-gel tryptic digestion 
Differentially expressed protein spots were excised manually from the 2D gels, 
and washed with 100 mM NH4HCO3 for 15 min. The gel plugs were then destained 
twice with 15 mM potassium ferricyanide/50 mM sodium thiosulphate with shaking 
until gel plugs became clear. After destaining, the gel plugs were reduced with 10 mM 
DTT at 60 °C for 30 min and alkylated with 55 mM iodoacetamide in the dark at room 
temperature for 20 min. The gel plugs were later washed thrice with 500 µl of 50 % 
ACN/ 50 mM NH4HCO3 for 20 min, dehydrated with 100 % ACN for 15 min and 
SpeedVac the gel plugs till dry. Finally the gel plugs were digested in 6 ng/µl trypsin 
(Pierce, Rockford, IL USA), in 50 mM NH4HCO3 at 37 °C for at least 16 h. Peptide 
mixtures were then extracted twice with 50 % ACN and 100 % ACN respectively and 
finally concentrated using Speedvac until completely dry. The dried peptide was then 
kept in -20 °C or reconstituted with 10 µL of 0.1 % FA prior to desalting using Zip Tip 
C18 micropipette tips (Millipore, Billerica, MA, USA). 
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3.2.11 Mass spectrometry and database searching 
Peptide mixtures were analysed by using a mass spectrometer (Applied 
Biosystems 4800 Plus MALDI TOF/TOF, Foster City, CA, USA). The trypsin digest 
were crystallised with alpha-cyano-4-hydroxycinnamic acid matrix solution (10 mg/ml, 
70 % ACN in 0.1 % (v/v) TFA aqueous solution) and spotted onto a MALDI target 
(192-well) plate. The MS results were automatically acquired with a trypsin autodigest 
exclusion list and the 20 most intense ions selected for MS/MS analysis, with a 
minimum S/N (signal/noise) of at least 25. The collision gas was nitrogen gas and the 
energy was 4.3 kV. Interpretation was carried out using the GPS Explorer software 
(Applied Biosystems, Foster City, CA, USA) and database searching using the in-house 
MASCOT program (Matrix Science, London, UK). Both combined MS and MS/MS 
searches were conducted with the following settings: Swiss-Prot database, Homo 
sapiens, peptide tolerance at 200 ppm, MS/MS tolerance at 0.4 Da, 
carbamidomethylation of cysteine (variable modification) and methionine oxidation 
(variable modifications). 
 
3.2.12 Western blot 
Three of the altered proteins, ethanolamine-phosphate cytidylyltransferase 
(PCYT2), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 10 
(NDUFA10) and ubiquinol-cytochrome-c reductase complex core protein 2 (UQCRC2) 
were selected to be validated using Western blotting. HepG2 cells (3 X 10
6
) were 
treated with 0.06 mg/ml T. indica fruit extract for 24 h. The cells were then trypsinised 
and lysed with RIPA buffer (150 mM NaCl; 50 mM Tris-HCl, pH 7.4; 1 mM EDTA; 1 
% Triton X-100; 1 % sodium deoxycholate; 0.1 % SDS). The total cell lysate proteins 
were quantified using BCA assay kit (Pierce, Rockford, IL, USA). Forty micrograms of 
cell lysate protein was separated on a 12.5 % SDS-PAGE, and the separated proteins 
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were transferred onto a PVDF membrane with 0.45 µm pore size (Thermo Scientific, 
IL, USA) at 100 V, 110 mA for 90 min. The blot was then blocked overnight and 
developed against anti-PCYT2 (ab126142, rabbit polyclonal, Abcam, UK), anti-
NDUFA10 (ab103026, rabbit polyclonal, Abcam, UK), anti-UQCRC2 (ab103616, 
rabbit polyclonal, Abcam, UK) and anti-beta actin (ab8227, rabbit polyclonal, Abcam, 
UK), the loading control using the WesternDot 625 Goat Anti-Rabbit Western Blot kit 
(Invitrogen, Oregon, USA). Quantification of the band intensity was calculated using 
ImageJ software. 
 
3.2.13 Data mining using Ingenuity Pathways Analysis (IPA) software 
The proteomics data were further analysed using the Ingenuity Pathways 
Analysis (IPA) software (Ingenuity
®
 Systems, www.ingenuity.com) to predict networks 
that are affected by the differentially expressed proteins. Details of proteins identified to 
be differentially released, their quantitative expression values (fold change difference of 
at least 1.5) and p-values (p < 0.05) were imported into the IPA software. Each protein 
identifier was mapped to its corresponding protein object and was overlaid onto a global 
molecular network developed from information contained in the Ingenuity Knowledge 
Base. Network of proteins were then algorithmically generated based on their 
connectivity.  Right-tailed Fischer’s exact test was used to calculate a p-value indicating 
the probability that each biological function assigned to the network is due to chance 
alone.  
 
  
51 
 
3.2.14 Lipid Studies 
3.2.14.1 Cell culture and treatment to study lipid-lowering effects of T. indica fruit 
extract in HepG2 cells 
HepG2 cells were cultured in Dulbecco’s modified Eagle medium (DMEM), 
with 5 mM glucose, supplemented with 10 % foetal bovine serum (HyClone, Australia), 
0.37 % (w/v) sodium bicarbonate and 0.48 % (w/v) HEPES, pH 7.4, in a CO2 humid 
incubation chamber at 37 °C. To study the lipid-lowering effects of methanol extract of 
T. indica fruit pulp on HepG2 cells, steatosis was first induced in the cells by culturing 
them in palmitic acid-containing media. The cells were seeded and incubated for 18–24 
h, after which they were treated with 0.3 mM palmitic acid complexed to fatty acid-free 
bovine serum albumin and T. indica fruit extract or 0.1 mM fenofibrate (a positive 
control) or 0.02 % DMSO (vehicle, a negative control). The cells were then incubated 
for 24 or 48 h before various assays were performed. 
 
3.2.14.2 Preparation of palmitic acid/fatty acid-free bovine serum albumin 
complex 
Ten percent fatty acid-free bovine serum albumin (FA free-BSA) was prepared 
by dissolving the FA free-BSA powder in phosphate buffered saline (PBS) and the pH 
was adjusted to 7.0 using 7.5 % (w/v) sodium bicarbonate. The solution was then 
sterile-filtered using a 0.2 µm filter syringe.  
 
A stock solution of 100 mM palmitic acid was prepared by dissolving the 
palmitic acid in 0.1 M NaOH at 70 °C. Before complexing the palmitic acid to the FA 
free-BSA, the 10 % FA free-BSA solution was first incubated at 55 °C, and palmitic 
acid solution was added slowly to the FA free-BSA solution while swirling to achieve 
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the desired concentration. The solution was then sterile-filtered using a 0.45 µm filter 
syringe and kept in -20 °C. 
 
3.2.14.3 Cell viability 
 To assess the cell viability of HepG2 during the treatment, MTT assay was 
performed. Briefly, cells were plated at a density of 216,000 cells per well in a 24-well 
plate. After 24 h, the media was removed and the wells were washed gently with PBS 
twice.  The cells were then incubated for 24 or 48 h in DMEM supplemented with 
different concentrations of palmitic acid/10 % FA-free BSA and treatments with 0.1 
mM fenofibrate or different concentrations of T. indica fruit extract or 0.02 % DMSO 
(vehicle). After incubation, 50 µL of 5 mg/ml MTT (Merck, Germany) was added to 
each well and incubated for another 4 h. The media was then removed and 1 mL of 
isopropanol was added to each well to dissolve the formazan crystal. The optical density 
of the sample was read at 570 nm.  
 
3.2.14.4 Oil Red O staining 
 Oil Red O staining was performed to stain the lipid droplets in the cells. Cells 
were seeded in a 24-well plate and cultured as described in Section 3.2.14.1. After 
removing the media, the plate was rinsed gently with PBS twice and fixed in 10 % 
formalin for 1 h. The formalin was then removed and each well was rinsed gently with 
double distilled water. Sixty percent (v/v) isopropanol was added to each well to fix the 
cells for 5 min. After that, the isopropanol was removed and Oil Red O working 
solution was added to each well to stain the lipid droplets in the cells for 5 min. Before 
viewing, Oil Red O was removed and the plate was rinsed with water until the water 
rinsed off clear.  
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3.2.14.5 Triglyceride quantification 
After treatment, three million of cells were homogenised in 300 µl of 5 % 
Triton-X100 in water and were slowly heated to 90 °C for 5 min. The samples were 
cooled down to room temperature before heating them again to solubilise all 
triglycerides. The samples were then centrifuged for 5 min to remove any insoluble 
materials. Samples were diluted 10-fold with double distilled water before the 
quantification assay using the triglyceride quantification kit (Abcam, UK) was 
performed. Assay was done in triplicate and the data were normalised to the amount of 
protein for each sample to eliminate statistical bias caused by cell death. 
 
3.2.14.6 Cholesterol quantification 
After treatment, three million of cells were dissolved in 500 µl of 
chloroform:isopropanol:Triton X-100 (7:11:0.1) solution. The samples were then 
centrifuged for 5 min at 17,000 x g. The supernatant was then transferred to a new tube 
and air-dried at 50 °C to remove chloroform. After removing the chloroform, the 
samples were put under vacuum to remove traces of organic solvents or until dry. Prior 
to the quantification assay, the dried lipid was reconstituted with 200 µl of cholesterol 
assay buffer and quantitated using the cholesterol/cholesteryl ester quantification kit 
(Abcam, UK). The quantification assay was performed in triplicate and the data were 
normalised to the amount of protein for each sample to eliminate statistical bias caused 
by cell death. 
 
3.2.15 DNA microarray analyses 
3.2.15.1 Total cellular RNA (tcRNA) extraction 
 HepG2 cells were cultured as described in Section 3.2.14.1. The cells were then 
harvested and total cellular RNA (tcRNA) was extracted using the RNeasy mini kit 
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(Qiagen, Germany), and DNase I (Qiagen, Germany) was used to remove 
contaminating DNA. The extracted tcRNA was then quantitated using GeneQuantpro 
Spectrophotometre (GE Healthcare, USA) and the integrity of the tcRNA extracted was 
assessed using Agilent Bioanalyzer 2100 and agarose gel electrophoresis. The extracted 
tcRNA was then kept at -20 °C until use. 
 
3.2.15.2 tcRNA to cDNA conversion  
 The tcRNA was converted to cDNA for the microarray analyses using the 
Applause WT-AMP ST System (NuGEN Technologies, USA) in accordance to the 
manufacturer’s instructions. Briefly, 200 ng of tcRNA was used to prepare the first 
strand cDNA using a unique first strand DNA/RNA chimeric primer mix and reverse 
transcriptase. The resulting cDNA/mRNA hybrid molecule was then used to generate a 
DNA/RNA heteroduplex double-stranded cDNA. This was then amplified and cDNA 
with sequence complementary to the original mRNA was generated. After purifying the 
resulting cDNA with MinElute Reaction Cleanup Kit (Qiagen, Germany), 2.5 µg of 
cDNA was then fragmented and labelled with biotin using Encore Biotin Module 
(NuGEN Technologies, USA). The biotinylated fragments were then hybridised to 
Affymetrix Human Gene 1.0 ST array at 45 °C for 16 h in Hybridization Oven 640 
(Affymetrix, USA). After this, the gene chips were stained and washed in the 
Affymetrix GeneChip Fluidics Station 450 using Affymetrix protocol FS450_0007. The 
stained arrays were scanned at 532 nm using Affymetrix GeneChip Scanner 3000 7G 
and CEL files were generated using Affymetrix GeneChip Operating Software (GCOS). 
The quality of the data was assessed using Affymetrix GeneChip Command Console 
Version 3. 
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3.2.15.3 Data analyses using Partek Genomic Suite (GS) software  
The CEL files generated from each array were imported into Partek Genomic 
Suite software for statistical analyses and visualisation of the microarray data. The CEL 
files were normalised using the Robust Multi-array Average (RMA) algorithm and GC 
content was adjusted for pre-background adjustment. The gene list produced was then 
filtered for statistically significant genes based on the one-way analysis of variance 
(ANOVA) of P value less than 0.05 and fold-change of at least 1.5-fold. The 
significantly regulated genes were then subjected to Gene Ontology (GO) Enrichment 
tool in the Partek Genomic Suite Software to categorise the genes based on their 
involvement in biological processes, molecular function and cellular component. 
 
3.2.15.4 Functional analyses using IPA software 
 Significantly regulated genes identified using Partek GS software were 
subjected to functional analyses using Ingenuity Pathways Analysis (IPA) software. The 
application was used to query databases for interactions between sets of differentially 
expressed genes and all other genes stored in the Ingenuity Knowledge Base to generate 
a set of interactive networks taking into consideration canonical pathways, relevant 
biological interactions as well as cellular and disease processes. The IPA system 
computes a score for each network according to the fit of the set of the supplied ‘‘focus 
genes’’. The p-value scores for such a set indicate the likelihood of focused genes to 
belong to a network versus those obtained by chance. 
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3.2.15.5 DNA microarray data validation using quantitative real-time polymerase 
chain reaction (qRT-PCR) 
 Eight significantly regulated genes from DNA microarray analysis were chosen 
to be validated using qRT-PCR. Primer sets for qPCR were designed using Primer-
BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) with the following 
settings: PCR product size, 70-180 bp; optimum  melting temperature, 60 °C; exon 
junction spanning; organism: Homo sapiens. The primer sets were further analysed 
using online nucleotide tool, BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
to ensure the specificity of the amplification product. The list of primers is listed in 
Table 3.1.  
 
Two micrograms of tcRNA extracted from the control and treated cells were 
converted to cDNA using High Capacity RNA-to-cDNA kit (Applied Biosystems, 
USA). qPCR was carried out using the StepOne Real-Time PCR System (Applied 
Biosystems, USA) with 40 amplification cycles. Melting curve analyses were 
performed for all primers to ensure single amplification product. Each reaction 
consisted 20 ng of cDNA, 0.2 mM forward and reverse primers, 2X Fast SYBR® Green 
Master Mix (Applied Biosystems, USA) in a final volume of 20 µl. All qRT-PCR 
experiments were repeated with 3 biological replicates from different experiments and 
reactions were performed in triplicates. Gene expressions were normalised against beta 
actin, a housekeeping gene and fold change was expressed as mean ± SEM. 
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Table 3.1: Primer sequences of genes selected for verification of DNA microarray analysis in qRT-PCR. 
Gene name GenBank ID Primer sequences 
Product 
size (bp) 
Melting 
temperature 
(°C) 
%GC 
content 
Cytochrome P450, family 
7,subfamily A, polypeptide 
1 (CYP7A1) 
NM_000780 Forward: 5’-TTGCTACTTCTGCGAAGGCA-3’ 
Reverse: 5’-TCCGTGAGGGAATTCAAGGC-3’ 
124 56.9 
57.4 
50.0 
55.0 
Starch binding domain 1 
(STBD1) 
NM_003943 Forward: 5’- GAGAAAGACGCCCCTCTTGG-3’ 
Reverse: 5’- GAAGATGCTCTGGTTTGGTGAC-3’ 
115 57.9 
56.0 
60.0 
50.0 
Solute carrier family 2, 
member 1 (SLC2A1) 
NM_006516 Forward: 5’- CTGGCATCAACGCTGTCTTC-3’ 
Reverse: 5’- GTTGACGATACCGGAGCCAA-3’ 
98 56.5 
57.2 
55.0 
55.0 
Carnitine 
palmitoyltransferase 1A 
(CPT1A) 
NM_001876 Forward: 5’- TGCTGATGACGGCTATGGTG-3’ 
Reverse: 5’- TGAGAATCCGTCTCAGGGCA-3’ 
99 57.4 
58.1 
55.0 
55.0 
Amphiregulin (AREG) NM_001657 Forward: 5’- GTGGTGCTGTCGCTCTTGATAC-3’ 
Reverse: 5’-AGAGTAGGTGTCATTGAGGTCCAAT-3’ 
72 58.0 
57.4 
54.5 
44.0 
Prominin 1 (PROM1) NM_001145847 Forward: 5’-TCAGCGTCTTCCTATTCAGG-3’ 
Reverse: 5’-AAAAATCACGATGAGGGTCA-3’ 
163 53.9 
51.9 
50.0 
40.0 
Phospholipase A2, group 
IIA (PLA2G2) 
NM_000300 Forward: 5’-GAAAGGAAGCCGCACTCAGTT-3’ 
Reverse: 5’-CAGACGTTTGTAGCAACAGTCA-3’ 
122 57.9 
55.3 
52.3 
45.4 
Keratin 23 (KRT23) NM_015515 Forward: 5’-CGGCAGAACAATGAATACCA-3’ 
Reverse: 5’-GCCTTGATCTTTGGAGTTGC-3’ 
155 53.0 
54.3 
45.0 
50.0 
Beta actin (ACTB) NM_001101 Forward: 5’- ACAGAGCCTCGCCTTTGCCG-3’ 
Reverse: 5’- ACATGCCGGAGCCGTTGTCG-3’ 
104 62.9 
63.1 
65.0 
65.0 
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CHAPTER 4 
RESULTS 
 
4.1 Cell viability in serum-free medium 
 MTT analysis was carried out to determine the influence of serum-free medium 
and methanol extract of T. indica fruit pulp on viability of HepG2 cells. Our results 
showed no significant difference in viability of cells that were grown in complete or 
serum-free media (Figure 4.1). Viability of HepG2 cells that were grown in the 
presence of the methanol extract of the T. indica fruit pulp at a final concentration of 60 
µg/ml was also not significantly different from those grown in the control serum-free 
medium in the presence of 0.02 % (v/v) DMSO (Figure 4.1). 
 
4.2 Proteomic analyses of secreted proteins and cell lysate of HepG2 cells 
4.2.1 Optimisation of 2D-GE for secreted proteins and cell lysate 
 In order to obtain a good representation of the HepG2 proteome, the optimum 
protein quantity to be loaded per gel was optimised. Ideally the proteins should be well 
separated and of high resolution with minimal streaking. Based on these, the optimum 
protein amount to be loaded per gel was determined to be 40 µg for both secreted 
proteins (Figure 4.2) and cell lysate (Figure 4.3). 
 
 The sample was first cleaned-up using the 2D-cleanup kit (GE Healthcare, USA) 
to minimise the streaking at the acidic pH region of the gel caused by excessive salt in 
the cell lysate protein sample (Figure 4.4A). DeStreak reagent (GE Healthcare, USA) 
was also added to the rehydration solution to reduce the gap in the basic pH region of 
the gel which was caused by non-specific oxidation of the proteins (Figure 4.4B).  
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Figure 4.1: MTT analysis to assess the cell viability of HepG2 cells in A) serum and 
serum-free media B) control (serum-free medium + 0.02% DMSO) and 0.06 mg/ml 
methanol extract of T. indica fruit pulp in serum-free condition. All data are 
expressed as mean ± S.E.M. (standard error of means). 
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Figure 4.2: Optimisation of protein amount to be loaded per gel for secreted 
protein 
A) 20 µg; B) 30 µg; C) 40 µg (optimum); D) 50 µg. 
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C D 
61 
 
 
 
Figure 4.3: Optimisation of protein amount to load per gel for cell lysate protein 
A) 20 µg; B) 30 µg; C) 40 µg (optimum); D) 60 µg. 
  
A B 
C D 
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Figure 4.4: Minimising streaking in the 2D-GE of HepG2 cell lysate proteins 
A) Streaking at the acidic pH region of the gel caused by excessive salt in protein 
sample; B) Gap at the basic pH region of the gel caused by non-specific oxidation of 
proteins. 
  
A B 
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4.2.2 2D-GE of secreted proteins and cell lysate proteins 
4.2.2.1 2D-GE of secreted proteins 
 Forty micrograms of secreted proteins extracted from control and treated HepG2 
cells were separated on a 13 cm pH 3-10 non-linear IPG strips for the first dimension 
and subsequently on a 12.5 % SDS-PAGE for the second dimension (n = 4 gels derived 
from 4 individual culture flasks for each group; total n = 8 gels). A total of 
approximately 1500 spots were detected for each gel (Figure 4.5). 
 
4.2.2.2 2D-GE of cell lysate proteins 
Similarly, 40 µg of cell lysate extracted from control and treated HepG2 cells 
were separated using the same running profiles and conditions as the secreted proteins 
(n = 6 gels derived from 3 individual culture flasks for each group, 2 technical replicates 
of each individual culture flasks; total n = 12 gels). A total of approximately 2500 spots 
were detected for each gel (Figures 4.6 and 4.7). 
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Figure 4.5: 2D-GE of secretomes of HepG2 cells of A) control; B) treatment with 0.06 mg/ml methanol extract of T. indica fruit pulp. 
Approximately 1500 spots per gel within the pH 3-10 range for secretome of HepG2 cells were detected. Seven spots (circled and labelled) were 
differentially expressed (adjusted p < 0.03125) in which 4 were significantly up-regulated and 3 were significantly down-regulated. 
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Figure 4.6: 2D-GE of cell lysate of HepG2 cells of A) control; B) treatment with 0.06 mg/ml methanol extract of T. indica fruit pulp. 
Approximately 2500 spots per gel within the pH 3-10 range for cell lysate of HepG2 cells were detected. Twenty spots (circled and labelled) were all 
significantly down-regulated (p < 0.05). 
  80 
  50 
  40 
  25 
  20 
  12 
  10 
120 
180 
MW (kDa) A B 
66 
 
 
Figure 4.7: An enlarged proteome map of HepG2 cell lysate. 
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4.2.3 Gel image analyses  
4.2.3.1 Secretome analysis 
Using ImageMaster 2D Platinum V 7.0 software, the percentage of volume for 
each spot was obtained and the fold change was acquired. Spots that were significantly 
regulated at more than 1.5 fold (p < 0.05) and must be present in all 4 gels were filtered 
out. Based on these criteria, 9 protein spots were differentially expressed in which 4 
were significantly up-regulated and 5 were significantly down-regulated. The spots 
were further subjected to false discovery rate (FDR) analysis and two spots were found 
to be false-positive based on the Benjamini-Hochberg’s method (Benjamini, 1995), 
leaving only 7 spots to be truly differentially expressed (Table 4.1). 
 
4.2.3.2 Cell lysate analysis 
 Using the same software, approximately 2500 spots were detected in each gel. 
After acquiring the percentage of volume for each spot, the fold change for each spot 
was obtained. Spots that are significantly regulated at more than 1.5 fold (p < 0.05) and 
must be present in at least 5 gels were filtered out. Based on these criteria, 20 spots 
were significantly altered and they were all down-regulated (Table 4.2). 
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Table 4.1: Average percentage of volume of spots, adjusted p-values and the fold 
change of secreted proteins in T. indica-treated cells versus control. 
Spot 
ID 
Average Percentage of Volume ± SEM Adjusted p-value 
(p < 0.03125) 
Fold 
Change Control Treated 
46 0.731 ± 0.205 0.289 ± 0.136 0.0113 -2.5 
148 0.214 ± 0.014 0.096 ± 0.014 < 0.001 -2.2 
460 0.292 ± 0.103 0.613 ± 0.194 0.0265 +2.1 
468 0.175 ± 0.023 0.349 ± 0.098 0.0136 +2.0 
661 0.034 ± 0.014 0.070 ± 0.012 0.0084 +2.1 
666 0.045 ± 0.021 0.113 ± 0.014 0.0018 +2.5 
810 0.475 ± 0.095 0.278 ± 0.088 0.0227 -1.7 
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Table 4.2: Average percentage of volume of spots, p-values and the fold change of 
cell lysate proteins in T. indica-treated cells versus control.  
Spot 
ID 
Average Percentage of Volume ± SEM p-value 
(p < 0.05) 
Fold 
Change Control Treated 
363 0.0273 ± 0.0016 0.0187 ± 0.0019 0.0052 -1.5 
398 0.0214 ± 0.0021 0.0134 ± 0.0020 0.0173 -1.6 
540 0.0128 ± 0.0019 0.0073 ± 0.0011 0.0291 -1.8 
590 0.0892 ± 0.0073 0.0609 ± 0.0039 0.0066 -1.5 
615 0.0240 ± 0.0023 0.0157 ± 0.0016 0.0133 -1.5 
637 0.0254 ± 0.0033 0.0156 ± 0.0011 0.0158 -2.0 
655 0.0499 ± 0.0033 0.0328 ± 0.0056 0.0250 -1.5 
657 0.0655 ± 0.0088 0.0360 ± 0.0035 0.0109 -1.8 
675 0.0660 ± 0.0067 0.0440 ± 0.0017 0.0094 -1.5 
722 0.0223 ± 0.0022 0.0144 ± 0.0014 0.0127 -1.5 
751 0.0420 ± 0.0038 0.0235 ± 0.0027 0.0028 -1.8 
765 0.0470 ± 0.0031 0.0315 ± 0.0040 0.0123 -1.5 
796 0.0162 ± 0.0011 0.0093 ± 0.0009 0.0006 -1.7 
900 0.0394 ± 0.0048 0.0206 ± 0.0044 0.0163 -1.9 
914 0.0279 ± 0.0015 0.0177 ± 0.0012 0.0003 -1.6 
1084 0.0305 ± 0.0015 0.0209 ± 0.0017 0.0017 -1.5 
1254 0.0154 ± 0.0018 0.0078 ± 0.0007 0.0023 -2.0 
1355 0.0107 ± 0.0018 0.0054 ± 0.0010 0.0253 -2.0 
1634 0.0746 ± 0.0125 0.0435 ± 0.0031 0.0359 -1.7 
1649 0.0639 ± 0.0069 0.0416 ± 0.0032 0.0149 -1.5 
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4.2.4 Identification of differentially expressed proteins 
4.2.4.1 Secretome 
Among the seven protein spots that were altered in expression, five spots 
(protein spot ID: 46, 148, 460, 468 and 810) were identified by mass spectrometry and 
database search. Spots 661 and 666 were not successfully identified by MS/MS analysis 
as their scores were lower than the cut off value for positive inclusion criteria. This 
could probably be due to their close proximity to the high abundant proteins which 
hinder the detection of their peptides. The five differentially expressed proteins that 
were identified include transthyretin (TTR – spot 46), two isoforms of apolipoprotein 
A-I (ApoA-I – spots 148 and 810), alpha enolase (ENO1 – spot 460) and rab GDP 
dissociation inhibitor beta (GDI-2 – spot 468) (Table 4.3).  ENO1 and GDI-2 were 
apparently up-regulated by approximately 2-fold, while TTR was down-regulated by 
2.5-fold. The two spots identified as ApoA-1 was down-regulated by 2.2- and 1.7-folds. 
 
4.2.4.2 Cell lysate 
Among the 20 protein spots that were significantly reduced in abundance, 14 
were successfully identified by mass spectrometry and database search (Table 4.4).  Six 
spots (protein spot ID 398, 615, 637, 1254, 1355 and 1649) were considered not 
successfully identified as their scores were lower than the cut-off value for positive 
inclusion criteria. The 14 identified proteins may be grouped according to their 
biological processes using the UniProt Protein Knowledgebase (UniProtKB).  NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 10, ubiquinol-cytochrome-c 
reductase complex core protein 2 and NADH dehydrogenase (ubiquinone) flavoprotein 
1 were grouped under “mitochondrial respiratory chain” category. Three proteins, i.e. 
eukaryotic translation initiation factor 3 subunit 3, elongation factor Tu and tyrosyl-
tRNA synthetase are involved in “protein biosynthesis”.  Another six proteins were 
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categorised under “metabolism”, with glyceraldehyde-3-phosphate dehydrogenase and 
GDP-L-fucose synthetase being involved in carbohydrate metabolism, GMP reductase 2 
and UMP synthase in nucleotide and nucleoside metabolism, S-methyl-5-thioadenosine 
phosphorylase in polyamine metabolic process, and ethanolamine-phosphate 
cytidylyltransferase in biosynthesis of phospholipids. Prohibitin, on the other hand, was 
categorised under “cell proliferation and differentiation”, while heterogeneous nuclear 
ribonucleoprotein H3 did not belong to any of the above groups and therefore 
categorised as “others”. 
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 Table 4.3: List of differentially expressed secreted proteins in T. indica fruit extract-treated cells identified by MALDI-MS/MS. 
Spot 
no. 
Protein description 
SWISS-PROT 
Accession No. 
MASCOT 
score 
pI/MW 
(kDa) 
Av. % of 
Vol. ratio
a
 
% 
Cov
b
 
Matched Peptide 
Sequences 
46 Transthyretin precursor (TTR) P02766 252 5.52/15.88 -2.5 18 42-54; 55-68; 56-68 
148 Apolipoprotein A-I precursor (ApoA-I) P02647 216 5.56/30.76 -2.2 35 121-130; 132-140; 185-195 
460 Alpha enolase (ENO1) P06733 257 7.01/47.14 +2.1 16 
16-28; 33-50; 184-193; 
240-253; 270-281; 407-412 
468 
Rab GDP dissociation inhibitor beta 
(GDI-2) 
P50395 618 6.11/50.63 +2.0 47 
36-54; 56-68; 69-79; 90-98; 
143-156; 194-208; 211-218; 
279-288; 300-309; 310-328; 
391-402; 403-418; 424-436 
810 Apolipoprotein A-I precursor (ApoA-I) P02647 437 5.56/30.76 -1.7 33 
52-64; 121-130; 132-140; 
165-173; 185-195; 231-239; 
251-262 
a
 Positive value signifies up-regulation against control samples and negative value signifies down-regulation in terms of fold-differences. All ratio is 
statistically significant with p < 0.05 (Student’s t-test). 
b
 % Coverage of the identified sequence. 
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     Table 4.4: List of cell lysate proteins of altered abundance in T. indica fruit extract-treated cells identified by MALDI-TOF/TOF MS/MS. 
Spot 
no. 
Protein description Acc. No. Score 
pI/MW 
(kDa) 
Av. % 
FC
a
 
% 
Cov
b
 
Matched peptide sequences 
Functional 
category 
657 
NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex 
subunit 10 (CI-42 kD) 
O95299 194 
8.67/ 
40.73 
–1.8 44 
117-122; 13-139; 140-161; 
253-261; 290-295 
Mitochondrial 
respiratory chain 
765 
Ubiquinol-cytochrome-c reductase 
complex core protein 2, 
mitochondrial precursor 
(Coreprotein II) 
P22695 537 
8.74/ 
48.41 
–1.5 28 
71-84; 163-183; 184-196; 
200-217; 232-241 
900 
NADH dehydrogenase 
(ubiquinone) flavoprotein 1, 
mitochondrial precursor (CI-51 
kD) 
P49821 275 
8.51/ 
50.79 
–1.9 33 
72-81; 153-159; 160-174; 
376-386; 441-449 
796 
Ethanolamine-phosphate 
cytidylyltransferase 
Q99447 339 
6.44/ 
43.81 
–1.7 38 185-199; 262-271; 333-348 
Phospholipid 
biosynthesis 
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Table 4.4, continued        
Spot 
no. 
Protein description Acc. No. Score 
pI/MW 
(kDa) 
Av. % 
FC
a
 
% 
Cov
b
 
Matched peptide sequences 
Functional 
category 
590 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
P04406 192 
8.57/ 
36.03 
–1.5 18 235-248; 310-323 
Carbohydrate 
metabolism 
722 GDP-L-fucose synthetase Q13630 280 
6.13/ 
35.87 
–1.5 49 
26-44; 82-88; 90-107; 200-
214; 291-297; 307-320 
655 GMP reductase 2  Q9P2T1 386 
6.79/ 
37.85 
–1.5 52 
70-78; 178-189; 192-213; 
277-286; 278-286; 292-298; 
292-306 
Nucleotide and 
nucleoside 
metabolism 
914 
Uridine 5’-monophosphate 
synthase (UMP synthase) 
P11172 379 
6.81/ 
52.20 
–1.6 37 
6-22; 30-41; 146-155; 353-
363; 389-405; 460-467; 469-
477 
363 
S-methyl-5-thioadenosine 
phosphorylase (MTAP) 
Q13126 253 
6.75/ 
31.23 
–1.5 43 
12-29; 72-82; 83-99; 100-
116; 134-147; 181-187; 272-
282 
Polyamine 
metabolism 
1634 Prohibitin P35232 66 
2.27/ 
29.79 
–1.7 21 134-143 
Cell proliferation 
and differentiation 
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Table 4.4, continued        
Spot 
no. 
Protein description Acc. No. Score 
pI/MW 
(kDa) 
Av. % 
FC
a
 
% 
Cov
b
 
Matched peptide sequences 
Functional 
category 
675 
Eukaryotic translation initiation 
factor 3 subunit 3 (elF3h) 
O15372 279 
6.09/ 
39.91 
–1.5 43 
52-75; 242-249; 260-265; 
304-313; 314-331 
Protein 
biosynthesis 
751 
Elongation factor Tu, 
mitochondrial precursor (EF-Tu) 
P49411 114 
7.26/ 
49.51 
–1.8 29 105-120; 239-252 
1084 
Tyrosyl-tRNA synthetase, 
cytoplasmic (TyrRS) 
P54577 96 
6.61/ 
59.11 
–1.5 21 85-93; 179-189; 433-450 
540 
Heterogenous nuclear 
ribonucleoprotein H3 (hnRNP H3) 
P31942 409 
6.37/ 
36.90 
–1.7 39 
56-67; 85-90; 98-104; 206-
222; 223-232; 262-287; 288-
301 
Others 
a
Negative value signifies down-regulation in terms of fold-differences. All ratios are statistically significant with p < 0.05 (Student’s t-test).  
b
 % Coverage of the identified sequence. 
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4.2.5 Western blot analyses 
To validate the effects of the T. indica fruit pulp extract on HepG2 proteins, 
Western blotting was performed using antisera raised against the cellular proteins. In 
view of the scarce amount of HepG2 cell lysate protein extract that was generated in 
this study, three proteins, i.e. ethanolamine-phosphate cytidylyltransferase (PCYT2), 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 10 (NDUFA10) and 
ubiquinol-cytochrome-c reductase complex core protein 2 (UQCRC2) that represent 
those involved in the mitochondrial and metabolic activities were selected.  
Densitometry scanning of bands detected by the antisera showed that the abundance of 
PCYT2, NDUFA10 and UQCRC2 was indeed lower in HepG2 cells-treated T. indica 
fruit pulp extract compared to the controls, with fold differences of –1.7, –1.5 and –1.5, 
respectively (Figure 4.8). 
 
4.2.6 Pathway interactions and biological process analysis 
When the differentially expressed secreted proteins were analysed using IPA, 
the software identified “Lipid Metabolism, Molecular Transport and Small Molecule 
Biochemistry” as the sole putative network linking three of the differentially expressed 
proteins with other interactomes, with a score of 9.  A score of 2 or higher indicates at 
least a 99% confidence of not being generated by random chance and higher scores 
indicate a greater confidence. When both the differentially expressed secreted proteins 
and cell lysate proteins were included in the analysis, the same network showed an even 
higher score, with a score of 31. The combination of both sets of data signifies that lipid 
metabolism may be the main system being regulated after treatment with T. indica fruit 
extract. Figures 4.9 and 4.10 show a graphical representation of the predicted molecular 
relationships between the regulated proteins. A canonical pathway analysis ranked the 
LXR/RXR activation with the highest significance (p < 1.29 x 10
-04
; Figure 4.11). 
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Figure 4.8: Western blot analyses of NDUFA10, PCYT2 and UQCRC2 
A) Western blot cropped images of NDUFA10, PCYT2, UQCRC2 and beta actin bands 
detected by antisera against the respective proteins; B) Densitometry analyses of 
Western blot using ImageJ software.  Assay was done in triplicate and data were 
represented as mean ± standard deviation. 
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Figure 4.9: IPA graphical representation of the molecular relationships between 
differentially expressed secreted proteins in HepG2 cells treated with T. indica 
fruit extract 
The network is displayed graphically as nodes (proteins) and edges (the biological 
relationships between the nodes). Nodes in red indicate up-regulated proteins while 
those in green represent down-regulated proteins. Nodes without colours indicate 
unaltered expression. Various shapes of the nodes represent the functional class of the 
proteins. The different arrow shapes represent different types of interactions. Edges are 
displayed with various labels that describe the nature of the relationship between the 
nodes. Names of proteins corresponding to the abbreviations are as follows: APOA1, 
Apolipoprotein A-1; APOA2, Apolipoprotein A-2; APOA4, Apolipoprotein A-4; 
APOA5, Apolipoprotein A-5;  APOC1, Apolipoprotein C-1; APOC2, Apolipoprotein 
C-2; APOE, Apolipoprotein E; APOM, Apolipoprotein M; APOL1, Apolipoprotein L-
1; ACACB, acetyl-CoA-carboxylase 2; SAA2, serum amyloid A2; LCAT, lecithin 
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cholesterol  acyltransferase; PLTP, phospholipid transfer protein; CETP, 
cholesterylester transfer protein; PTGIS, prostaglandin I synthase; RAB9A, Ras-related 
protein Rab 9A; RAB6A, Ras-related protein Rab 6A; GDI2, Rab GDP dissociation 
inhibitor beta; RAB2A, Ras-related protein Rab 2A; KCNMA1, Potassium large 
conductance calcium-activated channel, subfamily M, alpha member 1; DDR1, 
discoidin domain receptor tyrosine kinase 1; TTR, transthyretin; RBP4, retinol binding 
protein 4; LIPC, hepatic triglyceride lipase; LIPG, endothelial lipase; PON1, 
paraoxonase 1; HPX, haemopexin; Tcf 1/2/3, T-cell factor -1, -2, -3; Rbp, retinol 
binding proteins. 
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Figure 4.10: IPA graphical representation of the molecular relationships between 
HepG2 secreted and cytosolic proteins after treatment 
The network is displayed graphically as nodes (proteins) and edges (the biological 
relationships between the nodes). Nodes in red indicate up-regulated proteins while 
those in green represent down-regulated proteins. Nodes without colours indicate 
unaltered expression. Various shapes of the nodes represent functional class of the 
proteins. Edges are displayed with various labels that describe the nature of the 
relationship between the nodes. Transthyretin, TTR; thyroglobulin, TG; interleukin-1 
beta, IL1B; tumour necrosis factor, TNF; apolipoprotein A-1, APOA1; apolipoprotein 
C-1, APOC1; lecithin cholesterol acyltransferase, LCAT; endothelial lipase, LIPG; 
haptoglobin, HP; phospholipase A2, PLA2G2A; cholesterylester transfer protein, 
CETP; ATP-binding cassette transporter sub-family C member 9, ABCC9; ATP-
81 
 
sensitive inward rectifier potassium channel 11, KCNJ11; ectonucleotide 
pyrophosphatase/phosphodiesterase family member 1, ENPP1; amyloid precursor 
protein, APP; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; alpha enolase, 
ENO1; adenylate kinase, AK1; ubiquinol-cytochrome-c reductase complex core protein 
2, UQCRC2; xanthine dehydrogenase, XDH; cystathionine beta-synthase, CBS; 
methionine adenosyltransferase I, alpha, MAT1A; rab GDP dissociation inhibitor beta, 
GDI2; NLR (nucleotide-binding domain and leucine rich repeat containing family) 
family, pyrin domain containing 3, NLRP3; Vacuolar ATP synthase subunit E, 
ATP6V1E1; elongation factor Tu, TUFM; prohibitin, PHB; choline-phosphate 
cytidylyltransferase A, PCYT1A; uridine 5'-monophosphate synthase, UMPS; NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 10, NDUFA10; NADH 
dehydrogenase (ubiquinone) flavoprotein 1, NDUFV1; mediator of RNA polymerase III 
transcription subunit 30, MED30; transcription factor E2F1, E2F1; suppressor of G2 
allele of SKP1 homolog, SUGT1. 
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Figure 4.11: Predicted canonical pathway affected by T. indica fruit extract 
IPA identified ‘LXR/RXR activation’ as the canonical pathway with the highest 
predicted potential/significance of being affected by the altered levels of TTR, ApoA-I 
and GDI-2 in HepG2 cells that were treated with T. indica fruit extract. Lines between 
the proteins represent known interactions. Red nodes indicate over expression of genes 
induced by the extract, which was based on our previous report (Razali, et al., 2010).  
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Abbreviation: ABCA1, ATP-binding cassette sub-family A member 1; ABCG1, ATP-
binding cassette sub-family G member 1; ABCG5, ATP-binding cassette sub-family G 
member 5;  ABCG8, ATP-binding cassette sub-family G member 8;  ECHS, enoyl CoA 
hydratase; HADH, hydroxyacyl-CoA dehydrogenase; HMGCR, HMG-CoA reductase; 
CYP7A1, cytochrome P450, family 7, subfamily A, polypeptide 1; LDLR, low density 
lipoprotein receptor; CETP, cholesterylester transfer protein; CD36, cluster of 
differentiation 36; NCOR, nuclear receptor corepressor; LXR, liver X receptor; RXR, 
retinoid X receptor; 9-cis-RA, 9-cis-retinoic acid; LPL, lipoprotein lipase; PLTP, 
phospholipid transfer protein; SREBP-1c, sterol regulatory element-binding protein 1c; 
FASN, fatty acid synthase; SCD1, stearoyl-conzyme A desaturase 1; ACC, acetyl-CoA 
carboxylase; APOA4, apolipoprotein A-4; LDL, low density lipoprotein; HDL, high 
density lipoprotein. 
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4.3 In vitro evaluation of hypolipidaemic properties of T. indica fruit pulp extract 
To further investigate the lipid-lowering effects of T. indica fruit pulp, the 
following lipid studies were conducted where the lipid amount was quantified 
enzymatically as well as examined optically with Oil Red O staining after treatments. 
The mechanism of action was investigated by analysing the gene expression incurred by 
the treatment using DNA microarray and software analyses.  
 
In this study, HepG2 cells were induced to develop steatosis by treatment with 
palmitic acid. There were 4 treatment groups in this study, HepG2 cells treated with 
palmitic acid only (PA), cells treated with a lipid-lowering drug, fenofibrate and 
palmitic acid (FF+PA), cells treated with methanol extract of T. indica fruit pulp and 
palmitic acid (TI+PA) and cells treated with 0.02 % DMSO (vehicle) only (control). 
The triglyceride and cholesterol levels were quantified using enzyme assays and the 
lipid droplets in the cells were visualised using Oil Red O staining. The total cellular 
RNA was then extracted for transcriptomic studies using DNA microarray. The gene 
expressions were then analysed using data mining software to elucidate the mechanism 
of action of T. indica lipid-lowering effect.  
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4.3.1 Cell viability and Oil Red O staining of HepG2 cells in different 
concentrations of palmitic acid and T. indica fruit extract 
 In order to determine the concentration of palmitic acid to best induce steatosis 
in HepG2 cells without causing extensive cell death, MTT assay was performed and 
lipid droplets were stained using Oil Red O staining. In this study, different 
concentrations of palmitic acid ranging from 0.2 to 1 mM were tested for 24 and 48 h. 
The MTT assay showed a concentration-dependent reduction in cell viability upon 
treatment with palmitic acid, with 48 h treatment showing a more prominent cell death 
than 24 h (Figure 4.12). Oil Red O staining of the lipid droplets in HepG2 cells showed 
a dose-dependent increase of lipid droplet size and number (Figure 4.13). 
 
 Similarly, the viability of HepG2 cells treated with 0.3 mM palmitic acid and 
different concentrations of T. indica fruit extract was also determined using MTT assay 
(Figure 4.14). The assay showed that generally the cells were more than 90 % viable 
when they were treated with concentrations of less than 0.2 mg/ml T. indica fruit 
extract. The Oil Red O staining of lipid droplets of HepG2 cells showed that the lipid 
droplets were fewer in number and smaller in size in fenofibrate-treated HepG2 cells 
compared to cells treated with palmitic acid only. As for the T. indica fruit-treated cells, 
Oil Red O staining showed a dose-dependent reduction in lipid droplets. However, 
when the cells were treated with 0.3 mg/ml T. indica fruit extract, the lipid droplets 
appeared to be more abundant as compared to the 0.2 mg/ml T. indica fruit-treated cells 
(Figure 4.15). 
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Figure 4.12: MTT analysis to assess the viability of HepG2 cells treated with 
different concentrations of palmitic acid after 24 and 48 h.  
Assay was done in triplicate and all data were expressed as mean ± SD (standard 
deviation). 
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Figure 4.13: Oil Red O staining of lipid droplets in HepG2 cells treated with 
different concentrations of palmitic acid  
HepG2 cells were treated with A) fatty acid-free bovine serum albumin only; B) 0.2 
mM palmitic acid; C) 0.3 mM palmitic acid and D) 0.8 mM palmitic acid for 24 h. 
There was a dose-dependent increment in number of lipid droplets as well as the sizes.  
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Figure 4.14: MTT assay of HepG2 cells treated with different concentrations of T. 
indica fruit extract (TI) and 0.3 mM palmitic acid (PA) for 24 h. 
Assays were done in triplicates and data were represented as mean ± standard deviation.  
Abbreviation: PA- Palmitic acid, TI- T. indica fruit extract 
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Figure 4.15: Oil Red O staining of lipid droplets in HepG2 cells treated with fenofibrate and different concentrations of T. indica fruit extract 
Lipid droplets were visible after treatment with palmitic acid (PA only), and the amount of droplets reduced after treatment with fenofibrate 
(PA+fenofibrate). The reduction in droplet amount was dose dependent in treatment with 0.02 mg/ml to 0.2 mg/ml T. indica (PA+0.02 mg/ml TI – 
PA+0.2 mg/ml TI). At 0.3 mg/ml T. indica treatment (PA+0.3 mg/ml TI), the lipid droplets increased in size and quantity. 
Abbreviation: PA- palmitic acid; TI- T. indica fruit extract 
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4.3.2 Total triglyceride and cholesterol quantification 
 Total triglyceride and total cholesterol were also quantified in HepG2 cells 
treated with T. indica fruit extract and palmitic acid, as shown in Figures 4.16 and 4.17, 
respectively. Total triglyceride in palmitic acid-treated HepG2 cells was reduced 
significantly (p < 0.05) by around 35 % in the presence of fenofibrate, a commonly used 
hypolipidaemic drug. The T. indica fruit pulp extract at the concentrations of 0.1 mg/ml 
and 0.2 mg/ml, were able to significantly (p < 0.01) reduce the total triglyceride level to 
a level comparable to that of fenofibrate. However, at the concentration of 0.3 mg/ml of 
T. indica fruit extract, the total triglyceride level was increased by 36 % when compared 
to 0.2 mg/ml T. indica fruit-treated cells (Figure 4.15).  
 
 Total cholesterol in HepG2 cells treated with 0.3 mM palmitic acid and different 
concentrations of T. indica fruit extract also showed a similar trend whereby the total 
cholesterol increased at higher concentrations of T. indica fruit extract treatment (Figure 
4.17). Total cholesterol was reduced by around 25 % after treatment with fenofibrate. 
The cholesterol lowering effect of the fruit was not significant as compared to the 
triglyceride lowering effect. At 0.05 mg/ml T. indica fruit treatment, the total 
cholesterol was reduced by around 9 %, while at 0.1 mg/ml T. indica fruit treatment, the 
total cholesterol was reduced by around 18 %, and decreased to 8 % at 0.2 mg/ml T. 
indica fruit extract treatment. At 0.3 mg/ml T. indica fruit concentration, the total 
cholesterol increased by 12 %.  
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Figure 4.16: Measurement of total triglyceride in HepG2 cells after treatment 
Assays were done in triplicates and data were represented as mean ± standard deviation. 
*p < 0.05 and ** p < 0.01 when compared to PA only treatment 
Abbreviation: PA- palmitic acid; TI- T. indica fruit extract  
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Figure 4.17: Measurement of total cholesterol in HepG2 cells after treatment 
Assays were done in triplicates and data were represented as mean ± standard deviation. 
*p < 0.05 when compared to PA only treatment  
Abbreviation: PA- palmitic acid; TI- T. indica fruit extract  
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4.4 Transcriptomic studies 
4.4.1 Assessment of the integrity of tcRNA extracted from HepG2 cells 
 Total cellular RNA (tcRNA) extracted from the HepG2 cells were assessed to 
ensure that the tcRNA quality and integrity was high. This is important as the quality 
and integrity of the tcRNA extracted is essential to obtain reproducible results in the 
downstream applications, especially in microarray analysis. Figure 4.18A shows the 
denaturing agarose gel electrophoresis of the tcRNA extracted from HepG2 cells. The 
presence of two distinct bands with 28S band approximately twice the intensity of 18S 
band with no smearing indicates that the tcRNA is intact (Figure 4.18A). Besides the 
conventional use of denaturing agarose gel electrophoresis, Agilent Bioanalyzer 2100 
was also used to determine the integrity of the tcRNA. RNA integrity number (RIN) of 
more than 8 shows that the tcRNA is intact. The two peaks generated in the 
chromatogram represents 18S and 28S respectively (Figure 4.18B). 
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Figure 4.18: Assessment of tcRNA integrity using denaturing agarose gel 
electrophoresis and Agilent Bioanalyzer 2100 
A) Denaturing agarose gel electrophoresis of tcRNA extracted from HepG2 cells. B) An 
example of a tcRNA sample analysed using Agilent Bioanalyzer 2100.  
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4.4.2 Principal component analysis (PCA) mapping of different treatment groups 
  PCA is a statistical technique for determining the key variables in a 
multidimensional data set that explain the differences in the observations. Figure 4.19 
demonstrates the PCA mapping of different treatment groups in the DNA microarray 
analysis. It can be seen that the control group is furthest from all other treatments, 
indicating that the gene expression differed the most. Other treatments were closer to 
each other, forming 3 clusters but remained separated, signifying different sets of gene 
were being regulated. 
 
4.4.3 Identification of significantly regulated genes using Partek Software 
 A total of 160, 77 and 169 genes were significantly regulated (p < 0.05) by at 
least 1.5-fold in HepG2 cells treated with 0.1 mg/ml T. indica fruit extract (TI+PA vs 
control), fenofibrate (FF+PA vs control) and palmitic acid (PA vs control), respectively 
when compared to control (Figure 4.20). Thirty seven genes were significantly altered 
in all 3 treatments (Figure 4.20) and the names of the genes are listed in Table 4.5. 
Twenty four genes were commonly regulated in T. indica and fenofibrate treatments 
(Table 4.6) while 34 genes were commonly regulated in T. indica treatment and 
palmitic acid treatment alone (Table 4.7). Only 3 genes were commonly altered in 
fenofibrate treatment and palmitic acid treatment (Table 4.8). Sixty five, 13 and 95 
genes were uniquely regulated in T. indica treatment, fenofibrate treatment and palmitic 
acid treatment respectively (Tables 4.9, 4.10 and 4.11). 
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Figure 4.19: PCA mapping of 4 different treatment groups in DNA microarray 
analysis 
Abbreviation: TI- T. indica fruit extract; PA- palmitic acid; FF- fenofibrate 
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Figure 4.20: Venn diagram of number of genes that were significantly regulated (p 
< 0.05) by at least 1.5-fold in DNA microarray analyses 
Abbreviation: TI+PA- T. indica fruit extract and palmitic acid; FF+PA- fenofibrate and 
palmitic acid; PA- palmitic acid 
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Table 4.5: Genes commonly regulated in all treatment groups (TI+PA vs control, PA vs control and FF+PA vs control) 
Gene ID Symbol Gene Name 
Fold Change 
TI+PA vs 
control 
FF+PA vs 
control 
PA vs control 
8095744 AREG/AREGB amphiregulin 11.6 6.4 12.0 
8095736 AREG/AREGB amphiregulin 6.6 3.8 6.8 
8123651 TUBB2B tubulin, beta 2B class IIb 3.1 1.7 1.9 
8015133 KRT23 keratin 23 (histone deacetylase inducible) 2.5 1.8 2.6 
7964460 DDIT3 DNA-damage-inducible transcript 3 2.5 1.8 1.7 
8138381 AGR2 anterior gradient 2 homolog (Xenopus laevis) 2.4 2.2 2.6 
8106098 MAP1B microtubule-associated protein 1B 2.4 1.8 2.6 
8007429 G6PC glucose-6-phosphatase, catalytic subunit 2.3 1.6 1.5 
8117630 ZNF165 zinc finger protein 165 2.3 1.8 1.7 
7965979 ALDH1L2 aldehyde dehydrogenase 1 family, member L2 2.3 1.8 1.7 
7958262 TCP11L2 t-complex 11, testis-specific-like 2 2.3 1.6 2.2 
7995895 
 
HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1 
2.2 1.7 1.5 
8042503 MXD1 MAX dimerization protein 1 2.2 1.8 1.7 
8135480 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.2 1.6 1.8 
8021653 SERPINB8 serpin peptidase inhibitor, clade B (ovalbumin), member 8 2.1 1.7 1.5 
8158167 LCN2 lipocalin 2 2.1 1.7 1.5 
8131996 CREB5 cAMP responsive element binding protein 5 1.9 1.7 1.6 
7917530 GBP2 guanylate binding protein 2, interferon-inducible 1.8 1.8 2.5 
8147145 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 1.8 1.8 2.1 
7962559 SLC38A4 solute carrier family 38, member 4 1.8 2.1 2.7 
8142307 PNPLA8 patatin-like phospholipase domain containing 8 1.8 1.5 1.7 
8113064 LYSMD3 LysM, putative peptidoglycan-binding, domain containing 3 1.8 1.6 1.7 
8103951 ACSL1 acyl-CoA synthetase long-chain family member 1 1.6 1.7 1.6 
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Table 4.5, continued    
Gene ID Symbol Gene Name 
Fold Change 
TI+PA vs 
control 
FF+PA vs 
control 
PA vs control 
8150002 FBXO16 F-box protein 16 1.6 1.7 1.6 
8175288 MOSPD1 motile sperm domain containing 1 1.6 1.6 1.5 
7997740 MAP1LC3B microtubule-associated protein 1 light chain 3 beta 1.5 1.6 1.6 
8092169 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 1.5 1.6 1.6 
8008885 mir-21 microRNA 21 -2.4 -2.9 -4.5 
8122144 SNORA33 small nucleolar RNA, H/ACA box 33 -2.0 -1.7 -2.0 
7985317 KIAA1199 KIAA1199 -1.8 -1.8 -1.9 
8114797 SPRY4 sprouty homolog 4 (Drosophila) -1.7 -1.6 -1.7 
8160213 TTC39B tetratricopeptide repeat domain 39B -1.7 -1.7 -1.5 
8048864 CCL20 chemokine (C-C motif) ligand 20 -1.7 -1.8 -1.6 
7982597 THBS1 thrombospondin 1 -1.6 -1.7 -1.8 
7934979 ANKRD1 ankyrin repeat domain 1 (cardiac muscle) -1.6 -2.1 -1.7 
7995783 MT2A  metallothionein 2A -1.5 -1.6 -1.6 
8122265 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 -1.5 -1.6 -1.6 
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Table 4.6: Significantly regulated genes in T. indica treatment group and fenofibrate treatment group (TI+PA vs control and FF+PA vs 
control) 
Gene ID Symbol Gene Name 
Fold change 
TI+PA vs control FF+PA vs control 
8030128 PPP1R15A protein phosphatase 1, regulatory subunit 15A 2.5 1.8 
8115831 DUSP1 dual specificity phosphatase 1 2.4 1.6 
8126629 GTPBP2 GTP binding protein 2 2.0 1.8 
8095826 STBD1 starch binding domain 1 1.9 1.7 
7952145 HYOU1 hypoxia up-regulated 1 1.9 1.6 
7912750 FBXO42 F-box protein 42 1.9 1.6 
8018264 HID1 HID1 domain containing 1.8 1.5 
7970301 TMCO3 transmembrane and coiled-coil domains 3 1.8 1.6 
8154381 LURAP1L leucine rich adaptor protein 1-like 1.8 1.6 
8124365 SLC17A2 solute carrier family 17 (sodium phosphate), member 2 1.8 1.5 
7924450 DUSP10 dual specificity phosphatase 10 1.7 1.6 
8040211 KLF11 Kruppel-like factor 11 1.7 1.6 
7949971 CPT1A carnitine palmitoyltransferase 1A (liver) 1.7 1.6 
7909610 ATF3 activating transcription factor 3 1.6 1.5 
8174239 BEX2 brain expressed X-linked 2 1.6 1.6 
8103535 GK3P glycerol kinase 3 pseudogene 1.6 1.6 
7922773 NCF2 neutrophil cytosolic factor 2 1.5 1.6 
7952339 HSPA8  heat shock 70kDa protein 8 -3.0 -2.3 
8146115 C8orf4 chromosome 8 open reading frame 4 -2.0 -2.5 
8118322 SNORD52 small nucleolar RNA, C/D box 52 -1.8 -1.6 
7922416 SNORD75 small nucleolar RNA, C/D box 75 -1.7 -1.5 
7915472 SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 -1.6 -1.6 
8034390 ZNF799 zinc finger protein 799 -1.6 -1.6 
8169504 SLC6A14 solute carrier family 6 (amino acid transporter), member 14 -1.5 -1.7 
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Table 4.7: Significantly regulated genes in T. indica treatment group and palmitic acid treatment group (TI+PA vs control and PA vs control) 
Gene ID Symbol Gene Name 
Fold change 
TI+PA vs control PA vs control 
8041644 
 
PLEKHH2 pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 2 2.1 1.7 
7965423 BTG1 B-cell translocation gene 1, anti-proliferative 1.8 1.8 
8052798 AAK1 AP2 associated kinase 1 1.8 1.6 
8162276 NFIL3 nuclear factor, interleukin 3 regulated 1.7 1.5 
8020847 DTNA dystrobrevin, alpha 1.7 1.6 
8069532 HSPA13 heat shock protein 70kDa family, member 13 1.7 1.5 
7988767 CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 1.6 1.6 
8105908 OCLN occludin 1.6 1.6 
7971388 SLC25A30 solute carrier family 25, member 30 1.6 1.6 
8044450 ZC3H6 zinc finger CCCH-type containing 6 1.6 1.5 
7946089 TRIM5 tripartite motif containing 5 1.6 1.5 
8115397 FAXDC2 fatty acid hydroxylase domain containing 2 1.6 1.6 
8094719 N4BP2 NEDD4 binding protein 2 1.6 1.5 
8084219 KLHL24 kelch-like 24 (Drosophila) 1.6 1.7 
7925342 ERO1LB ERO1-like beta (S. cerevisiae) 1.5 1.6 
7916112 RAB3B RAB3B, member RAS oncogene family 1.5 1.5 
8102848 SETD7 SET domain containing (lysine methyltransferase) 7 1.5 1.5 
8106516 JMY junction mediating and regulatory protein, p53 cofactor 1.5 1.9 
8005202 SNORD49A small nucleolar RNA, C/D box 49A -1.9 -1.9 
7948902 SNHG1  small nucleolar RNA host gene 1 (non-protein coding) -1.8 -2.1 
7948904 SNORD28 small nucleolar RNA, C/D box 28 -1.8 -1.8 
7948900 SNORD30 small nucleolar RNA, C/D box 30 -1.8 -2.2 
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Table 4.7, continued   
Gene ID Symbol Gene Name 
Fold change 
TI+PA vs control PA vs control 
7948896 SNHG1 small nucleolar RNA host gene 1 (non-protein coding) -1.7 -2.1 
7948898 SNHG1  small nucleolar RNA host gene 1 (non-protein coding) -1.7 -2.4 
8005951 SNORD42B small nucleolar RNA, C/D box 42B -1.7 -2.9 
7914212 SNHG12  small nucleolar RNA host gene 12 (non-protein coding) -1.7 -1.6 
7948908 SNHG1  small nucleolar RNA host gene 1 (non-protein coding) -1.6 -2.4 
8059538 SLC19A3 solute carrier family 19, member 3 -1.6 -1.9 
7948906 SNHG1  small nucleolar RNA host gene 1 (non-protein coding) -1.5 -2.0 
8084704 EIF4A2  eukaryotic translation initiation factor 4A2 -1.5 -1.6 
8061564 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein -1.5 -1.5 
7995797 MT1E metallothionein 1E -1.5 -1.5 
7910134 MIXL1 Mix paired-like homeobox -1.5 -1.5 
7952335 SNORD14E small nucleolar RNA, C/D box 14E -1.5 -1.6 
 
 
 
 
 
  
103 
 
Table 4.8: Significantly regulated genes in fenofibrate treatment group and palmitic acid treatment group (FF+PA vs control and PA vs 
control) 
Gene ID Symbol Gene Name 
Fold change 
FF+PA vs control PA vs control 
8014342 CCL16 chemokine (C-C motif) ligand 16 1.6 1.8 
8108370 EGR1 early growth response 1 -1.8 -2.4 
8178435 IER3  immediate early response 3 -1.7 -1.6 
 
 
Table 4.9: Genes exclusively regulated in fenofibrate treatment group (FF+PA vs control) 
Gene ID Symbol Gene Name 
Fold change 
FF+PA vs control 
8024754 CREB3L3 cAMP responsive element binding protein 3-like 3 1.6 
7953943 GABARAPL1 GABA(A) receptor-associated protein like 1 1.6 
8087224 SLC25A20 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 1.5 
8049534 LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 -1.9 
8124848 IER3  immediate early response 3 -1.6 
8179704 IER3  immediate early response 3 -1.6 
8142270 NRCAM neuronal cell adhesion molecule -1.5 
8095362 MT2A  metallothionein 2A -1.5 
8053278 EVA1A eva-1 homolog A (C. elegans) -1.5 
8084880 HES1 hairy and enhancer of split 1, (Drosophila) -1.5 
7943413 BIRC3 baculoviral IAP repeat containing 3 -1.5 
 
 
 
  
104 
 
Table 4.10: Genes exclusively regulated in T. indica treatment group (TI+PA vs control) 
Gene ID Symbol Gene Name 
Fold change 
TI+PA vs control 
8132694 IGFBP1 insulin-like growth factor binding protein 1 2.2 
8077441 BHLHE40 basic helix-loop-helix family, member e40 2.2 
7956426 INHBE inhibin, beta E 2.2 
7931810 KLF6 Kruppel-like factor 6 2.0 
7916609 JUN jun proto-oncogene 1.9 
8000574 NUPR1 nuclear protein, transcriptional regulator, 1 1.8 
7991587 VIMP VCP-interacting membrane protein 1.7 
7953291 CD9 CD9 molecule 1.7 
8157933 ZBTB43 zinc finger and BTB domain containing 43 1.7 
8155630 LOC286297 uncharacterized LOC286297 1.7 
8045289 RHOQ ras homolog family member Q 1.6 
7953135 TULP3 tubby like protein 3 1.6 
8060344 TRIB3 tribbles homolog 3 (Drosophila) 1.6 
8153002 NDRG1 N-myc downstream regulated 1 1.6 
8110055 CPEB4 cytoplasmic polyadenylation element binding protein 4 1.6 
7947496 SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 1.6 
8160297 PLIN2 perilipin 2 1.6 
8018902 DNAH17 dynein, axonemal, heavy chain 17 1.6 
8174103 GK glycerol kinase 1.6 
8037071 RABAC1 Rab acceptor 1 (prenylated) 1.6 
7905938 SLC50A1 solute carrier family 50 (sugar transporter), member 1 1.6 
7969677 MBNL2 muscleblind-like splicing regulator 2 1.6 
8072876 LGALS1 lectin, galactoside-binding, soluble, 1 1.6 
8053648 KRCC1 lysine-rich coiled-coil 1 1.6 
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Table 4.10, continued  
Gene ID Symbol Gene Name 
Fold change 
TI+PA vs control 
8005171 TRPV2 transient receptor potential cation channel, subfamily V, member 2 1.6 
7927082 HSD17B7P2 hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 1.5 
8163002 KLF4 Kruppel-like factor 4 (gut) 1.5 
8117045 RBM24 RNA binding motif protein 24 1.5 
8040340 LPIN1 lipin 1 1.5 
8137709 ZFAND2A zinc finger, AN1-type domain 2A 1.5 
7990080 LARP6 La ribonucleoprotein domain family, member 6 1.5 
7927146 CSGALNACT2 chondroitin sulfate N-acetylgalactosaminyltransferase 2 1.5 
8147206 RIPK2 receptor-interacting serine-threonine kinase 2 1.5 
7981290 WARS tryptophanyl-tRNA synthetase 1.5 
8113073 ARRDC3 arrestin domain containing 3 1.5 
8088167 SELK selenoprotein K 1.5 
8135576 TES testis derived transcript (3 LIM domains) 1.5 
8124040 ATXN1 ataxin 1 1.5 
8110032 CREBRF CREB3 regulatory factor 1.5 
8003939 TM4SF5 transmembrane 4 L six family member 5 1.5 
8130211 SYNE1 spectrin repeat containing, nuclear envelope 1 1.5 
8127072 GSTA1 glutathione S-transferase alpha 1 -2.0 
8127065 GSTA2 glutathione S-transferase alpha 2 -2.0 
7922406 SNORD79 small nucleolar RNA, C/D box 79 -1.9 
7967107 HNF1A-AS1 HNF1A antisense RNA 1 -1.7 
8014755 SNORA21 small nucleolar RNA, H/ACA box 21 -1.7 
7922807 COLGALT2 collagen beta(1-O)galactosyltransferase 2 -1.7 
7922807 GLT25D2 glycosyltransferase 25 domain containing 2 -1.7 
8117594 HIST1H2BM histone cluster 1, H2bm -1.6 
7901048 SNORD46 small nucleolar RNA, C/D box 46 -1.6 
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Table 4.10, continued  
Gene ID Symbol Gene Name 
Fold change 
TI+PA vs control 
7927631 DKK1 dickkopf 1 homolog (Xenopus laevis) -1.6 
7981943 PAR5 Prader-Willi/Angelman syndrome-5 -1.6 
8117288 SCGN secretagogin, EF-hand calcium binding protein -1.6 
8034393 ZNF443 zinc finger protein 443 -1.6 
7951030 TAF1D  TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 41kDa -1.6 
8139482 SNORA5A small nucleolar RNA, H/ACA box 5A -1.6 
7961026 LOC728715 ovostatin homolog 2-like -1.6 
7903022 RPL5 ribosomal protein L5 -1.5 
7922402 GAS5 growth arrest-specific 5 (non-protein coding) -1.5 
8044212 SULT1C2 sulfotransferase family, cytosolic, 1C, member 2 -1.5 
7922408 SNORD78 small nucleolar RNA, C/D box 78 -1.5 
7953873 OVOS/OVOS2 ovostatin 2 -1.5 
8095390 UGT2B10 UDP glucuronosyltransferase 2 family, polypeptide B10 -1.5 
8066254 LOC388796 uncharacterized LOC388796 -1.5 
7942527 POLD3 polymerase (DNA-directed), delta 3, accessory subunit -1.5 
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Table 4.11: Genes exclusively regulated in palmitic acid treatment group (PA vs control) 
Gene ID Symbol Gene Name 
Fold change 
PA vs control 
7920873 SNORA42 small nucleolar RNA, H/ACA box 42 3.0 
7951077 SESN3 sestrin 3 2.1 
8114964 SPINK1 serine peptidase inhibitor, Kazal type 1 2.1 
7961524 ERP27 endoplasmic reticulum protein 27 2.0 
8150920 CYP7A1 cytochrome P450, family 7, subfamily A, polypeptide 1 2.0 
8156160 KIF27 kinesin family member 27 1.9 
8151890 TP53INP1 tumor protein p53 inducible nuclear protein 1 1.8 
8156060 TLE4 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 1.8 
8156905 TMEFF1 transmembrane protein with EGF-like and two follistatin-like domains 1 1.7 
8028194 ZNF382 zinc finger protein 382 1.7 
8102877 CLGN Calmegin 1.7 
8151559 SLC10A5 solute carrier family 10 (sodium/bile acid cotransporter family), member 5 1.7 
7947156 MUC15 mucin 15, cell surface associated 1.7 
8113602 CCDC112 coiled-coil domain containing 112 1.7 
8121277 AIM1 absent in melanoma 1 1.7 
8002283 TMED6 transmembrane emp24 protein transport domain containing 6 1.7 
8058477 KLF7 Kruppel-like factor 7 (ubiquitous) 1.7 
7989037 CCPG1 cell cycle progression 1 1.7 
7954729 FGD4 FYVE, RhoGEF and PH domain containing 4 1.7 
8047401 CFLAR CASP8 and FADD-like apoptosis regulator 1.6 
8142098 ATXN7L1 ataxin 7-like 1 1.6 
7989069 PYGO1 pygopus homolog 1 (Drosophila) 1.6 
8083779 SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), member 1 1.6 
7936419 C10orf118 chromosome 10 open reading frame 118 1.6 
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Table 4.11, continued  
Gene ID Symbol Gene Name 
Fold change 
PA vs control 
8127234 DST Dystonin 1.6 
7990879 EFTUD1 elongation factor Tu GTP binding domain containing 1 1.6 
8155794 C9orf85 chromosome 9 open reading frame 85 1.6 
8078033 CCDC174 coiled-coil domain containing 174 1.6 
8099476 PROM1 prominin 1 1.6 
8163839 C5 complement component 5 1.6 
7919780 GOLPH3L golgi phosphoprotein 3-like 1.6 
8004184 XAF1 XIAP associated factor 1 1.6 
8047078 MFSD6 major facilitator superfamily domain containing 6 1.6 
8162006 GKAP1 G kinase anchoring protein 1 1.6 
8098084 ETFDH electron-transferring-flavoprotein dehydrogenase 1.6 
8128553 BVES blood vessel epicardial substance 1.6 
8030908 ZNF480 zinc finger protein 480 1.5 
8058509 PLEKHM3 pleckstrin homology domain containing, family M, member 3 1.5 
7974697 DAAM1 dishevelled associated activator of morphogenesis 1 1.5 
7909332 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1.5 
8154416 CCDC171 coiled-coil domain containing 171 1.5 
7965060 BBS10 Bardet-Biedl syndrome 10 1.5 
8056060 BAZ2B bromodomain adjacent to zinc finger domain, 2B 1.5 
8069565 BTG3 BTG family, member 3 1.5 
8022666 CHST9 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 1.5 
8124492 
 
HIST1H2BJ/ 
HIST1H2BK 
histone cluster 1, H2bk 1.5 
8043995 IL1R1 interleukin 1 receptor, type I 1.5 
8113403 GIN1 gypsy retrotransposon integrase 1 1.5 
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Table 4.11, continued  
Gene ID Symbol Gene Name 
Fold change 
PA vs control 
8154670 IFT74 intraflagellar transport 74 homolog (Chlamydomonas) 1.5 
8096733 SGMS2 sphingomyelin synthase 2 1.5 
8146427 PCMTD1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 1.5 
8061780 BPIFB2 BPI fold containing family B, member 2 -2.1 
8127989 SNORD50B small nucleolar RNA, C/D box 50B -2.0 
8127987 SNORD50A small nucleolar RNA, C/D box 50A -1.9 
8001547 PLLP Plasmolipin -1.9 
7966749 TESC Tescalcin -1.8 
8063345 SNORD12C small nucleolar RNA, C/D box 12C -1.8 
8019273 ALYREF Aly/REF export factor -1.8 
8178059 LY6G5B lymphocyte antigen 6 complex, locus G5B -1.8 
8084708 EIF4A2  eukaryotic translation initiation factor 4A2 -1.8 
8019772 ALYREF Aly/REF export factor -1.8 
7902400 RABGGTB  Rab geranylgeranyltransferase, beta subunit -1.7 
8006655 DHRS11 dehydrogenase/reductase (SDR family) member 11 -1.7 
8123562 GMDS GDP-mannose 4,6-dehydratase -1.7 
7969574 KRT18  keratin 18 -1.7 
7969574 mir-622 microRNA 622 -1.7 
8170863 RPL10  ribosomal protein L10 -1.7 
8023259 SNORD58A small nucleolar RNA, C/D box 58A -1.7 
8024900 UHRF1 ubiquitin-like with PHD and ring finger domains 1 -1.6 
8043187 MAT2A methionine adenosyltransferase II, alpha -1.6 
8025498 RPL10  ribosomal protein L10 -1.6 
7995362 GPT2 glutamic pyruvate transaminase (alanine aminotransferase) 2 -1.6 
8122142 SNORD101  small nucleolar RNA, C/D box 101 -1.6 
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Table 4.11, continued   
Gene ID Symbol Gene Name 
Fold change 
PA vs control 
7976783 DLK1 delta-like 1 homolog (Drosophila) -1.6 
8106278 FAM169A family with sequence similarity 169, member A -1.6 
8003298 SLC7A5 solute carrier family 7 (amino acid transporter light chain, L system), member 5 -1.6 
7945573 POLR2L polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa -1.6 
7904433 PHGDH phosphoglycerate dehydrogenase -1.6 
8001457 CES1 carboxylesterase 1 -1.6 
7938291 RPL27A  ribosomal protein L27a -1.6 
7942594 SNORD15B small nucleolar RNA, C/D box 15B -1.6 
8120315 TINAG tubulointerstitial nephritis antigen -1.6 
7995825 MT1F metallothionein 1F -1.6 
8064978 JAG1 jagged 1 -1.6 
8079294 EXOSC7 exosome component 7 -1.5 
7973896 GSTM2 glutathione S-transferase mu 2 (muscle) -1.5 
7994928 PHKG2 phosphorylase kinase, gamma 2 (testis) -1.5 
8136336 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) -1.5 
8065868 EIF6 eukaryotic translation initiation factor 6 -1.5 
8046488 CDCA7 cell division cycle associated 7 -1.5 
8163328 PTGR1 prostaglandin reductase 1 -1.5 
8001531 MT1G metallothionein 1G -1.5 
8154725 KRT18 keratin 18 -1.5 
8162744 CORO2A coronin, actin binding protein, 2A -1.5 
7928705 TSPAN14 tetraspanin 14 -1.5 
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4.4.4 Functional analyses of significantly regulated genes using IPA software 
 The significantly regulated genes were subjected to functional analyses using 
IPA Core Analysis software. The genes were mapped to the Ingenuity Knowledge Base 
creating molecular networks which were generated de novo. The software also 
determines over represented signalling and metabolic canonical pathways and identifies 
the cascade of upstream transcriptional regulators that can explain the observed gene 
expression changes in the study, from which illuminates the biological activities 
occurring in the cells being studied. 
 
4.4.4.1 Network and functional analysis 
 Network analysis of significantly regulated genes in all treatments revealed that 
different network functions were involved (Table 4.12). In all three treatments, cancer, 
cell growth and proliferation, as well as cell death-related networks appeared as the 
dominant associated network functions. Lipid metabolism-related network was shown 
to be regulated in TI+PA vs control treatment group only, with a score of 40. In the 
FF+PA vs control group, carbohydrate metabolism was generated as one of the 
associated network functions, with a score of 42 and 28. On the other hand, in the PA vs 
control group, cellular growth and proliferation-related networks were dominant.  
  
 Figure 4.21 illustrates the molecular relationships in “Lipid Metabolism, Small 
Molecule Biochemistry, Metabolic Disease” network generated in TI+PA vs control 
group. It can be seen from the network that the nodes converged to a few central nodes, 
namely the Rxr, ERK1/2, MAP2K1/2, CYP19A1, FSH and LH, indicating that these 
genes may be of significant importance in regulating this particular network.  
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Functional analysis showed that oxidation of fatty acid was activated in the 
TI+PA vs control group, with an activation Z-score of 2.175. Activation Z-score of 
more than 2 indicates activation while less than -2 indicates inhibition. Table 4.13 
shows the genes related to oxidation of fatty acid that were significantly regulated in the 
microarray analyses of the different treatments on HepG2 cells. Four out of 6 genes 
were involved in the “Lipid Metabolism, Small Molecule Biochemistry, Metabolic 
Disease” network, which were overlaid in the network figure in Figure 4.21. 
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Table 4.12: Top three networks generated by Ingenuity Pathways Analysis (IPA) 
software when significantly regulated genes from different treatments were 
analysed  
Treatment Associated network functions Score
a 
TI+PA vs 
control 
1) Cancer, Cell Morphology, Cellular Function and 
Maintenance 
51 
2) Lipid Metabolism, Small Molecule Biochemistry, 
Metabolic Disease 
40 
3) Tissue Development, Cellular Development, Cell Death 
and Survival 
31 
FF+PA vs 
control 
1) Cell Death and Survival, Renal Necrosis/Cell Death, 
Carbohydrate Metabolism 
42 
2) Endocrine System Disorders, Gastrointestinal Disease, 
Hereditary Disorder 
36 
3) Cell Death and Survival, Carbohydrate Metabolism, Drug 
Metabolism 
28 
PA vs 
control 
1) Cellular Development, Cellular Growth and Proliferation, 
Tumor Morphology 
44 
2) Cell Morphology, Organ Morphology, Tissue Morphology 44 
3) Cell-To-Cell Signalling and Interaction, Cellular Growth 
and Proliferation, Connective Tissue Development and 
Function 
32 
a
A score of 2 or higher indicates at least a 99 % confidence of not being generated by 
random chance and higher scores indicate a greater confidence. 
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Table 4.13: Genes related to oxidation of fatty acid that were significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells 
Gene 
Symbol 
Literature 
findings on 
gene regulation 
when oxidation 
of fatty acid is 
activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
PA vs 
control 
FF+PA 
vs 
control 
ACSL1 ↑ (Caviglia et al., 2004; J. H. Kim, Kim, 
Kim, & Hwang, 2011) 
Acyl-CoA synthetase long-chain family 
member 1 
1.6 1.6 1.7 
CPT1A ↑ (Akkaoui et al., 2009; S. Fu et al., 2012; 
Perdomo et al., 2004; Rubi et al., 2002; 
Sebastian et al., 2009) 
Carnitine palmitoyltransferase 1A (liver) 1.7  1.6 
CYP19A1 ↑ (Egawa et al., 2003; Nemoto et al., 2000) Cytochrome P450, family 19, subfamily 
A, polypeptide 1 
1.6 1.6  
LPIN1 ↑ (Finck et al., 2006) Lipin 1 1.5   
PNPLA8 Affected (Mancuso et al., 2007; Mancuso et al., 
2010) 
Patatin-like phospholipase domain 
containing 8 
1.8 1.7 1.5 
SLC2A1/ 
GLUT1 
↓ (J. Yan et al., 2009) Solute carrier family 2 (facilitated 
glucose transporter), member 1 
-1.6  -1.6 
a 
Oxidation of fatty acid was predicted to be activated in TI+PA vs control  group based on the IPA software. (Activation z-score in TI+PA vs control = 
2.175)
 
↑ indicates up-regulation of the gene while ↓ indicates down-regulation of the gene in literature findings; affected indicates that the gene is shown to be 
up-regulated and down-regulated in literature findings. 
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Figure 4.21: IPA graphical representation of the molecular relationships in “Lipid 
Metabolism, Small Molecule Biochemistry, Metabolic Disease” network in TI+PA 
vs control treatment overlaid with oxidation of fatty acid function 
The network is displayed graphically as nodes (genes) and edges (the biological 
relationships between the nodes). Nodes in red indicate up-regulated genes while those 
in green represent down-regulated genes. Nodes without colours indicate unaltered 
expression. Various shapes of the nodes represent the functional class of the proteins. 
The different arrow shapes represent different types of interactions. Edges are displayed 
with various labels that describe the nature of the relationship between the nodes. 
Names of genes corresponding to the abbreviations are as follows: MAX dimerization 
protein 1, MXD1; carnitine palmitoyltransferase 1A, CPT1A; perilipin 2, PLIN2; 
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sprouty homolog 4, SPRY4; retinoid receptor, Rxr; glucose-6-phosphatase, G6PC; 
hypoxia up-regulated 1, HYOU1; phosphoenolpyruvate carboxykinase, PEPCK; 
glutathione S-transferase alpha 1, GSTA1; glutathione S-transferase alpha 2, GSTA2; 
JNK p54, JINK1/2; lutenizing hormone, Lh; chorionic gonadotrophin, Cg; glycerol 
kinase, GK; acyl-coA synthetase long-chain family member 1, ACSL1; follicle-
stimulating hormone, FSH; lipocalin 2, LCN2; activating transcription factor 3, ATF3; 
metallothionein 2A, MT2A; inhibitor of DNA binding 1, dominant negative helix-loop-
helix protein, ID1; dual specificity phosphatase 1, DUSP1; phosphotyrosine 
phosphatase, PTPase; microtubule-associated protein 1 light chain 3 beta, MAP1LC3B; 
starch binding domain 1, STBD1; basic helix-loop-helix family e40, BHLHE40; 
cytochrome p450, family 19, subfamily A, polypeptide 1, CYP19A1; solute carrier 
family 2 (facilitated glucose transporter), member 1, SLC2A1. 
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4.4.4.2 Canonical pathway analysis 
 The top three canonical pathways generated by IPA software are shown in Table 
4.14. PXR/RXR activation was shown as the top canonical pathway in TI+PA vs 
control and PA vs control treatment groups with p-values of 1.03E-04 and 1.47E-02 
respectively. Figure 4.22 illustrates the relationship between the regulated genes with 
other interactomes in the PXR/RXR pathway and their implications on gluconeogenesis 
and lipid metabolism. 
 
Mitochondrial L-carnitine shuttle pathway was one of the top three canonical 
pathways in TI+PA vs control and FF+PA vs control treatment groups with p-values of 
6.97E-03 and 1.86E-03, respectively. Figure 4.23 depicts the molecular relationships of 
the regulated genes and other interactomes in the pathway.  
 
Other pathways like LPS/IL-1 mediated inhibition of RXR function was the 
second canonical pathway generated in the TI+PA vs control treatment. P38 MAPK 
signalling and TNFR2 signalling were involved in FF+PA vs control treatment while 
alanine degradation III and alanine biosynthesis II were predicted to be regulated in PA 
vs control treatment.  
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Table 4.14: Top three canonical pathways generated by Ingenuity Pathway 
Analysis (IPA) software when significantly regulated genes from different 
treatments were analysed.  
Treatment Top Canonical Pathways p-value
 
TI+PA vs 
control 
1) PXR/RXR Activation 1.03E-04 
2) LPS/IL-1 Mediated Inhibition of RXR Function 1.2E-03 
3) Mitochondrial L-carnitine Shuttle Pathway 6.97E-03 
FF+PA vs 
control 
1) p38 MAPK Signalling  1.08E-03 
2) Mitochondrial L-carnitine Shuttle Pathway 1.86E-03 
3) TNFR2 Signalling 5.27E-03 
PA vs 
control 
1) PXR/RXR Activation 1.47E-02 
2) Alanine Degradation III 1.73E-02 
3) Alanine Biosynthesis II 1.73E-02 
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Figure 4.22: PXR/RXR activation pathway generated by IPA software in the 
canonical pathway analysis 
This figure demonstrates that G6PC, IGFBP1 and CPT1A are involved in the 
PXR/RXR activation pathway generated by IPA software. This pathway was shown to 
be one of the top three canonical pathways in the TI+PA vs control and PA vs control 
treatment groups, with p-values of 1.03E-04 and 1.47E-02, respectively.  
Names of genes corresponding to the abbreviations are as follows: insulin receptor. 
INSR; forkhead box O1, FOXO1; nuclear receptor subfamily 1, group I, member 2, 
PXR; retinoid X receptor, alpha, RXRα; phosphoenolpyruvate carboxykinase 2 
(mitochondrial), PEPCK; glucose-6-phosphatase, G6PC; insulin-like growth factor 
binding protein 1, IGFBP1; forkhead box O3, FOXO2; HMG-CoA synthetase, 
HMGCS2; carnitine palmitoyltransferase 1A, CPT1A; stearoyl CoA desaturase, SCD1.  
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Figure 4.23: Mitochondrial L-carnitine shuttle pathway generated by IPA software 
in the canonical pathway analysis 
Mitochondrial L-carnitine shuttle pathway were predicted to be involved in both TI+PA 
vs control and FF+PA vs control treatment groups, with p-values of 6.97E-03 and 
1.86E-03, respectively. Two genes were shown to be up-regulated in this pathway, 
namely the long-chain fatty-acid-CoA ligase (ACSL) and 2.3.1.21 or carnitine 
palmitoyltransferase 1A (CPT1A), both of which were highlighted in red in the figure.   
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4.4.4.3 Upstream regulators analysis 
 The upstream regulator analysis is based on prior knowledge of expected effects 
between transcriptional regulators and their target genes stored in the Ingenuity 
Knowledge Base. The analysis examines how many known targets of each transcription 
regulator are present in the dataset, and also compares their direction of change to what 
is expected from the literature in order to predict likely relevant transcriptional 
regulators.  
  
 Table 4.15 shows the upstream regulators predicted to be regulated in HepG2 
cells exposed to the different treatments. Activation Z-score of more than 2 indicates 
activation while less than -2 indicates inhibition. Twelve transcription factors were 
predicted to be regulated in the TI+PA vs control treatment, in which 11 were up-
regulated and 1 was down-regulated. In the FF+PA vs control treatment, 5 were 
predicted to be altered while 3 were predicted to be activated in the PA vs control 
treatment group. XBP1 was shown to be commonly activated in all treatments. PPARA 
and FOXO3 were predicted to be activated in TI+PA vs control group and FF+PA vs 
control group. 
 
 Tables 4.16 and 4.17 show the significantly regulated genes that were involved 
in the downstream mechanism of the predicted activation of PPARA and PPARG. 
Figure 4.24 displays the molecular interactions between the 4 upstream regulators and 
the downstream molecules.  
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Table 4.15: Upstream regulators predicted to be regulated in different treatments 
using IPA software 
Upstream regulators 
Gene 
symbol 
Activation z-score
a 
TI+PA 
vs 
control 
FF+PA 
vs 
control 
PA vs 
control 
Peroxisome proliferator-activated receptor 
alpha  
PPARA 2.745 2.379  
Peroxisome proliferator-activated receptor 
gamma  
PPARG 2.309   
Forkhead box O3  FOXO3 2.038 2.151  
X-box binding protein 1  XBP1 2.961 2.200 2.607 
Activating transcription factor 4  ATF4 2.602   
Nuclear protein, transcriptional regulator, 1  NUPR1 2.065   
Progesterone receptor  PGR 2.345   
cAMP responsive element binding protein 1  CREB1 2.219   
Activating transcription factor 2  ATF2 2.199   
Tumor protein p53  TP53 2.185   
Peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha  
PPARGC1A 2.394   
DNA-damage-inducible transcript 3 DDIT3 2.408   
v-myc myelocytomatosis viral oncogene 
homology  
MYC -2.460   
CCAAT/enhancer binding protein, beta  CEBPB  2.228  
Nuclear factor of kappa light polypeptide 
gene enhancer in B cells 1  
NFKB1  -2.224  
Interferon regulatory factor 7  IRF7   2.000 
Signal transducer and activator of 
transcription 1  
STAT1   2.219 
a 
Activation z-score of more than 2 is considered activated (orange) while less than -2 
is considered inhibited (blue). This score was generated by the IPA software. 
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Table 4.16: Genes related to PPARA activation that were significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells 
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when PPARA 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
STBD1 ↑ (Sanderson, Boekschoten, Desvergne, Muller, 
& Kersten, 2010) 
Starch binding domain 1 1.9 1.7  
PLIN2 ↑ (Bindesboll, Berg, Arntsen, Nebb, & Dalen, 
2013; Nielsen, Grontved, Stunnenberg, & 
Mandrup, 2006; Tachibana et al., 2006) 
Perilipin 2 1.6   
OCLN ↑ (Huang, Eum, Andras, Hennig, & Toborek, 
2009) 
Occludin 1.6  1.6 
NCF2 ↑ (Teissier et al., 2004) Neutrophil cytosolic factor 2 1.5 1.6  
KRT23 ↑ (Sanderson, et al., 2010) Keratin 23 (histone deacetylase 
inducible) 
2.5 1.8 2.6 
CPT1A ↑ (Ammerschlaeger, Beigel, Klein, & Mueller, 
2004; Begriche, Igoudjil, Pessayre, & 
Fromenty, 2006; Clemenz et al., 2008; M. H. 
Hsu, Savas, Griffin, & Johnson, 2001; 
Lawrence et al., 2001; Vega, Huss, & Kelly, 
2000) 
Carnitine palmitoyltransferase 1A 
(liver) 
1.7 1.6  
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Table 4.16, continued      
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when PPARA 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
ACSL1 ↑ (Finck et al., 2002; Schoonjans et al., 1995; 
Tachibana, et al., 2006) 
Acyl-CoA synthetase long-chain 
family member 1 
1.6 1.7 1.6 
G6PC Affected (Bandsma et al., 2004; Y. Fan et al., 2011) Glucose-6-phosphatase, catalytic 
subunit 
2.3 1.6 1.5 
IGFBP1 Affected (Degenhardt, Matilainen, Herzig, Dunlop, & 
Carlberg, 2006) 
Insulin-like growth factor binding 
protein 1 
2.2   
GK ↑ (Patsouris et al., 2004) Glycerol kinase 1.6   
a
 PPARα was predicted to be activated in T. indica treated group and fenofibrate treated group based on the IPA software. (Activation z-score in 
TI+PA vs control= 2.745; Activation z-score in FF+PA vs control = 2.379) 
↑ indicates up-regulation of the gene while ↓ indicates down-regulation of the gene in literature findings; affected indicates that the gene is shown to be 
up-regulated and down-regulated in literature findings. 
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Table 4.17: Genes related to PPARG activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells 
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when PPARG 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
PA vs 
control 
FF+PA 
vs 
control
 
TRIB3 ↑ (Hu et al., 2012; Koo et al., 2004) Tribbles homolog 3 (Drosophila) 1.6   
TNFSF10 ↑ (Ho et al., 2011) Tumor necrosis factor (ligand) 
superfamily, member 10 
1.5 1.6 1.6 
PLIN2 ↑ (Bhalla et al., 2011; Nielsen, et al., 2006; 
Schadinger, Bucher, Schreiber, & Farmer, 
2005) 
Perilipin 2 1.6   
OCLN ↑ (Huang, et al., 2009) Occludin 1.6 1.6  
NDRG1 ↑ (Pino, Wang, McDonald, Qiang, & Farmer, 
2012) 
N-myc downstream regulated 1 1.6   
KLF4 ↑ (Drori et al., 2005; S. Li, Zhou, He, Zhao, & 
Liu, 2013; Rageul et al., 2009) 
Kruppel-like factor 4 (gut) 1.5   
CYP19A1 ↑ (W. Fan et al., 2005) Cytochrome P450, family 19, 
subfamily A, polypeptide 1 
1.6 1.6  
ACSL1 ↑ (Francis, Fayard, Picard, & Auwerx, 2003; 
Schoonjans, et al., 1995; Way et al., 2001) 
Acyl-CoA synthetase long-chain 
family member 1 
1.6 1.6 1.7 
KLF6 ↓ (Schupp et al., 2009) Kruppel-like factor 6 2.0   
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Table 4.17, continued  
 
 
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when PPARG 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
PA vs 
control 
FF+PA 
vs 
control
 
CPT1A Affected (Begriche, et al., 2006) Carnitine palmitoyltransferase 1A 
(liver) 
1.7  1.6 
G6PC Affected (Way, et al., 2001; S. Yu et al., 2003) Glucose-6-phosphatase, catalytic 
subunit 
2.3 1.5 1.6 
GSTA1 Affected (E. Y. Park, Cho, & Kim, 2004) Glutathione S-transferase alpha 1 -2.0   
HYOU1 Affected (M. Jiang et al., 2010) Hypoxia up-regulated 1 1.9  1.6 
IGFBP1 Affected (Degenhardt, et al., 2006) Insulin-like growth factor binding 
protein 1 
2.2   
JUN Affected (Anghel et al., 2007) Jun proto-oncogene 1.9   
SLC2A1/ 
GLUT1 
Affected (Anghel, et al., 2007) Solute carrier family 2 (facilitated 
glucose transporter), member 1 
-1.6  -1.6 
a
 PPARγ was predicted to be activated in T. indica treated group based on the IPA software. (Activation Z-score for TI+PA vs control= 2.309).  
↑ indicates up-regulation of the gene while ↓ indicates down-regulation of the gene in literature findings; affected indicates that the gene is shown to be 
up-regulated and down-regulated in literature findings. 
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Figure 4.24: IPA illustration of upstream analysis of the genes dataset linked to 
PPARA, PPARG, PPARGC1A and FOXO3 in TI+PA vs control treatment 
This figure shows the molecular relationship between the significantly regulated genes 
to the predicted upstream regulators, i.e. PPARG, PPARGC1A, PPARA and FOXO3. 
PPARG, PPARGC1A, PPARA and FOXO3 were predicted to be activated based on the 
direction of downstream gene expressions which was expressed as Z-score.  
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4.4.5 Identification of significantly regulated genes that were reverted to 
expression level similar to control  
 A set of significantly regulated genes were found to revert to control level after 
treatment with either TI+PA or FF+PA or both when compared to PA only treatment. 
Nine genes in which 7 were down-regulated and 2 were up-regulated reverted to the 
expression level similar to control after treatment with TI+PA and FF+PA (Table 4.18). 
In the TI+PA treatment, six genes were reverted to level similar to control where 3 were 
up-regulated and 3 were down-regulated (Table 4.19). All 9 genes but 1 were up-
regulated to control level in the FF+PA treatment (Table 4.20).   
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Table 4.18: Significantly regulated genes that were reverted to a level similar to 
that of a control after treatment with TI+PA and FF+PA 
Symbol Gene Name 
Fold Change 
TI+PA vs 
PA 
FF+PA vs 
PA 
PA vs 
control 
AIM1 Absent in melanoma 1 -1.8 -1.8 1.7 
CES1 Carboxylesterase 1 1.6 1.7 -1.6 
CFLAR CASP8 and FADD-like apoptosis 
regulator 
-1.6 -1.5 1.6 
CYP7A1 Cytochrome P450, family 7, 
subfamily A, polypeptide 1 
-1.8 -1.6 2.0 
ERP27 Endoplasmic reticulum protein 27 -1.8 -1.5 2.0 
MUC15 Mucin 15, cell surface associated -2.2 -1.7 1.7 
PHGDH Phosphoglycerate dehydrogenase 1.7 1.7 -1.6 
PROM1 Prominin 1 -1.6 -1.9 1.6 
SERPINI1 Serpin peptidase inhibitor, clade 1 
(neuroserpin), member 1 
-1.7 -1.5 1.6 
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Table 4.19: Significantly regulated genes that were reverted to a level similar to 
control after treatment with TI+PA 
Symbol Gene Name 
Fold Change 
TI+PA vs 
PA 
PA vs 
control 
CHST9 Carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 9 
-1.7 1.5 
EGR1 Early growth response 1 1.5 -2.4 
HIST1H2BJ Histone cluster 1, H2bk -1.7 1.5 
JAG1 Jagged 1 1.5 -1.6 
SLC7A5 Solute carrier family 7 (amino acid 
transporter light chain, L system), member 5 
1.7 -1.6 
SPINK1 Serine peptidase inhibitor, Kazal type 1 -1.7 2.1 
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Table 4.20: Significantly regulated genes that were reverted to a level similar to 
control after treatment with FF+PA 
Symbol Gene Name 
Fold Change 
FF+PA vs 
PA 
PA vs 
control 
ALYREF Aly/REF export factor 1.7 -1.8 
DHRS11 Dehydrogenase/reductase (SDR family) 
member 11 
1.6 -1.7 
EIF6 Eukaryotic translation initiation factor 6 1.5 -1.5 
GSTM2 Glutathione S-transferase mu 2 (muscle) 1.6 -1.5 
LY6G5B Lymphocyte antigen 6 complex, locus G5B 1.6 -1.8 
PHKG2 Phosphorylase kinase, gamma 2 (testis) 1.6 -1.5 
PTGR1 Prostaglandin reductase 1 1.6 -1.5 
RPL10 Ribosomal protein L10 1.5 -1.7 
SESN3 Sestrin 3 -1.6 2.1 
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4.4.6 Validation of microarray data using qRT-PCR 
 Transcript levels of selected genes were measured by quantitative real-time 
polymerase chain reaction (qRT-PCR) to validate the gene expressions in the DNA 
microarray analysis. Three biological replicates of each treatment group were used in 
the analysis and was normalised against beta actin, an endogenous control. Eight genes 
were chosen based on the function in energy metabolism and their magnitude of fold 
change. PROM1 and CYP7A1 were chosen to validate the reversion of gene expression 
to control in different treatments as compared to PA only treatment. CPT1A, STBD1, 
SLC2A1 and KRT23 were chosen because of their involvements in PPARA and PPARG 
pathways. PLA2G2A was selected for its function in inflammation process and lastly, 
AREG was selected due to its large magnitude of fold change in the microarray data. 
Generally, the results were in good agreement with the microarray data in terms of 
direction and magnitude of change, thus validating the microarray gene expression data 
(Figure 4.25).  
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Figure 4.25: Validation of microarray data using quantitative real-time polymerase chain reaction (qRT-PCR) 
Assays were done using three biological replicates and three technical replicates and data were represented as mean ± standard error. 
Legend abbreviations: TI- T. indica fruit extract; PA- palmitic acid; FF- fenofibrate 
Gene name abbreviations: AREG, amphiregulin; KRT23, keratin 23; PLA2G2, phospholipase A2, group IIA; PROM1, prominin 1; CYP7A1, cytochrome P450, family 7, subfamily 
A, polypeptide 1; SLC2A1, solute carrier family 2, member 1; STBD1, starch binding domain 1; CPT1A, carnitine palmitoyltransferase 1A.   
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CHAPTER 5  
DISCUSSIONS 
 
Previous microarray study by Razali et al. (2010) revealed that T. indica fruit 
extract significantly regulated genes that are involved in lipid metabolism and 
antioxidant activities; however the molecular mechanism has yet to be deciphered. 
Therefore, this is a continuation study from Razali et al. (2010), with the main objective 
is to further investigate the mechanism of action of the lipid-lowering effect of the T. 
indica fruit pulp extract. In view of the extensive possibilities that could attribute to the 
hypolipidaemic effect, proteomic analyses were first performed on the cell lysate and 
secretome of HepG2 cells treated with T. indica fruit extract to narrow down the 
possible mechanisms. Based on the proteins that were significantly altered in proteomic 
study and genes that were differentially expressed in the previous microarray data, a 
proposed mode of action was formulated, which was then tested using DNA microarray. 
The lipid-lowering activities of T. indica fruit were also measured in HepG2 cells. 
 
5.1 Proteomic studies 
In this study, proteomic techniques were used to analyse the expression of 
cytosolic proteins as well as proteins that were released by HepG2 cells in response to 
treatment with the methanol extract of T. indica fruit pulp. Serum-free DMEM culture 
media from HepG2 cells grown for 24 h in the absence and presence of T. indica fruit 
pulp extract were initially subjected to 2D-GE. The use of serum-free medium was 
necessary for the proteomic analysis to avoid masking of the proteins released by the 
cells as opposed to the highly abundant proteins present in FBS. The results of our MTT 
assays showed that viability of the HepG2 cells was not affected by use of serum-free 
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medium and neither was it significantly different when the cells were exposed to the T. 
indica fruit pulp extract. 
 
5.1.1 Methanol extract of T. indica fruit pulp altered the secretion of proteins from 
HepG2 cells 
Among the thousands of protein spots that were detected in the 2D-GE profiles 
of culture media isolated from HepG2 cells grown in the absence or presence of the 
methanol extract of T. indica fruit pulp, only seven were found to be altered in 
expression. Five of the protein spots were identified by using mass spectrometry 
analysis and found to be those of TTR, ENO1, GDI-2 and ApoA-I (2 isoforms), whilst 
two spots were not successfully identified. Exposure of the HepG2 cells to the T. indica 
fruit pulp extract appeared to have caused the increased release of ENO1 and GDI-2 but 
decreased secretion of TTR and ApoA-I.  While the two latter proteins are known to be 
secretory proteins, ENO1 and GDI-2 are apparently cytosolic proteins (Pfeffer, Dirac-
Svejstrup, & Soldati, 1995).  However, several earlier studies had also detected the 
presence of ENO1 and GDI-2 in the culture media of HepG2 cells (Bottoni, Giardina, 
Vitali, Boninsegna, & Scatena, 2009; Higa et al., 2008). 
 
When the differentially expressed proteins were subjected to analysis using IPA, 
all but ENO1 were found to be interconnected with interactomes in lipid metabolism.  
ENO1, although more popularly known as a glycolytic enzyme, is apparently a 
multifunctional protein that also acts as a receptor, activator and regulator molecule 
(Pancholi & Fischetti, 1998; Subramanian & Miller, 2000). Hence, the ENO1 that was 
detected in the culture media in this study may not be involved in glycolysis. Due to the 
multiple roles played by ENO1, it is difficult to speculate the reason why the release of 
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the protein was increased when HepG2 cells were exposed to the T. indica fruit pulp 
extract. 
 
Interestingly, the three differentially expressed proteins that are involved in lipid 
metabolism appeared to be commonly associated with the same hormonal regulation, 
i.e., estradiol, and the homeostasis of cholesterol. GDI-2 functions to translocate 
prenylated Rab proteins from the cytosol to the membrane to form nascent transport 
vesicles. The protein also assists the subsequent retrieval of Rab proteins (Pfeffer, et al., 
1995; Stenmark & Olkkonen, 2001), which are key regulators for the transport of lipids 
and proteins between cell organelles from target membranes (Pfeffer, 2001; Stenmark & 
Olkkonen, 2001; Zerial & McBride, 2001). To date, approximately 70 Rab proteins had 
been identified but their specific functions are still largely unknown (Agola, Jim, Ward, 
Basuray, & Wandinger-Ness, 2011). These include Rab11, whose over expression has 
been shown to block the recycling of cholesterol from the endosome recycling 
compartment to the plasma membrane (Holtta-Vuori, Tanhuanpaa, Mobius, 
Somerharju, & Ikonen, 2002; Soccio & Breslow, 2004). On the other hand, Rab8 has 
been shown to assist the redistribution of cholesterol from late endosomes to the cell 
periphery and stimulate cholesterol efflux through the ABCA1/ApoA-I pathway (Linder 
et al., 2007). The increased release of GDI-2 by HepG2 cells when they were exposed 
to the methanol extract of T. indica fruit pulp was probably to enable the recycling of 
Rab proteins that are involved in the cholesterol homeostasis in the cell. 
 
TTR is a protein that is mainly synthesised in the liver and the choroid plexus of 
the brain (Aleshire, Bradley, Richardson, & Parl, 1983). Its two main functions are to 
transport thyroxine and retinol through binding to the hormone and retinol-binding 
protein, respectively (Hagen & Solberg, 1974; Raz & Goodman, 1969). However, a 
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small fraction of plasma TTR (1-3 %) is apparently associated with ApoA-I, the major 
apoprotein found in the anti-atherogenic lipoprotein HDL. ApoA-I is synthesised in the 
liver (as well as the intestine) and its secretion is believed to be either in a lipid-
free/poor or pre-lipidated forms (intracellularly assembled nascent HDL) (Chisholm, 
Burleson, Shelness, & Parks, 2002). Ohnsorg (Ohnsorg et al., 2011), Liz (Liz, Gomes, 
Saraiva, & Sousa, 2007) and their co-workers showed that TTR cleaves the C-terminus 
of ApoA-I, which is necessary for the transport of lipid-free ApoA-I through the aortic 
endothelial cells. When HepG2 cells were exposed to the tamarind extract in this study, 
secretion of both TTR and ApoA-I was reduced by more than 2-fold. The two proteins 
were also shown to be interconnected via our IPA analysis. This alteration reflects the 
indirect effects of T. indica fruit pulp extract in regulating the function of HDL in the 
reverse transport of cholesterol and also in line with the earlier findings on the 
cholesterol and triacylglycerol lowering effects of the fruit extract in 
hypercholesterolaemic hamsters (Martinello, et al., 2006) and in humans (Iftekhar, et 
al., 2006). 
 
Earlier report by Razali et al. (2010), described the up-regulated expression of 
the APOA1 gene by 1.2-fold when HepG2 cells were exposed to the same concentration 
of T. indica fruit pulp extract (Razali, et al., 2010). The high ApoA-I mRNA levels that 
were detected in HepG2 cells upon exposure to the extract as opposed to the low levels 
of ApoA-I that appeared in the media could be either due to the decrease in the rate of 
export of the apoprotein or that the mRNA may not be translated into ApoA-I. Previous 
study by the same group also showed that the T. indica fruit pulp extract induced the 
expression of the ABCG5 gene. ABCG5 apparently forms a dimer with ABCG8 to 
assist the secretion of cholesterol into the bile and its subsequent excretion via the 
faeces. Therefore, the lower ApoA-I secretion that was detected in the present study 
138 
 
suggests that the T. indica fruit pulp extract may be promoting the excretion of 
cholesterol via the ABCG5 instead of the ApoA-I transport system. Interestingly, the 
ABCG5/8-mediated cholesterol excretion and absorption and ABCA-1-mediated 
cholesterol efflux are apparently controlled by the liver X receptors, LXRs, which was 
also in agreement to the canonical pathway generated in IPA analysis (Figure 4.11). 
 
5.1.2 Methanol extract of T. indica fruit pulp altered the abundance of cytosolic 
proteins in HepG2 cells 
In this study, the abundance of 20 cell lysate proteins was found to be 
significantly reduced when HepG2 cells were exposed to the T. indica fruit pulp extract. 
Fourteen of the proteins were identified by mass spectrometry and database search, and 
the reduced abundance of three representative identified HepG2 mitochondrial and 
metabolic proteins were subsequently validated by Western blotting. 
 
Among the identified HepG2 proteins, three components of the mitochondrial 
respiratory chain, i.e. ubiquinol-cytochrome-c reductase complex core protein 2 
(UQCRC2), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 10 
(NDUFA10) and NADH dehydrogenase (ubiquinone) flavoprotein 1 (NDUFV1), were 
found to be reduced in abundance when HepG2 cells were exposed to T. indica fruit 
pulp extract. UQCRC2 belongs to complex III of the mitochondrial respiratory chain 
while NDUFA10 and NDUFV1 are components of complex I. In mitochondria, only 
complex I (Barja & Herrero, 1998; Genova et al., 2001) and complex III (Boveris, 
Cadenas, & Stoppani, 1976) of the respiratory chain are known to produce reactive 
oxygen species (ROS). Hence, the decreased amount of the three mitochondrial 
components may indicate reduced production of free radicals, although the functionality 
of the mitochondria is yet to be confirmed. Nevertheless, earlier studies in obese rat 
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muscles have shown that reduced levels of respiratory chain complex I and diminished 
ROS production that were induced by chronic supplementation with grape seed 
proanthocyanidins did not affect the function of the mitochondria (Pajuelo et al., 2011).  
 
In addition to the mitochondrial respiratory chain proteins, the glycolytic 
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as well as GDP-L-
fucose synthetase (TSTA3), also appeared to be down-regulated after treatment with T. 
indica fruit pulp extract. Oxidative stress is known to induce up-regulation of GAPDH 
levels (De Marco et al., 2012; Ito, Pagano, Tornheim, Brecher, & Cohen, 1996). Hence, 
the reduced amount of GAPDH in this case may possibly indicate a state of repressed 
oxidative stress. This, together with the earlier data on the reduced mitochondrial 
respiratory chain proteins, may shed some light on molecular mechanisms involved in 
the well acclaimed antioxidant properties of T. indica (Martinello, et al., 2006; 
Sudjaroen, et al., 2005).  
 
The fruit pulp extract of T. indica also appeared to cause decreased abundance 
of proteins involved in the metabolism of nucleic acids and polyamines in HepG2 cells.  
To the best of our knowledge, these have not been previously reported and their 
rationale is not quite understood. On the other hand, decreased abundance of 
ethanolamine-phosphate cytidylyltransferase (PCYT2), the rate-limiting enzyme which 
catalyses conversion of phosphoethanolamine to cytidylylphosphoethanolamine in the 
biosynthesis of phosphatidylethanolamine, in HepG2 cells exposed to the fruit extract of 
T. indica may compromise availability of the phospholipid, which stores arachidonic 
acid for the production of prostaglandins. This could possibly explain the anti-
inflammatory action of T. indica that was earlier reported (Rimbau, et al., 1999).   
 
A 
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Prohibitin is another mitochondrial protein that was shown to be of reduced 
abundance in HepG2 cells exposed to T. indica fruit pulp extract. The depletion of 
prohibitin has been reported to promote the lifespan of an organism, although it has not 
been shown on higher organisms and it is dependent on the metabolic state of the 
organism (Artal-Sanz & Tavernarakis, 2010). Prohibitin is an evolutionary highly 
conserved protein that is located in the mitochondria. Many roles have been suggested 
for this protein such as acting like a chaperone (Nijtmans et al., 2000), protease 
(Steglich, Neupert, & Langer, 1999) and scaffolding proteins (Osman et al., 2009). 
Certain review papers also mentioned that it plays a role in cell cycle regulation, 
regulation of transcription and cell surface signalling (Mishra, Murphy, & Murphy, 
2006; Rajalingam & Rudel, 2005). However, the true biochemical function of prohibitin 
remains elusive. While some studies showed that the depletion of prohibitin shortened 
the lifespan of wild-type Caenorhabditis elegans (Artal-Sanz & Tavernarakis, 2009) 
and yeast (Berger & Yaffe, 1998), a study by Artal-Sanz and Tavernarakis (2009) had 
shown that under certain metabolic conditions, the reduced prohibitin can prolong the 
lifespan of the animal. It is interesting that the result from the study coincides with this 
study in certain manner, for example prohibitin depletion results in reduced fat content, 
in all genetic backgrounds where prohibitin deficiency extends lifespan (Artal-Sanz & 
Tavernarakis, 2009). T. indica has been used traditionally to treat hyperlipidaemia, and 
studies have shown that it possesses hypolipidaemic effect in vivo (Lim, et al., 2013; 
Martinello, et al., 2006). In this study, prohibitin was down-regulated by 1.7-fold. While 
there may be no direct relationship in between prohibitin depletion and lipid-lowering-
effect, the depletion of prohibitin in HepG2 cells upon exposure to the fruit pulp extract 
of T. indica appears to suggest a similar mechanism in attempt to extend lifespan of the 
cells.   
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Adding to that, the reduced amount of proteins involved in protein biosynthesis, 
i.e. eukaryotic translation initiation factor 3 subunit 3 (eIF3H), tyrosyl-tRNA synthetase 
(YARS) and elongation factor Tu (EFTU), which may indicate lowered protein 
synthesis rate, had been shown to increase lifespan of C. elegans (Hansen et al., 2007; 
Pan et al., 2007; Syntichaki, Troulinaki, & Tavernarakis, 2007). Hipkiss, AR (2007) 
pointed out that this could be due to lesser error proteins such as misfolded proteins 
being produced, therefore increasing the availability of proteases and chaperones for the 
removal of erroneous proteins that may lead to amyloidal accumulation. These reduced 
proteins involved in protein biosynthesis may be key regulatory points of action of the 
fruit pulp extract of T. indica. Suppression of these proteins by the extract may reflect 
the underlying epigenetic mechanism that ultimately caused the reduced expression of 
all the mitochondrial and metabolic proteins and enzymes. 
 
Subjecting the altered abundance proteins to IPA analysis generated a single 
network on “Hereditary disorder, metabolic disease, molecular transport”, which ranked 
mitochondrial dysfunction with the highest significance (p < 3.65 x 10
-4
). However, 
“Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry” became the 
top network involved when IPA was reanalysed to include proteins that were previously 
shown to be differentially secreted by HepG2 cells treated with the same fruit extract. 
This network was not generated in the earlier analysis as PCYT2 was the sole cellular 
protein involved in lipid metabolism that was affected when HepG2 cells were exposed 
to T. indica fruit pulp extract. In the earlier IPA analysis of secreted proteins of altered 
abundance from HepG2 exposed to the T. indica fruit pulp extract, a score of 9 was 
obtained and this improved to 31 when the data were reanalysed to include cell lysate 
proteins of reduced abundance, signifying markedly higher probability. In addition, the 
IPA software also identified tumour necrosis factor (TNF) and interleukin-1 beta (IL-
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1), both of which are potent inflammatory mediators, as interactomes in the network 
affected by T. indica. This further supports our earlier speculation of the molecular 
mechanism involved in anti-inflammatory effects of T. indica.   
 
5.1.3 PPARα activation: possible mode of action of lipid-lowering effect of T. indica 
fruit pulp extract 
 Peroxisome proliferator-activated receptors or PPARs are nuclear receptors. 
There are 3 isoforms identified in humans: PPARα, PPARβ/δ and PPARγ. PPARα is 
highly expressed in liver, brown adipose tissue, heart, skeletal muscle, kidney, and at 
lower levels in other organs. PPARγ is highly expressed in adipose tissues and is 
present in the colon and lymphoid organs while PPARβ/δ is expressed ubiquitously, but 
its levels may vary considerably. 
 
 In this study, we proposed that the T. indica fruit extract exerts its lipid-lowering 
effects through the activation of PPARα. In the liver, PPARα promotes fatty acid 
oxidation and it is the target for the hypolipidaemic fibrates, such as fenofibrate, 
clofibrate and gemfibrozil, which are used in the treatment of hypertriglyceridaemia. 
This was shown by the up-regulation of genes involved in the mitochondrial β-
oxidation in the microarray analysis after T. indica fruit treatment (Figure 5.1) (Razali, 
et al., 2010). Besides promoting fatty acid oxidation, it also mediates its action through 
the activation of liver X receptor alpha (LXRα) (Johnston & Waxman, 2008), which 
was also derived as the one of the canonical pathways generated in Ingenuity Pathway 
Analysis (IPA) software (Figure 4.11). LXRs are oxysterol-activated nuclear receptors, 
which control cholesterol homeostasis by modifying expression of genes involved in 
cholesterol absorption and efflux from peripheral tissues. This process is mediated 
through ABCA1-mediated cholesterol efflux and ABCG5/8-mediated cholesterol 
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excretion and absorption. In the microarray study, ABCG5 was up-regulated by 1.8-fold 
(Razali, et al., 2010).  
 
LXRs also regulate genes essential in lipogenesis, glucose metabolism, and 
inflammation. A possible explanation for the anti-inflammatory action of T. indica fruit 
pulp is that it reduces the arachidonic acid reservoir pool, the principal substrate of the 
prostanoid inflammatory mediators by inhibiting phospholipid synthesis. Ethanolamine-
phosphate cytidylyltransferase (PCYT2) is the rate-limiting enzyme that catalyses the 
conversion of phosphoethanolamine to cytidylylphosphoethanolamine in the Kennedy’s 
pathway or the biosynthesis of phosphatidylethanolamine. After the treatment with T. 
indica fruit extract, cytosolic PCYT2 expression was down-regulated by 1.7-fold which 
is hypothesised to lead to lower production of phosphatidylethanolamine (PE). As one 
of the component of the HDL phospholipids, its reduction could enhance the ABCA1-
mediated efflux and reduce the SR-BI- mediated efflux (Yancey et al., 2004). ABCA1-
mediated efflux has a higher efflux potential compared to SR-BI-mediated efflux. 
Microarray study by Razali et al. (2010) also showed that choline kinase alpha (CHKA) 
was down-regulated by 1.8-fold, which may lead to a decreased level of 
phosphatidylcholine (PC). The lowered amount of phospholipids (PE and PC) could 
reduce the availability of arachidonic acid, which will in turn reduce the prostaglandin 
produced. This could possibly explain the anti-inflammatory action of this plant as 
reported by many. Besides this, the network generated by the IPA software also 
identified tumour necrosis factor (TNF) and interleukin-1 beta (IL1B) as two of the 
interactomes in the network, both of which are potent inflammatory mediators (Figure 
4.10). This suggests that the fruit may also play a role in mediating the inflammation 
pathway, besides regulating the lipid metabolism. 
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 Although studies have shown that PPARα raises the HDL in human plasma, 
some researchers showed that it was otherwise (Berthou et al., 1996; Duez et al., 2002). 
Huuskonen et al. (2006) reported that the LXR agonist, T0901317 inhibited the 
synthesis of apoA-1. The lowered amount of transthyretin and apoA-1 is possibly due to 
the inhibition of orphan nuclear receptor hepatocyte nuclear factor 4 (HNF4) by PPARα 
activation. It has been shown that the PPARα agonist, Wy 14643, reduced the 
expression of HNF4 in HepG2 cells (Marrapodi & Chiang, 2000).  HNF4 is a liver-
enriched transcription factor that controls embryonic liver development and 
regulates tissue-specific gene expression in adult liver cells. HNF4 activates several 
hepatocyte-specific genes, including the gene encoding apoA-1 (Malik & Karathanasis, 
1996) and transthyretin (J. W. Park, Lee, Choi, Park, & Jung, 2010; Z. Wang & Burke, 
2007). Therefore, the inhibition of HNF4 by PPARα may account for the lowered 
amount of apoA-1 and transthyretin after the treatment with T. indica fruit extract. 
 
The lipid-lowering effects induced by plant polyphenols have been reported by 
many. In fact, there is an upcoming trend of researches revealing the potentials of plant 
polyphenols in regulating metabolic processes in vitro and in vivo. Methanolic extract 
of T. indica fruit pulp contains catechin, epicatechin, procyanidins, naringenin, 
apigenin, luteolin, taxifolin and eriodictyol (Sudjaroen, et al., 2005).  It was shown that 
tea catechins like epigallocatechin gallate (EGCG) and epigallocatechin (EGC) were 
able to activate PPARα (K. Lee, 2004). Naringenin from grapefruit was shown to 
regulate lipid metabolism through partial activation of PPARα (Goldwasser, et al., 
2010). Another study showed that flavangenol extracted from pine bark was able to 
enhance fatty acid oxidation, mainly attributed to procyanidin B1 (Shimada, et al., 
2012). This shows that a number of polyphenols were able to regulate nuclear receptors 
such as PPAR and LXR. Earlier studies have also shown that proanthocyanidins, which 
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constitutes more than 73 % of the total phenolic content of T. indica extract (Sudjaroen, 
et al., 2005), were able to modulate the activation of LXR/RXR (Jiao, et al., 2010).  
Hence, the data of this study, when taken together with that of our earlier report by 
Razali et al. (2010), suggest that the T. indica fruit pulp extract exerts its lipid-lowering 
effects and anti-inflammatory actions through the modulation of the LXRs, a conception 
that was similarly derived from the canonical pathway analysis; or at a higher order, 
that is the activation of PPARα, both of which were highly interrelated in terms of gene 
regulated by their activations.     
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Figure 5.1: Proposed mechanism of action induced by T. indica fruit pulp through 
activation of peroxisome proliferator-activated receptor alpha (PPARα) 
The gene names in bold are proteins regulated in this proteomic study; while the gene 
names in normal font are genes significantly regulated in the previous microarray study 
(Razali, et al., 2010). 
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5.2 Transcriptomic studies 
 To further investigate the earlier hypothesis that T. indica fruit pulp extract 
exerts its lipid-lowering effects through the activation of PPARα, transcriptome profiles 
in steatotic HepG2 cells treated with either T. indica fruit extract or fenofibrate, a 
PPARα agonist and a hypolipidaemic drug, were compared. HepG2 cells were treated 
with palmitic acid to simulate steatotic condition, and the total triglyceride and 
cholesterol were quantitated after treatment with the fruit. Cell viability was assessed 
using MTT assay in order to determine the concentration of palmitic acid to best induce 
steatotic effect in HepG2 cells without causing extensive cell death. A cell viability of 
more than 90 % after treatment was considered to be appropriate for this study. Based 
on this, treatment with 0.3 mM palmitic acid for 24 h was considered to induce 
hyperlipidaemic effect in HepG2 cells. Oil Red O staining of the lipid droplets also 
showed that at 0.3 mM of palmitic acid treatment, the lipid droplets were clearly visible. 
Although at a higher concentration of palmitic acid treatment (0.8 mM palmitic acid) 
the lipid droplets were much bigger and abundant, the cell death was quite extensive; 
only 65 % of cells were still viable after 24 h. 
 
The total triglyceride and cholesterol in HepG2 cells after treatment with 
different concentrations of T. indica fruit extract was also quantified. At 0.1 mg/ml T. 
indica fruit concentration, both total triglyceride and cholesterol content were reduced. 
The lipid-lowering effect of the fruit extract was more prominent in reducing total 
triglyceride than total cholesterol; even to the level comparable to that of fenofibrate at 
the concentration of 0.1 mg/ml T. indica fruit extract. This is also in agreement to the 
fact that fenofibrate was more efficient in lowering triglyceride than cholesterol, 
probably signifying that the fruit may exert a similar mechanism to that of fenofibrate, 
that is through the activation of PPARα. However, further analysis is still needed to 
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confirm the hypothesis. At higher concentrations of T. indica fruit treatment, the lipid 
levels were increased. This was also supported by the Oil Red O staining of HepG2 
cells which showed a more abundant lipid droplet in cells treated with high 
concentration of T. indica fruit extract. The adverse effects of T. indica fruit extract at 
high concentration could be due to the excessive oxidative stress exerted by compounds 
like proanthocyanidin, the major polyphenol in T. indica fruit extract. It has been shown 
that grape seed proanthocyanidins can induce pro-oxidant toxicity in cardiomyocytes at 
high dose (Shao et al., 2003). However at low dose, proanthocyanidins are anti-oxidants 
and were shown to be cardioprotective (Corder et al., 2006). 
 
5.2.1 T. indica fruit extract regulated genes that are involved in fatty acid oxidation 
  Hepatic steatosis or fatty liver disease is characterised by accumulation of 
triglycerides in the vacuoles of liver cells. Fatty liver disease can progress from simple 
steatosis with no symptoms, through non-alcoholic steatohepatits (NASH), fibrosis and 
cirrhosis, which can result in liver cancer, liver failure and death. The current treatment 
for fatty liver disease is using drugs that are able to lower lipid levels particularly 
triglyceride to reduce the accumulation of triglycerides in the liver for example the 
fibrate drugs. The use of fibrate drug, which is a PPARα ligand induces fatty acid 
oxidation, which in turn increases lipid catabolism and thus reducing lipid levels in the 
liver. In this study, it was shown that the fruit exerts its lipid-lowering effect through the 
activation of fatty acid oxidation, which was supported by the up-regulation of genes 
involved in the process (ACSL1, CPT1A, CYP19A1, LPIN1, PNPLA8 and SLC2A1). 
This was also supported by the IPA analysis in which the process was shown to be 
activated with activation Z-score of 2.175.  
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Fatty acid oxidation is a process that breaks down fatty acids by beta-oxidation 
to produce acetyl-CoA and it takes place in the mitochondrion. Before catabolising 
long-chain fatty acids which are unable to pass through the inner mitochondrial 
membrane, the fatty acids are first converted to acyl-CoA to be transported into the 
mitochondria for the oxidation of fatty acid to occur. This process is mediated by the 
mitochondrial L-carnitine shuttle pathway, which was one of the top canonical 
pathways generated in the T. indica fruit and fenofibrate treatment groups. Two key 
genes involved in this pathway, CPT1A and ACSL1 were up-regulated in both treatment 
groups. ACSL1 gene codes for a rate limiting enzyme, acyl-CoA synthetase long-chain 
family member 1. It converts long chain fatty acid to acyl-coA, which is then 
transported across the outer mitochondrial membrane into the inner mitochondrial 
membrane. CPT1A gene codes for carnitine palmitoyltransferase 1A, which is an 
enzyme that catalyses the conversion of acyl-CoA into acylcarnitine. Acylcarnitine is 
then translocated into the mitochondrial matrix for beta-oxidation to occur. Therefore, 
the up-regulation of these 2 genes is indicative of increased fatty acid being shuttled 
into the mitochondria for beta-oxidation of fatty acid. 
 
CYP19A1 encodes a member of the cytochrome P450 superfamily of enzymes. 
The cytochrome P450 proteins are monooxygenases which catalyse many reactions 
involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This 
protein localises to the endoplasmic reticulum and catalyses the last steps of estrogen 
biosynthesis, three successive hydroxylations of the A ring of androgens. It has been 
shown that homozygous mutant mouse aromatase (Cyp19a1) gene knockout in mouse 
decreases beta-oxidation of palmitic acid in a cell-free system (Nemoto, et al., 2000). 
Egawa et al. (2003) had also reported that pitavastatin increases beta-oxidation of lauric 
acid in homogenate from mouse liver that is decreased by homozygous mutant mouse 
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Cyp19a1 gene knockout. This shows that the up-regulation of CYP19A1 is associated to 
increased beta-oxidation of fatty acid.  
 
LPIN1 was up-regulated by 1.5-fold in T. indica treatment group. This gene 
encodes lipin 1, a magnesium-ion-dependent phosphatidic acid phosphohydrolase 
enzyme that catalyses triglyceride synthesis including the dephosphorylation of 
phosphatidic acid to yield diacylglycerol. Expression of this gene is required for 
adipocyte differentiation, activation of hepatic fatty acid oxidation genes during fasting 
conditions and it also functions as a nuclear transcriptional coactivator with peroxisome 
proliferator-activated receptor a (PPARα) and PPARγ coactivator 1a (PPARGC1A) in a 
complex that modulates fatty acid oxidation gene expression (Finck, et al., 2006). 
Mutations in this gene are associated with metabolic syndrome, type 2 diabetes, and 
autosomal recessive acute recurrent myoglobinuria (ARARM) (Reue & Dwyer, 2009).  
 
SLC2A1 codes for GLUT 1, a major glucose transporter in the mammalian 
blood-brain barrier and it was down-regulated in both T. indica and fenofibrate 
treatment groups. Yan et al. (2009) reported that transgenic human SLC2A1 protein 
decreased oxidation of fatty acid in mouse heart that was increased by high fat diet. The 
down-regulation of this gene could imply an increase in fatty acid oxidation. However 
in a recent study the down-regulation of SLC2A1 was linked to increased lipid 
accumulation and oxidative stress in NAFLD induced liver. Despite the results, the 
group was unsure that the down-regulation of SLC2A1 induces triglyceride 
accumulation in liver or vice versa (Vazquez-Chantada et al., 2013). Nevertheless, 
given that this gene was also down-regulated in fenofibrate treated group in this study, 
which is a hypolipidaemic drug, the lowered expression of SLC2A1 is more likely to be 
involved in the oxidation of fatty acid. 
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PNPLA8 encodes a member of the patatin-like phospholipase domain containing 
protein family. Members of this family are phospholipases which catalyse the cleavage 
of fatty acids from membrane phospholipids. The up-regulation of this gene is 
correlated to increased fatty acid oxidation and this is in agreement with Mancuso et al. 
(2007) whom reported that transgenic human PNPLA8 protein in cardiac myocytes 
increased oxidation of palmitic acid in working isolated perfused heart from 4-7 month-
old adult mouse. However in 2010, the same author reported that homozygous mutant 
mouse PNPLA8 gene knockout increased the rate of oxidation of palmitic acid in 
epididymal adipose tissue explants from male mouse (Mancuso, et al., 2010).  
 
5.2.2 T. indica fruit extract regulated genes that are involved in gluconeogenesis 
 T. indica fruit treatment had also led to the regulation of genes involved in 
gluconeogenesis (G6PC, GK and SLC2A1). IPA analyses had also shown that T. indica 
fruit decreased polysaccharide synthesis particularly glycogen based on the regulation 
of genes involved in polysaccharide synthesis (G6PC, DKK1, VIMP, IGFBP1 and 
CSGALNACT2), with an activation z-score of -2.000.  
 
Gluconeogenesis is a metabolic process which produces glucose from non-
carbohydrate sources including glycerol derived from the breakdown of triglyceride. 
G6PC gene encodes glucose-6-phosphatase, which catalyses the hydrolysis of D-
glucose 6-phosphate to D-glucose and orthophosphate. It is a key enzyme in glucose 
homeostasis, functioning in gluconeogenesis and glycogenolysis. The up-regulation of 
this gene is implicated with the increased activity of glycogenolysis and this is 
supported by Aiston et al. (1999) whom reported that G6PC protein decreased synthesis 
of glycogen in hepatocytes. The up-regulation of G6PC gene in this study could 
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indicate reduced glycogen synthesis. GK gene codes for glycerol kinase, an enzyme that 
catalyses the conversion of glycerol to dihydroxyacetone phosphate, which will be 
utilised in gluconeogenesis or glycolysis pathway. SLC2A1 codes for glucose 
transporter 1 which facilitates transport of glucose across plasma membrane of 
mammalian cells. The reduced expression of this gene is linked to increased glucose 
levels (Hahn, Barth, Weiss, Mosgoeller, & Desoye, 1998). This may be a result of 
increased glucose production by the cell. Increased expressions of IGFBP1 and VIMP 
genes were also associated with decreased synthesis of glycogen (Gao et al., 2003; 
Menuelle, Binoux, & Plas, 1995). Taken together, the regulation of these genes 
indicates an increased production of glucose through gluconeogenesis or 
glycogenolysis. 
 
5.2.3 T. indica fruit extract lowers lipid through the activation of PPARα 
 Peroxisome proliferator activator receptor alpha or PPARα is a nuclear receptor 
that regulates lipid metabolism and glucose homeostasis. In the body, it is activated in 
fasting state and its activation will lead to regulations in an array of downstream genes 
that eventually increase lipid metabolism, gluconeogenesis, glycogenolysis and ketone 
bodies production.  
 
In this study, PPARα was predicted to be activated in both T. indica fruit and 
fenofibrate treatment groups in the IPA upstream regulator analysis, with activation z-
score of 2.745 and 2.379 respectively. While PPARα was expected to be activated in the 
fenofibrate group since it is a ligand to the PPARα receptor, the activation of PPARα by 
T. indica fruit treatment proved the hypothesis that was made prior to the microarray 
analyses, that is PPARα activation could be responsible for the lipid-lowering effect of 
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the fruit. This was shown by the simultaneous regulation of downstream genes involved 
in PPARα activation in both T. indica fruit and fenofibrate treatments.  
 
Fatty acid oxidation is the hallmark of PPARα activation and it was indeed 
shown to be activated in both T. indica and fenofibrate treatment groups. Two genes, 
CPT1A and ACSL1 which are involved in the mitochondrial L-carnitine shuttle pathway 
were shown to be up-regulated in both T. indica fruit and fenofibrate treatment. Besides 
this, they were also shown to be increased in PPARα activation (Ammerschlaeger, et 
al., 2004; Begriche, et al., 2006; Clemenz, et al., 2008; Finck, et al., 2002; M. H. Hsu, et 
al., 2001; Lawrence, et al., 2001; Schoonjans, et al., 1995; Tachibana, et al., 2006; 
Vega, et al., 2000). The up-regulation of both CPT1A and ACSL1 genes indicates that 
PPARα was being activated in T. indica fruit treatment group. Besides this, fatty acid 
oxidation genes were also shown to be up-regulated in the presence of lipin-1 gene, 
which was up-regulated in T. indica fruit treatment. In the cytoplasm, lipin-1 is an 
enzyme responsible in triglyceride accumulation and phospholipid synthesis; however 
when translocated to the nucleus, it functions as a transcriptional co-activator together 
with PPARGC1A to PPARα that leads to the induction of fatty acid oxidation genes 
(Finck, et al., 2006).  
 
PPARα activation also modulates glucose homeostasis. While contradictory 
findings regarding the regulation of glucose by PPAR activation had been reported 
(Peeters & Baes, 2010), it was certain that PPARα activation leads to the regulation of 
glucose levels in fasting conditions. This was supported by studies showing that fasting 
PPARα knockout mice displayed marked hypoglycaemia (Bandsma, et al., 2004; 
Chakravarthy et al., 2005; Kersten et al., 1999; Leone, Weinheimer, & Kelly, 1999; 
Patsouris, et al., 2004). As mentioned earlier, treatment with T. indica fruit regulated 
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genes involved in gluconeogenesis and it was supported by the IPA analysis which 
showed that the synthesis of polysaccharide particularly glycogen was reduced. Since 
glucose level or regulation is not studied in this experiment, a clear conclusion cannot 
be drawn at this juncture. However a few genes regulated in this study pointed to the 
activation of PPARα. For example, a key enzyme involved in gluconeogenesis and 
glycogenolysis, G6PC was demonstrated to be modulated in the event of PPARα 
activation. While it was shown that homozygous mutant mouse Ppara gene knockout 
decreased expression of mouse G6pc mRNA that involves fasting by mouse (Bandsma, 
et al., 2004), Fan et al. (2011) reported that inhibition of active human PPARA protein 
increases expression of human G6PC mRNA in serum-deprived HepG2 cells and a 
similar observation was seen in Ppara gene knockout mutant mouse. Another gene 
involved in PPARα activation is the GK gene, which codes for glycerol kinase. 
Patsouris et al. (2004) reported that PPARα induced gluconeogenic genes including 
glycerol kinase during fasting in wild-type mice but not in PPARα null mice, indicating 
that this gene is a target of PPARα activation. 
 
 PPARα activation is also implicated in the bile acid metabolism, although the 
mechanism of action by which PPARα controls bile acid homeostasis remains unclear. 
In this study, CYP7A1, a key gene responsible in the bile acid biosynthesis pathway, 
was reduced in expression to the level similar to control. It has been shown that Cyp7a1 
gene is down-regulated in PPARα null mice in fasting condition (Rakhshandehroo et 
al., 2007). Ironically, synthetic PPARα agonists reduce Cyp7a1 expression in both mice 
and human (Bertolotti et al., 1995; Post et al., 2001; Stahlberg, Angelin, & Einarsson, 
1989; Stahlberg et al., 1995). In agreement with the latter observation, fibrate treatment 
leads to decreased bile acid synthesis. The mechanism that led to change in Cyp7a1 
level is unclear as PPARα also modulates the expression of other nuclear hormone 
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receptors such as FXR and LXR. It has also been suggested that PPARα can antagonise 
LXR signaling and LXR-dependent activation of Cyp7a1 gene promoter (Gbaguidi & 
Agellon, 2002; Miyata, McCaw, Patel, Rachubinski, & Capone, 1996; Yoshikawa et al., 
2003). 
 
Other genes involved in PPARα activation that were also regulated in both T. 
indica fruit and fenofibrate treatment groups are STBD1, KRT23 and NCF2. STBD1 
encodes starch binding domain 1 while KRT23 codes for keratin 23. It was shown that 
in male mouse, homozygous mutant mouse Ppara gene knockout decreases expression 
of mouse Stbd1 and Krt23 mRNA in liver from male mouse that involves fasting 
(Sanderson, et al., 2010). Similarly, the up-regulation of NCF2 was reported to be 
associated with activation of PPARα in macrophages nuclei (Teissier, et al., 2004). 
Perilipin 2 (PLIN2), another target gene of PPARα in liver was also up-regulated in the 
treatment with T. indica fruit. A study showed that PPARα-induced-Plin2 prevents the 
formation of VLDL by diverting fatty acids from the VLDL assembly pathway into 
cytosolic triglycerides (Magnusson et al., 2006). Figure 5.2 depicts the significantly 
regulated genes involved in PPARα activation in T. indica fruit treatment.  
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Figure 5.2: Significantly regulated genes involved in PPARα activation in 
hepatocyte 
Red colour genes indicate up-regulated genes while green colour genes indicate down-
regulated genes in T. indica-treated HepG2 cells. Asterisk indicates that the gene was 
regulated in both T. indica fruit and fenofibrate treatment groups. 
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5.2.4 PPARGC1A or PGC1A: the key regulator of multiple nuclear receptors 
 Based on the genes that were significantly regulated after treatment with T. 
indica fruit in the microarray study, it was shown that many transcription factors were 
predicted to be activated and many of which are involved in lipid and glucose 
homeostasis (PPARA, PPARG, CREB1 and PPARGC1A). This implies that the fruit 
may have exerted its lipid-lowering effects through the activation of one or more of 
these transcription factors. It should be noted that cross-talk can occur between 
transcription factors, as seen in the overlapping of genes regulated by different 
transcription factors (Figure 4.24). This further complicates the identification of a 
precise mode of action of the fruit in lowering lipid. However the activation of PPARA 
by the fruit was eminent based on the fact that it regulated genes involved in fatty acid 
oxidation and was comparable to fenofibrate, both of which were predicted to activate 
PPARA. However, the prediction about the activation of other transcription factors 
could indicate that the fruit probably mediates its hypolipidaemic effects through 
regulation at a higher order, or at an entirely different mechanism of action altogether.  
 
 The activation of multiple transcription factors could be explained by the 
involvement of PPARGC1A. PPARGC1A or PGC1A is a transcriptional coactivator 
responsible for the regulation of many metabolic processes like gluconeogenesis, 
adaptive thermogenesis, positive regulator of mitochondrial biogenesis and respiration. 
(Handschin & Spiegelman, 2006). PGC-1 coactivators functionally interact with 
transcription factors like PPARG, PPARA, ERR, LXR and HNF-4a (Nagai et al., 2009; 
Puigserver & Spiegelman, 2003; Yang, Williams, & Kelly, 2009) and non-nuclear 
receptor transcription factors and regulatory elements including cAMP response 
element-binding protein (CREB), sterol regulatory element-binding protein-1c (SREBP-
1c) and forkhead box O1 (FOXO1) (Gupta et al., 2005; Nakae et al., 2002; Puigserver 
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et al., 2003; Yamagata et al., 1996; J. C. Yoon et al., 2001). In a review by Sugden et al. 
(2010), PGC1A works in orchestration with PPARA, FOXO1, HNF4A and CREB in 
inducing hepatic gluconeogenesis. It was also shown that lipin-1 (LPIN1), which was 
up-regulated in the microarray study, induces fatty acid oxidation by forming a complex 
with PGC1A and PPARA (Figure 5.3). The authors also proposed that SIRT1 may be 
the key molecule regulating the PPARs, PGCs and lipin-1 in modulating the metabolic 
responses in tissues including liver and adipose tissues in varying nutrient and 
physiological signals.  
 
The transactivation of PPARα can be mediated by PPARα ligands or by the 
presence of high levels of PPARGC1A (Sanderson et al., 2009). PPARGC1A was 
predicted to be activated in the T. indica treatment group in the IPA upstream regulator 
analysis, with an activation z-score of 2.394. The result was supported by the fact that 
genes that were involved in the PPARGC1A activation were up-regulated, i.e. TRIB3, 
PLIN2, LPIN1, G6PC and CPT1A. PPARGC1A is a transcription coactivator that 
modulates lipid metabolism, energy production and glucose metabolism. It was shown 
that lipin-1 (LPIN1) which was up-regulated in the T. indica fruit treatment enhanced 
fatty acid oxidation by forming a complex with PPARGC1A and PPARA (Finck, et al., 
2006) (Figure 5.3).  
 
The activation of PPARGC1A is also implicated in increased glucose production 
in the liver (Herzig et al., 2001). In this study CREB1, FOXO1 and PPARGC1A were 
predicted to be activated in the IPA analyses (Table 4.15). CREB was activated by 
TORC2 in the presence of glucagon during fasting. The activated CREB subsequently 
induces PPARGC1A and the formation of a complexion consisting of GR, FOXO1, 
HNF4A and PPARα induces genes involved in gluconeogenesis (Dentin et al., 2007; X. 
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Li, Monks, Ge, & Birnbaum, 2007). PPARGC1A was also reported to be involved in 
inducing gluconeogenesis through a non-classical pathway that does not involve 
glucocorticoids and glucagon by coactivating FOXO1 and HNF4A to induce 
gluconeogenesis-related genes (Rodgers et al., 2005).  
 
PPARα activation has been indicated in lipid-lowering activities mainly through 
fatty acid oxidation, which was indeed shown to be activated in both T. indica fruit and 
fenofibrate treatment groups. However its involvement in glucose homeostasis remains 
ambiguous. While two studies reported that the fruit exhibited glucose lowering 
properties in hyperglycaemic mice (Koyagura et al., 2013; Roy et al., 2010), our 
previous treatment using T. indica ethanolic extract on obese hamsters showed no 
significant changes in glucose level (Lim, et al., 2013). 
 
 
 
Figure 5.3: Lipin-1 (LPIN1) enhances fatty acid oxidation by forming a complex 
with PPARGC1A and PPARA 
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5.2.5 T. indica fruit activates PPARγ 
PPARγ, like PPARα is a member of the nuclear receptor superfamily of ligand-
activated transcription factors (Cornelius, MacDougald, & Lane, 1994) highly 
expressed in adipocytes (Chawla, Schwarz, Dimaculangan, & Lazar, 1994; Tontonoz, 
Hu, Graves, Budavari, & Spiegelman, 1994) and plays a role in improving glucose 
homeostasis and adipocyte differentiation (Kallwitz, McLachlan, & Cotler, 2008). 
Mutations of PPARγ results in the development of severe insulin resistant, type-2 
diabetes, hypertension in the absence of obesity, elevated triglycerides and low HDL 
levels and a number of components of the metabolic syndrome. Like other PPARs, free 
fatty acid and their derivatives can bind and activate PPARγ. However, specific 
mechanism of action related to fatty acids and their metabolites is still unclear as 
identification of specific endogenous PPARγ ligands remains ambiguous (Forman, 
Chen, & Evans, 1996; Forman et al., 1995). In contrast, synthetic ligands, such as 
thiazolidinediones or TZDs, are potent activators of PPARγ with robust insulin-
sensitising activities (Kung & Henry, 2012). While TZDs are highly effective 
hypoglycaemic drugs, side effects like weight gain, fluid retention and osteoporosis 
were reported (Kung & Henry, 2012).  
 
 The protein encoded by TRIB3 gene is a putative protein kinase that is induced 
by the transcription factor NF-kappaB. The encoded protein is a negative regulator of 
NF-kappaB and can also sensitise cells to TNF- and TRAIL-induced apoptosis. In 
addition, this protein can negatively regulate the cell survival serine-threonine kinase 
AKT1. The up-regulation of this gene could probably explain the anti-inflammatory 
action of this fruit (Rimbau, et al., 1999). Other than its involvement in apoptosis and 
inflammation processes, it has been shown that human TRIB3 decreased biosynthesis 
of fatty acid (Qi et al., 2006). Mouse Trib3 is involved in transport of glucose by 
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inhibiting Akt/PKB activation by insulin in liver (Du, Herzig, Kulkarni, & Montminy, 
2003). 
 
 PLIN2, a gene up-regulated in the presence of PPARα and PPARγ 
transactivation (Nielsen, et al., 2006), was shown to reduce fatty acid uptake, oxidation 
and lipolysis when PLIN2 protein was down-regulated (Faleck et al., 2010). However, a 
study using homozygous mutant mouse Plin2 gene knockout in obese mouse decreased 
quantity of triglyceride and glucose in mouse liver (B. H. Chang, Li, Saha, & Chan, 
2010). ACSL, which was shown to be up-regulated in fatty acid oxidation and PPARα 
activation, was also up-regulated in PPARγ activation (Finck, et al., 2002; Schoonjans, 
et al., 1995; Tachibana, et al., 2006).  
 
 The other two genes that were involved in lipid and glucose metabolism, CPT1A 
and G6PC, were found to be regulated in the event of PPARγ transactivation. Begriche 
et al. (2006) reported that CREB protein increased expression of CPT1A protein that 
involves PPARγ protein. In a study using diabetic rats, it was found that the activation 
of rat Pparg protein decreased expression of rat G6pc mRNA in fatty rat liver (Way, et 
al., 2001). However in another study using mutant mouse with a homozygous knockout 
of mouse Ppara gene, mouse PPARγ 1 protein increased the expression of mouse G6pc 
mRNA (S. Yu, et al., 2003). 
 
 The effects of TZDs against NAFLD are controversial, according to a review by 
Ables (2012). Studies using different experimental models showed either beneficial or 
undesirable effects when TZDs were used. It was shown that TZDs improved insulin 
sensitivity but with the concomitant development of hepatosteatosis, while some 
showed otherwise (Ables, 2012). In this study PPARγ was predicted to be activated in 
T. indica treatment, and the same effect was not shown in other groups like fenofibrate 
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and palmitic acid treatment groups based on the genes involved in PPARγ activation. 
This indicates that the transactivation of PPARγ was attributed to T. indica fruit pulp 
extract. While studies pointed that PPARγ can improve insulin sensitivity but induce 
fatty liver, the lipid study in this experiment showed otherwise. Treatment with T. 
indica fruit extract lowered triglyceride and cholesterol and the effect is comparable to 
fenofibrate at 0.1 mg/ml T. indica fruit extract and was supported by the Oil Red O 
staining showing lowered amount of lipid droplets in the cells after treatment. Taken 
together, PPARγ activation was shown to regulate genes related to lipid and glucose 
metabolism but without the adverse effect of lipid accumulation in liver cells. 
 
 It has been shown that PPARγ ligands have an anti-tumour effect in humans as 
these compounds decrease cell growth and induce apoptosis in several malignant human 
cell types, including hepatocellular carcinoma, breast adenocarcinoma and colon 
adenocarcinoma (Boitier, Gautier, & Roberts, 2003). This effect was also observed in 
the microarray study in which genes involved in apoptosis and cell death were 
significantly regulated. For example, up-regulation of TNFSF10 gene is linked to 
apoptosis (Baader et al., 2005; Ichikawa et al., 2001) and cell death (Di Pietro & Zauli, 
2004). The protein encoded by this gene is a cytokine that belongs to the tumour 
necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in 
transformed and tumour cells, but does not appear to kill normal cells although it is 
expressed at a significant level in most normal tissues. It has been shown that inhibition 
of active mouse Pparg protein by GW9662 prevented transactivation of human 
TNFSF10 gene in HuH7 cells that is dependent on human PPARG protein (Ho, et al., 
2011).  
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 Other genes like OCLN, NDRG1, GSTA1, HYOU1 and JUN involved in 
apoptosis were significantly regulated in the microarray study too. Occludin, the protein 
encoded by OCLN gene was shown to be increased by human PPARG protein in co-
cultured U937 cells (Huang, et al., 2009). Ndrg1 gene encode N-myc downstream 
regulated 1. This gene is a member of the N-myc downregulated gene family which 
belongs to the alpha/beta hydrolase superfamily. The protein encoded by this gene is a 
cytoplasmic protein involved in stress responses, hormone responses, cell growth, and 
differentiation. The encoded protein is necessary for p53-mediated caspase activation 
and apoptosis. Interference of mouse Pparg mRNA by siRNA was shown to decrease 
expression of mouse Ndrg1 mRNA in mature 3T3-L1 adipocytes that is increased by 
hypoxia (Pino, et al., 2012). GSTA1 and HYOU1 genes were found to be involved in 
activation of PPARγ. 9-cis-retinoic acid and prostaglandin J2 increased binding of 
PPRE from rat Gsta2 gene and a heterodimeric protein-protein complex consisting of 
rat Pparg and of rat Rxr (E. Y. Park, et al., 2004). As for HYOU1, the findings by Jiang 
et al. (2010) were contradictory. They reported that homozygous mutant mouse Pparg 
gene knockout increased expression of mouse Hyou1 mRNA in epithelium from mouse 
prostate gland. However, interference of mouse Pparg2 mRNA by siRNA decreased 
expression of mouse Hyou1 mRNA in epithelial cells from mouse prostate gland.   
 
 KLF4 and KLF6 were both up-regulated by 1.5- and 2.0-fold respectively. These 
genes encode members of the Kruppel-like family of transcription factors. The zinc 
finger protein is a transcriptional activator, and functions as a tumour suppressor. It was 
demonstrated that activation of PPARγ led to the increased expression of KLF4 protein 
and mRNA (Drori, et al., 2005; S. Li, et al., 2013; Rageul, et al., 2009). While for 
KLF6, it was shown that interference of mouse Pparg mRNA by siRNA increased 
expression of mouse Klf6 mRNA in mature terminally differentiated 3T3-L1 adipocytes 
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(Schupp, et al., 2009). Taken together, T. indica fruit was shown to activate PPARγ 
based on the genes regulated in microarray study. 
 
5.2.6 T. indica fruit modulates apoptosis and cell death 
T. indica fruit pulp is known to exhibit lipid-lowering effects and it has been 
shown in this study that it could be mediated by fatty acid oxidation through the 
activation of PPARα. While the regulations of lipid metabolism and to a certain extent, 
carbohydrate metabolism were being modulated, the number of genes involved in 
apoptosis and cell death were interestingly high. T. indica fruit extract has never been 
reported to exhibit anti-proliferative effect to the best of our knowledge, and the MTT 
assay in this study was in agreement to that fact. The extensive regulation of genes 
involved in apoptosis and cell death in all treatments could probably explain that cancer, 
cell growth and proliferation, as well as cell death-related networks as being the 
dominant associated network functions in the IPA network analysis. 
 
5.2.6.1 Induction of endoplasmic reticulum (ER) stress 
 Among the many mechanisms that could lead to apoptosis, one is associated 
with the induction of ER stress. ER is a site for Ca
2+
 storage and also responsible for 
synthesis, folding and maturation of secreted and transmembrane proteins. Pathological 
or physiological conditions that interrupt protein folding in the ER can cause stress in 
the endoplasmic reticulum and lead to the activation of signalling pathway known as the 
Unfolded Protein Response (UPR) pathway.  
 
In the IPA upstream regulator analysis, three transcription factors associated to 
ER stress, DDIT3, ATF4 and XBP1 were predicted to be activated. While DDIT3 and 
XBP1 were predicted to be activated in all treatment groups based on the genes 
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regulated, ATF4 was exclusively predicted to be activated in T. indica treatment group 
only. 
 
 DDIT3 or CHOP is one of the key markers in ER stress induced pathway, UPR 
pathway. It codes for C/EBP homologous protein, a member of the CCAAT/enhancer-
binding protein family. CHOP is implicated in adipogenesis and erythropoiesis, and is 
activated by ER stress, and promotes apoptosis. In this study, it was up-regulated in all 
treatments and its activation is supported by the IPA upstream regulator analysis based 
on the genes regulated the T. indica fruit treatment. There are 6 DDIT3 target genes that 
were significantly altered in this study, WARS, TRIB3, PPP1R15A, LCN2, ATF3, and 
ANKRD1. Out of these 6 genes, 4 genes (WARS, TRIB3, PPP1R15A and ATF3) were 
also shown to be regulated in the transactivation of ATF4, another transcription factor 
that was shown to be activated based on the genes regulated (J. Han et al., 2013).  
 
 Activating transcription factor 4 or ATF4 is also induced by ER stress through 
the UPR pathway. According to the IPA upstream regulator analysis, 9 genes have 
expression direction consistent with the activation of ATF4, namely WARS, NDRG1, 
MAP1LC3B, KLF4, HERPUD1, DDIT3, ATF3, TRIB3 and PPP1R5A. In a microarray 
analysis done by Jousse et al. (2007), it was shown that amino acid starvation of Mef 
cells increased expression of mouse genes like Wars, Herpud1, Ddit3, Areg and Trib3 
that involves mouse Atf4 protein. The activation of ATF4 was also supported by the 
regulations of genes like WARS, NDRG1, KLF4, HERPUD1 and ATF3 which were 
found to be decreased in expression when Atf4 gene was knockout in mouse (Harding et 
al., 2003). However in a recent study, tribbles 3 or TRIB3 which was up-regulated in 
this study was shown to be up-regulated in high-fat feeding mice and humans with 
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obesity and type-2 diabetes. When the gene was knockout in high-fat feeding mice, the 
mice showed improved insulin resistance in skeletal muscle (Koh et al., 2013). 
 
Although these results were linked to the induction of ER stress, it was shown 
that ER stress suppressed genes involved in maintaining energy and lipid homeostasis 
such as PPARα, PGC1a and FOXO1. (Rutkowski et al., 2008). This finding is in 
contrast with our results which were predicted to be activated based on the genes 
regulated in the microarray study. It should be noted that classical pro-apoptotic 
molecules like Bax, Bak, and caspases were not significantly regulated in this study, 
indicating that apoptosis may not occur in the cells. Besides this, T. indica fruit was able 
to lower lipid levels in HepG2 cells, which also defies the fact that ER stress leads to 
hepatosteatosis. Furthermore, the MTT assay did not exhibit anti-proliferative activity 
nor extensive cell death, thus eliminating the possibilities of ER stress-induced 
apoptosis.  
 
5.2.6.2 Tumour suppressing genes involved in TP53, FOXO3 and c-MYC 
downstream pathways 
 Besides this, the microarray results also showed regulation of genes involved in 
tumour suppressing activities. TP53 codes for tumour suppressor 53, which was 
predicted to be activated in the IPA upstream regulator analysis based on the genes 
regulated. As the name implies, it is a potent tumour suppressor in humans, based on the 
fact that most of the human tumours have mutations or deletions in p53 gene itself or in 
the p53 pathway (Vogelstein, Lane, & Levine, 2000). It responds to diverse cellular 
stresses to regulate expression of target genes, thereby inducing cell cycle arrest, 
apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in p53 have 
been linked to poor prognosis in a variety of human cancers, including lung (Quinlan, 
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Davidson, Summers, Warden, & Doshi, 1992), breast (Deng et al., 1994) and gastric 
cancers (Scott et al., 1991), as well as lymphomas (Gaidano et al., 1991; Lo Coco et al., 
1993). Other than its involvement in tumour suppressing activities, it was also reported 
to regulate fatty acid oxidation through the induction of lipin-1 (LPIN1), which was up-
regulated in the microarray study (Assaily et al., 2011).  
 
 Another tumour suppressor, FOXO3 is responsible for the expression of a 
program of genes involved in cell cycle arrest, DNA repair, hypoxia response and 
apoptosis (Bakker, Harris, & Mak, 2007; Brunet et al., 1999; Medema, Kops, Bos, & 
Burgering, 2000; Tran et al., 2002). It is negatively regulated in response to insulin and 
growth factors through phosphorylation-dependent nuclear export (Brunet, et al., 1999; 
Nakae, Park, & Accili, 1999), while positive regulation occurs in the presence of 
oxidative stress through JNK activity (Brunet et al., 2004; Essers et al., 2004). In recent 
studies, it was shown that transactivation of FOXO3 is hepatoprotective against acute 
and chronic alcohol-induced liver injury by inducing autophagy, a protective 
mechanism against alcohol-induced liver injury by removing damaged mitochondria 
(Ni, Du, You, & Ding, 2013; Tumurbaatar et al., 2013). 
 
 MYC is a transcription factor regulating genes involved in cell growth, cell 
proliferation, cell cycle and apoptosis (Dang, 1999). Its activation is associated with 
many types of cancers and its inhibition is a therapeutic target for anti-cancer research. 
In this study it was predicted to be inhibited based on the genes regulated in T. indica 
fruit treatment group (THBS1, TES, TAF1D, SNHG12, SLC2A1, RPL5, PPP1R15A, 
NDRG1, LGALS1, ID1, DUSP1, DDIT3, CPT1A, CD9, KLF6 and MT1E). Down-
regulation of c-Myc has been reported to mediate anti-cancer effect. In fact, a number of 
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plant extracts were shown to inhibit cancer cell proliferation by inhibiting c-Myc 
(Giessrigl et al., 2012; Othman et al., 2012; Unger et al., 2012). 
 
 The overall activation of tumour suppressors and inhibition of oncogene in this 
microarray study may suggest anti-cancer properties of the fruit. However it should be 
noted that the fruit did not affect cell viability significantly, as shown in the MTT assay 
results. Moreover, there has been no studies reporting any anti-cancer activities in 
relation to this fruit, although individual polyphenolic compounds found in the 
methanol extract of T. indica has been shown to exhibit anti-proliferative effects.  
 
5.3 Polyphenols in T. indica fruit that may attribute to the activities 
The lipid-lowering effects induced by plant polyphenols have been reported by 
many. In fact, there is an upcoming trend of researches revealing the potentials of plant 
polyphenols in regulating metabolic processes in vitro and in vivo. Methanolic extract 
of T. indica fruit pulp contains catechin, epicatechin, procyanidins, naringenin, 
apigenin, luteolin, taxifolin and eriodictyol (Sudjaroen, et al., 2005).  It was shown that 
tea catechins like epigallocatechin gallate (EGCG) and epigallocatechin (EGC) were 
able to activate PPARα (K. Lee, 2004). Naringenin from grapefruit was shown to 
regulate lipid metabolism through partial activation of PPARα (Goldwasser, et al., 
2010). This was also supported by Mulvihill et al.(2009) who had shown that 
naringenin was able to correct VLDL overproduction, ameliorate hepatic steatosis, and 
attenuate dyslipidemia without affecting caloric intake or fat absorption in LDL 
receptor null mice through the activation of PGC1A/PPARα activation. Interestingly, 
naringenin from black elder flowers was shown to increase activation of PPARγ too 
(Christensen, Petersen, Kristiansen, & Christensen, 2010). Another study showed that 
flavangenol extracted from pine bark was able to enhance fatty acid oxidation, mainly 
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attributed to procyanidin B1 (Shimada, et al., 2012). Proanthocyanidins from hawthorn 
had also been reported to lower lipid and glucose level by activating AMPK and 
PPARα (Shih, Lin, Lin, & Wu, 2013). Tart cherries rich in anthocyanins had also been 
shown to ameliorate hepatic steatosis and hyperlipidaemia through the activation of 
PPARα (Seymour et al., 2008). This shows that a number of polyphenols in the 
methanolic extract of T. indica fruit were able to regulate nuclear receptors such as 
PPARα.  
 
Although T. indica fruit did not exhibit anti-proliferative effect, genes related to 
apoptosis were seen significantly regulated. The polyphenols in the fruit could be 
accountable for the phenomenon. For instance procyanidins from grape seed and apple 
had been shown to induce apoptosis through the induction of caspases (C. P. Hsu et al., 
2009; Miura et al., 2008). Similarly, catechins and green tea catechins which consist of 
(−)-epigallocatechin-3-gallate (EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin-3-
gallate (ECG) and (−)-epicatechin (EC) were also reported to induce apoptosis in cancer 
cells (Al-Hazzani & Alshatwi, 2011; Alshatwi, 2010; Chung et al., 2001; Nakazato et 
al., 2005; Philips, Coyle, Morrisroe, Chancellor, & Yoshimura, 2009). However in a 
recent study, catechin was shown to increase viability and decrease apoptosis and 
proliferation of epithelial cells and vascular smooth muscle cells (Negrao et al., 2013). 
Apigenin is another polyphenol that exhibit anti-proliferative properties (Budhraja et al., 
2012; C. C. Lin et al., 2012; Zbidah et al., 2012). Yan et al. (2012) reported that luteolin 
exhibited anti-cancer effect in non-small cell lung cancer xenograft mouse model 
through the increased activity of TRAIL (TNFSF10), which was up-regulated in the 
microarray study. 
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CHAPTER 6  
CONCLUSION 
 
 In the present study, the lipid-lowering effect of T. indica fruit pulp was 
investigated systematically. The study was performed in three stages, i) proteomic 
analysis to corroborate with the previous microarray analysis and to formulate a 
hypothesis; ii) measurement of lipid levels in hepatosteatotic HepG2 cells and iii) 
transcriptomic analysis on T. indica fruit treated-hepatosteatotic HepG2 cells and 
comparing the transcriptomic profile with fenofibrate treated cells. The first stage of 
this study suggested that T. indica fruit could have exerted its hypolipidaemic effect 
through the activation of PPARα. Lipid studies showed that 0.1 mg/ml methanolic 
extract of T. indica fruit pulp was able to lower lipid (triglyceride and cholesterol) to a 
level comparable to fenofibrate treatment. Based on the transcriptomic studies, T. indica 
fruit mediates its hypolipidaemic effects by increasing fatty acid oxidation through the 
transactivation of PPARα, a method similar to fenofibrate. In summary, the results from 
this study suggest that such an integrated approach has led to a better understanding of 
the lipid-lowering effects of T. indica fruit pulp.  
 
6.1 Future study 
 The findings from this study demonstrated that T. indica fruit pulp is a 
promising lipid-lowering agent and more in-depth studies should be warranted in the 
future. To further validate the lipid-lowering action of T. indica fruit pulp through the 
activation of PPARα, PPARα reporter assay can be performed. This assay allows the 
monitoring of PPARα transcriptional activities in cells. Besides PPARα, other 
transcription factors that were predicted to be activated or inhibited can also be 
validated by using reporter assays for the respective transcription factors. The 
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hypothesis can also be tested in animal models by observing the effect of T. indica fruit 
pulp in PPARα-knockout mice.  
 
The individual compounds in T. indica fruit pulp extract can also be isolated and 
assessed for bioactive properties. While pure compound is often more potent than crude 
extract, it should be noted that complex mixture of compounds found in natural 
products often interacts with each other either synergistically or antagonistically, thus 
affecting the potency of the bioactive properties.    
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APPENDIX 
 
Supp. Table 1: Genes related to PPARGC1A activation that are significantly regulated in the microarray analyses of the different treatments 
on HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when 
PPARGC1A 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
TRIB3 ↑ (Koo, et al., 2004) Tribbles homolog 3 (Drosophila) 1.6   
PLIN2 ↑ (Koves et al., 2013) Perilipin 2 1.6   
LPIN1 ↑ (Finck, et al., 2006; D. K. Kim et al., 2011) Lipin 1 1.5   
GK ↑ (Feige et al., 2007; Tiraby et al., 2003) Glycerol kinase 1.6   
G6PC ↑ (J. Lin et al., 2004; Puigserver, et al., 2003; 
Rhee et al., 2003; J. C. Yoon, et al., 2001) 
Glucose-6-phosphatase, catalytic 
subunit 
2.3 1.6 1.5 
CPT1A ↑ (K. Ma, Zhang, Elam, Cook, & Park, 2005; 
Rhee, et al., 2003; Vega, et al., 2000; Y. Zhang 
et al., 2004) 
Carnitine palmitoyltransferase 1A 
(liver) 
1.7 1.6  
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Supp. Table 2: Genes related to CREB1 activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when CREB1 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
PPP1R15A ↑ (Lemberger, Parkitna, Chai, Schutz, & 
Engblom, 2008) 
Protein phosphatase 1, regulatory 
subunit 15A 
2.5 1.8  
NFIL3 ↑ (Lemberger, et al., 2008) Nuclear factor, interleukin 3 
regulated 
1.7  1.5 
CPT1A ↑ (Begriche, et al., 2006) Carnitine palmitoyltransferase 1A 
(liver) 
1.7 1.6  
BHLHE40 ↑ (Lemberger, et al., 2008) Basic helix-loop-helix family, 
member e40 
2.2   
ATF3 ↑ (Lemberger, et al., 2008) Activating transcription factor 3 1.6 1.5  
CYP19A1 Affected (Morales et al., 2003) Cytochrome P450, family 19, 
subfamily A, polypeptide 1 
1.6 1.6  
DUSP1 Affected (Abramovitch et al., 2004; Du, Asahara, Jhala, 
Wagner, & Montminy, 2000) 
Dual specificity phosphatase 1 2.4 1.6  
G6PC Affected (Carriere et al., 2005; B. Lin, Morris, & Chou, 
1997) 
Glucose-6-phosphatase, catalytic 
subunit 
2.3 1.6 1.5 
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Supp. Table 2, continued      
HERPUD1 Affected (Abramovitch, et al., 2004) Homocysteine-inducible, 
endoplasmic reticulum stress-
inducible, ubiquitin-like domain 
member 1 
2.2 1.7 1.5 
ID1 Affected (San-Marina, Han, Suarez Saiz, Trus, & 
Minden, 2008) 
Inhibitor of DNA binding 1, 
dominant negative helix-loop-helix 
protein 
-1.5  -1.5 
JUN Affected (Lamph, Dwarki, Ofir, Montminy, & Verma, 
1990; A. Rao, Luo, & Hogan, 1997) 
Jun proto-oncogene 1.9   
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Supp. Table 3: Genes related to ATF4 activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when ATF4 is 
activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
WARS ↑ (J. Han, et al., 2013; Harding, et al., 2003; 
Jousse, et al., 2007) 
Tryptophanyl-tRNA synthetase 1.5   
NDRG1 ↑ (Harding, et al., 2003) N-myc downstream regulated 1 1.6   
MAP1LC3
B 
↑ (Rouschop et al., 2010; Rzymski et al., 2010; 
Verfaillie, Salazar, Velasco, & Agostinis, 
2010) 
Microtubule-associated protein 1 
light chain 3 beta 
1.5 1.6 1.6 
KLF4 ↑ (Harding, et al., 2003) Kruppel-like factor 4 (gut) 1.5   
HERPUD1 ↑ (Carter, 2007; Harding, et al., 2003; Jousse, et 
al., 2007; Y. Ma & Hendershot, 2004) 
Homocysteine-inducible, 
endoplasmic reticulum stress-
inducible, ubiquitin-like domain 
member 1 
2.2 1.7 1.5 
DDIT3 ↑ (Carter, 2007; Jousse, et al., 2007; Y. Ma & 
Hendershot, 2004; Rouschop, et al., 2010; 
Verfaillie, et al., 2010) 
DNA-damage-inducible transcript 
3 
2.5 1.8 1.7 
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Supp. Table 3, continued      
ATF3 ↑ (Carter, 2007; Harding, et al., 2003; H. Y. Jiang 
et al., 2004; G. Liu et al., 2012; Shan, Ord, Ord, 
& Kilberg, 2009) 
Activating transcription factor 3 1.6 1.5  
AREG/ARE
GB 
Affected (Jousse, et al., 2007) Amphiregulin 11.6 6.4 12.0 
JUN Affected (L. Fu, Balasubramanian, Shan, Dudenhausen, 
& Kilberg, 2011) 
Jun proto-oncogene 1.9   
MT2A Affected (Hai & Curran, 1991) Metallothionein 2A -1.5 -1.6 -1.6 
PPP1R15A Affected (Carter, 2007; J. Han, et al., 2013) Protein phosphatase 1, regulatory 
subunit 15A 
2.5 1.8  
TRIB3 Affected (J. Han, et al., 2013; Jousse, et al., 2007) Tribbles homolog 3 (Drosophila) 1.6   
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Supp. Table 4: Genes related to DDIT3 activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when DDIT3 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
PPP1R15A ↑ (J. Han, et al., 2013; Verfaillie, et al., 2010) Protein phosphatase 1, regulatory 
subunit 15A 
2.5 1.8  
LCN2 ↑ (Hsin et al., 2012) Lipocalin 2 2.1 1.7 1.5 
TRIB3 ↑ (J. Han, et al., 2013; Verfaillie, et al., 2010; X. 
Yu, Lv, Zhu, Duan, & Ma, 2013) 
Tribbles homolog 3 (Drosophila) 1.6   
ANKRD1 ↓ (X. J. Han et al., 2005) Ankyrin repeat domain 1 (cardiac 
muscle) 
-1.6 -2.1 -1.7 
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Supp. Table 5: Genes related to XBP1 activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when XBP1 is 
activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
RABAC1 ↑ (Sriburi et al., 2007) Rab acceptor 1 (prenylated) 1.6   
MAP1LC3
B 
↑ (Margariti et al., 2013) Microtubule-associated protein 1 
light chain 3 beta 
1.5 1.6 1.6 
KLF4 ↑ (Sugiura et al., 2009) Kruppel-like factor 4 (gut) 1.5   
HYOU1 ↑ (Sriburi, et al., 2007) Hypoxia up-regulated 1 1.9  1.6 
HSPA13 ↑ (Sriburi, et al., 2007) Heat shock protein 70kDa family, 
member 13 
1.7 
 
1.5 
HERPUD1 ↑ (Sriburi, et al., 2007) Homocysteine-inducible, 
endoplasmic reticulum stress-
inducible, ubiquitin-like domain 
member 1 
2.2 1.7 1.5 
ERO1LB ↑ (Sriburi, et al., 2007) ERO1-like beta (S. cerevisiae) 1.5  1.6 
DNAJB9 ↑ (Carter, 2007; A. H. Lee, Iwakoshi, & 
Glimcher, 2003; Sriburi, et al., 2007; H. M. 
Zhang et al., 2010) 
DnaJ (Hsp40) homolog, subfamily 
B, member 9 
2.2 1.6 1.8 
DDIT3 ↑ (Verfaillie, et al., 2010) DNA-damage-inducible transcript 
3 
2.5 1.8 1.7 
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Supp. Table 6: Genes related to TP53 activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when TP53 is 
activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
TNFSF10 ↑ (Hussain et al., 2004; Lima et al., 2011) Tumor necrosis factor (ligand) 
superfamily, member 10 
1.5 1.6 1.6 
SLC2A1 ↓ (Daoud et al., 2003; Schwartzenberg-Bar-
Yoseph, Armoni, & Karnieli, 2004; Zawacka-
Pankau et al., 2011) 
Solute carrier family 2 (facilitated 
glucose transporter), member 1 
-1.6  -1.6 
PPP1R15A ↑ (Su et al., 2003) Protein phosphatase 1, regulatory 
subunit 15A 
2.5 1.8  
NDRG1 ↑ (Burrows, Smogorzewska, & Elledge, 2010; 
Stein et al., 2004) 
N-myc downstream regulated 1 1.6   
LPIN1 ↑ (Assaily, et al., 2011; Lotem, Benjamin, 
Netanely, Domany, & Sachs, 2004; Ongusaha 
et al., 2003) 
Lipin 1 1.5   
KLF4 ↑ (W. Zhang et al., 2000) Kruppel-like factor 4 (gut) 1.5   
HSPA8 ↓ (Daoud, et al., 2003; Ginsberg, Mechta, Yaniv, 
& Oren, 1991) 
Heat shock 70kDa protein 8 -3.0 -2.3  
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Supp. Table 6, continued      
DUSP1 ↑ (Begum, Hockman, & Manganiello, 2011; M. 
Li, Zhou, Ge, Matherly, & Wu, 2003) 
Dual specificity phosphatase 1 2.4 1.6  
DDIT3 ↑ (T. Liu et al., 2007; Su, et al., 2003) DNA-damage-inducible transcript 
3 
2.5 1.8 1.7 
BTG1 ↑ (Amundson et al., 2005; Campaner et al., 2011) B-cell translocation gene 1, anti-
proliferative 
1.8 
 
1.8 
BHLHE40 ↑ (Qian, Zhang, Yan, & Chen, 2008) Basic helix-loop-helix family, 
member e40 
2.2   
ATXN1 ↑ (Boiko et al., 2006) Ataxin 1 1.5   
ATF3 ↑ (Amundson et al., 1999; Campaner, et al., 
2011; Jeong, Hu, Belyi, Rabadan, & Levine, 
2010; H. Yoon et al., 2002) 
Activating transcription factor 3 1.6 1.5  
AREG/ARE
GB 
↑ (B. D. Chang et al., 2002; Hammond et al., 
2006) 
Amphiregulin 11.6 6.4 12.0 
THBS1 ↑ (Dameron, Volpert, Tainsky, & Bouck, 1994; 
Holmgren, Jackson, & Arbiser, 1998; Y. Liu et 
al., 1999; Vikhanskaya et al., 2001) 
Thrombospondin 1 -1.6 -1.7 -1.8 
NUPR1 ↓ (Vasseur et al., 2002) Nuclear protein, transcriptional 
regulator, 1 
1.8   
ID1 ↑ (Komarova et al., 1998; Qian & Chen, 2008; 
Wilson et al., 2001) 
Inhibitor of DNA binding 1, 
dominant negative helix-loop-helix 
protein 
-1.5  -1.5 
DKK1 ↑ (Caricasole et al., 2004; Harms & Chen, 2007; 
J. Wang, Shou, & Chen, 2000) 
Dickkopf 1 homolog (Xenopus 
laevis) 
-1.6   
JUN Affected (Ginsberg, et al., 1991; Komarova, et al., 1998) Jun proto-oncogene 1.9   
MBNL2 Affected (T. Liu, et al., 2007) Muscleblind-like splicing regulator 
2 
1.6   
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Supp. Table 7: Genes related to FOXO3 activation that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when FOXO3 
is activated 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
TNFSF10 ↑ (Ghaffari, Jagani, Kitidis, Lodish, & Khosravi-
Far, 2003; Modur, Nagarajan, Evers, & 
Milbrandt, 2002; Sakoe, Sakoe, Kirito, Ozawa, 
& Komatsu, 2010; van Grevenynghe et al., 
2011) 
Tumor necrosis factor (ligand) 
superfamily, member 10 
1.5 1.6 1.6 
PPP1R15A ↑ (Porcu & Chiarugi, 2005) Protein phosphatase 1, regulatory 
subunit 15A 
2.5 1.8  
MXD1 ↑ (Delpuech et al., 2007) MAX dimerization protein 1 2.2 1.8 1.7 
LCN2 ↑ (S. Park, Guo, Kim, & Cheng, 2009) Lipocalin 2 2.1 1.7 1.5 
DDIT3 ↑ (Greer et al., 2007) DNA-damage-inducible transcript 
3 
2.5 1.8 1.7 
CPT1A ↑ (Nakamura, Moore, Negishi, & Sueyoshi, 
2007) 
Carnitine palmitoyltransferase 1A 
(liver) 
1.7 1.6  
ATP6V0D2 ↑ (Greer, et al., 2007) ATPase, H+ transporting, 
lysosomal 38kDa, V0 subunit d2 
1.8 1.8 2.1 
MT1E ↑ (Greer, et al., 2007) Metallothionein 1E -1.5  -1.5 
IGFBP1 Affected (Brunet, et al., 1999; Datta, Brunet, & 
Greenberg, 1999) 
Insulin-like growth factor binding 
protein 1 
2.2   
231 
 
Supp. Table 8: Genes related to MYC inhibition that are significantly regulated in the microarray analyses of the different treatments on 
HepG2 cells.  
Gene 
Symbol 
Literature 
findings on 
gene 
regulation 
when MYC is 
inhibited 
References Gene Name 
Fold change 
TI+PA 
vs 
control
a 
FF+PA 
vs 
control
a 
PA vs 
control 
THBS1 ↓ (Baudino et al., 2002; Cairo et al., 2005; Oster, 
Ho, Soucie, & Penn, 2002; Thomas-
Tikhonenko et al., 2004) 
Thrombospondin 1 -1.6 -1.7 -1.8 
TES ↑ (Rounbehler et al., 2012) Testis derived transcript (3 LIM 
domains) 
1.5   
TAF1D ↓ (D. Wang, Wengrod, & Gardner, 2011) TATA box binding protein (TBP)-
associated factor, RNA polymerase 
I, D, 41kDa 
-1.6   
SNHG12 ↓ (D. Wang, et al., 2011) Small nucleolar RNA host gene 12 
(non-protein coding) 
-1.7 
 
-1.6 
SLC2A1 ↓ (Osthus et al., 2000; R. Wang et al., 2011) Solute carrier family 2 (facilitated 
glucose transporter), member 1 
-1.6  -1.6 
RPL5 ↓ (Guo et al., 2000; McConnell et al., 2003) Ribosomal protein L5 -1.5   
PPP1R15A ↑ (Amundson, Zhan, Penn, & Fornace, 1998) Protein phosphatase 1, regulatory 
subunit 15A 
2.5 1.8  
NDRG1 ↑ (Oster, et al., 2002) N-myc downstream regulated 1 1.6   
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Supp. Table 8, continued      
LGALS1 ↑ (Frye, Gardner, Li, Arnold, & Watt, 2003; S. 
Yan et al., 2009) 
Lectin, galactoside-binding, 
soluble, 1 
1.6   
ID1 ↓ (Murphy, Swigart, Israel, & Evan, 2004; 
Swarbrick et al., 2005) 
Inhibitor of DNA binding 1, 
dominant negative helix-loop-helix 
protein 
-1.5  -1.5 
DUSP1 ↑ (Louro et al., 2002; O'Connell et al., 2003; 
Thomas-Tikhonenko, et al., 2004) 
Dual specificity phosphatase 1 2.4 1.6  
DDIT3 ↑ (Amundson, et al., 1998; Babcock et al., 2013; 
Barsyte-Lovejoy, Mao, & Penn, 2004; Oster, et 
al., 2002) 
DNA-damage-inducible transcript 
3 
2.5 1.8 1.7 
CPT1A ↑ (Riu, Bosch, & Valera, 1996) Carnitine palmitoyltransferase 1A 
(liver) 
1.7 1.6  
KLF4 ↓ (O'Connell, et al., 2003; Yilmazer, de Lazaro, 
Bussy, & Kostarelos, 2013) 
Kruppel-like factor 4 (gut) 1.5   
G6PC ↓ (Collier et al., 2003) Glucose-6-phosphatase, catalytic 
subunit 
2.3 1.6 1.5 
DKK1 ↑ (Cowling, D'Cruz, Chodosh, & Cole, 2007) Dickkopf 1 homolog (Xenopus 
laevis) 
-1.6   
CD9 Affected (Mu, Yin, & Prochownik, 2002) CD9 molecule 1.7   
KLF6 Affected (Terragni et al., 2011) Kruppel-like factor 6 2.0   
MT1E Affected (Frye, et al., 2003; Oster, et al., 2002) Metallothionein 1E -1.5  -1.5 
 
